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Abstract
The research presented within this thesis focuses on the role of peroxisome 
proliferator-activated receptor y (PPARy) in lung epithelial cells. PPARs are ligand 
activated transcription factors and have been implicated in diverse pathways and thus 
disease states. PPARy ligands are reported to possess anti-inflammatory properties 
however there is much controversy over the mechanisms of action. The aim of this 
work was to clarify the role of PPARy ligands in regulating inflammatory responses in 
A549 (human lung epithelial) cell line, and identify the signalling pathways and 
mechanism involved in doing this. Firstly this work characterises two 
phosphoinositide 3-kinase (PI3K) inhibitors and investigates the signalling pathways 
involved in the regulation of a pro-inflammatory enzyme, cyclooxygenase-2 (COX-2), 
by cytokines. Secondly this work investigates the effects of PPARy ligands on the 
regulation of COX-2 in A549 cell line.
In vitro lipid kinase assays revealed that two PI3K inhibitors, LY294002 and 
wortmannin had differential selectivity to PI3K isoforms. The rank order of selectivity 
of LY294002 was p85-associated PI3K> PI3K-C2a> PI3K-C2P, whereas the rank 
order of selectivity of wortmannin was p85-associated PI3K> PI3K-C2p and had no 
inhibitory effect on PI3K-C2a. Due to the differential selectivity care must be taken 
when utilising these inhibitors to assess the role of PI3K pathway.
The pro-inflammatory cytokines TNFa and IL-lp activated the PI3K and mitogen- 
activated protein kinase pathway (MAPK) in a concentration and time-dependent 
manner. Both cytokines time-dependently induced the expression of COX-2 and 
microsomal prostaglandin E synthase (mPGES) and prostaglandin E2 (PGE2) 
production. TNFa-induced COX-2 expression and PGE2 was sensitive to the PI3K 
inhibitor LY294002, the MEK inhibitor PD98059 and the p38 inhibitor SB202190, 
but was insensitive to the PI3K inhibitor wortmannin and the PKC inhibitor Ro-32- 
0432. TNFa activated the NFkB pathway, as shown by IkB degradation, p65 
phosphorylation and activation and NFkB gene reporter activity. These data suggest 
the role of PI3K, MAPK and NFkB in regulation of COX-2 expression by TNFa.
The synthetic PPARy ligand troglitazone activated the PI3K and MAPK, whereas the 
endogenous PPARy ligand, 15-deoxy-A12,14-prostaglandin J2 (15d-PGJ2), only 
activated the PI3K pathway. 15d-PGJ2 had no detectable effects on COX-2, mPGES 
expression, or PGE2 production. However, troglitazone induced time-dependent 
COX-2 expression, which was insensitive to PPARy antagonists, but was abrogated 
by inhibitors of PI3K and the ERK MAP kinase pathway. Furthermore, troglitazone 
induced mPGES expression and PGE2 production. Neither troglitazone nor 15d-PGJ2 
was able to convincingly activate NFkB in A549 cells. Further heterogeneity in the 
responses to troglitazone and 15d-PGJ2 was observed in the regulation of gene 
expression as assessed by microarray analysis.
In summary, this study provides compelling evidence that troglitazone (like 15d- 
PGJ2) can exert functional effects independently of actions via PPARy. Moreover, it 
identifies unique biochemical and functional actions of troglitazone that are not shared 
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Chapter 1 - Introduction
1. INTRODUCTION
1.1 History
Since 1965, it has been known that a group of structurally diverse agents, 
collectively known as peroxisome proliferators, were able to promote an increase in 
the number of hepatic peroxisomes when administered to rodents (Hess et al., 1965). 
This phenomenon is associated with an increase in transcription of genes involved in 
fatty acid oxidation (de la Iglesia et al., 1996). The ability of peroxisome 
proliferators to activate gene transcription raised the possibility that they were acting 
through a receptor-mediated mechanism. This eventually led to the identification of 
peroxisome proliferator-activated receptor (PPAR)a, the first member of the PPAR 
subfamily to be identified (Issemann and Green, 1990). The group now also includes 
PPARy (of which there are three isoforms yl, y2 and y3) (Fajas et al., 1998) and 
PPAR5.
PPARs form an important subfamily of the nuclear hormone receptor superfamily 
and are ligand activated transcription factors. PPARs have been implicated in many 
diverse pathways including lipid and glucose homeostasis, control of cellular 
proliferation and differentiation, and thus play a role in many human diseases 
including diabetes, obesity, atherosclerosis, hypertension and cancer. Recently 
PPARs have also become an important focus in inflammatory diseases such as 
asthma (Benayoun et al., 2001) due to their anti-inflammatory effects in cells of the 
immune system (Jiang et al., 1998; Ricote et al., 1998a). However the mechanisms 
by which ligands of PPARs, and in particular PPARy, induce anti-inflammatory
1
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effects are not only poorly understood but also very controversial. This thesis 
focuses on the role of PPARy in lung epithelial cells. Firstly I will set the scene by 
introducing the “inflammatory response” and the key players involved. Next I will 
describe some of the important signalling pathways that have been well recognised 
in mediating messages from receptors to inducing functional inflammatory 
responses. Finally I will describe PPARs, the signalling pathways and mechanisms 
they utilise and how they have been linked to inflammation.
1.2 Inflammation
1.2.1. Background
Inflammation is a beneficial host response to foreign challenge or tissue injury that 
leads ultimately to the restoration of tissue structure and function. The inflammatory 
response requires innate immunity and, in some cases, an adaptive immune response, 
which are the two main integral components of the host’s defence system. Innate 
immunity not only acts as the first line of defence against noxious material, but after 
recognition of an appropriate stimulus, it provides the necessary signals to instruct 
the adaptive immune system to mount a response. In turn, the adaptive response 
relies on the innate immune system to provide the necessary effectors, in the form of 
phagocytes and granulocytes, to deal with the initiating stimulus.
Inflammation is a reaction of the microcirculation that is characterized by the 
movement of serum proteins and leukocytes from the blood to the extravascular 
tissue. This movement is regulated by the sequential release of vasoactive and
2
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chemotactic mediators, which contribute to the cardinal signs of inflammation-heat, 
redness, swelling, pain and loss of tissue function (Figure 1.1). Local vasodilation 
increases regional blood flow to the inflamed area and, together with an increase in 
microvascular permeability, results in the loss of fluid and plasma proteins into the 
tissues. Concomitantly, there is an upregulation of expression of adhesion molecules 
on endothelial cells and the release of chemotactic factors from the inflamed site, 
which facilitate the adherence of circulating cells to the vascular endothelium and 
their migration into the affected area. Phagocytic cells such as macrophages ingest 
foreign material and cell debris. They also release hydrolytic and proteolytic 
enzymes, and generate reactive oxygen species that eliminate and digest invading 
organisms. Finally, the injurious stimulus is cleared and normal tissue structure and 
function is restored. Thus the phases of inflammation have been loosely defined as 
acute, chronic and resolution.
HEAT < VREDNESS '<SWKLMNi m i  oss o f .FUNCTION
Figure 1.1 Cardinal signs of inflammation. This cartoon depicts five Greeks representing the 
cardinal signs of inflammation-heat, redness, swelling, pain and loss of function, which was first 
described by Celsus more than 2000 years ago. Figure taken from (Lawrence et al., 2002).
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There are many mediators that coordinate the initial events of acute inflammation 
(Table 1.1). Vasoactive amines, lipid-derived eicosanoids, cytokines and chemokines 
regulate vascular changes and inflammatory-cell recruitment (Larsen and Henson, 
1983). Cell-adhesion molecules facilitate the movement of inflammatory cells from 
the peripheral circulation to the inflammatory site. Pro-inflammatory cytokines, such 
as tumour-necrosis factor (TNF) and interleukin-lp (IL-ip), activate signalling 
pathways in endothelial cells that regulate the expression of these adhesion 
molecules to initiate the capture of circulating leukocytes (Shanley et al., 1995).
Amines and peptides Histamine, bradykinin Adrenaline, noradrenaline
Lipid mediators p g e 2, p g i2. l t b 4, l t c 4 PGJ2, PGAi^ , lipoxins
Complement C3a, C5a Clq receptor
Cyclic nucleotides cGMP cAMP
Adhesion molecules E-selectin, P-selectin, OCvp3 integral, TSP
ICAM-1, VCAM-1 receptor, PS receptor
Cytokines TNF, IL-1 (3, IL-6 TGF-pl, IL-10
Chemokines IL-8, GRO, MIPa, MCP1 -
Reactive oxygen species 0 2-, OH-, H20 2, NO, 
ONOO-
Steroid hormones - Glucocorticoids
Table 1.1. Mediators that regulate the acute inflammatory response (Lawrence et al., 2002). 
Abbreviations: cAMP, cyclic adenosine 3,5 monophosphate; cGMP, cyclic 3,5 monophosphate; 
H20 2, hydrogen peroxide; ICAM-1, intercellular adhension molecule-1; EL, interleukin; LT, 
leukotriene; MCP1, monocyte chemotactic protein 1; M IPla, macrophage inflammatory protein la ; 
N O , nitric oxide; 0 2- ,  superoxide anion radical; OH-, hydroxyl radical; ONOO-, peroxynitrite; PG, 
prostaglandin; PS, phosphatidyl serine; TG F-pl, transforming growth factor-Pl; TNF, tumour- 
necrosis factor; TSP, thrombospondin; VCAM-1, vascular cell adhesion molecule-1.
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1.2.2. Key mediators of inflammation
Reactive oxygen species
Oxidant species are prevalent, at least transiently, in all active sites of metabolism, 
and are especially important in the pulmonary epithelium, where oxygen and oxidant 
exposure is continuous. A number of reactive species have been shown to affect cell 
function, including the oxygen species: superoxide anion radical (0 2 *-), hydroxyl 
radical (OH), hydrogen peroxide (H2O2), and the nitrogen species: nitric oxide 
(NO ), and peroxynitrite (0N 00-). Reactive oxygen and nitrogen species, known 
effectors of intracellular signalling in many cell types, are beginning to be 
recognized as intracellular signalling molecules in airway epithelium. Hydroxyl 
radical has also been implicated as an intracellular signalling molecule for 
intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of 
normal human bronchial epithelial cells and a human bronchial epithelial cell line 
(Krunkosky et al., 1996). Nitric oxide is produced by a small group of specific nitric 
oxide synthase (NOS) enzymes which includes the inducible form of NOS (iNOS). 
Nitric oxide (NO) appears to function in the intracellular regulation of secretion of 
mucus and ciliary motion in airway epithelial cells. NO can also be produced by the 
airway epithelium in response to primary inflammatory mediators, such as TNFa 
and platelet activating factor (PAF), possibly serving to signal the upregulation of 
cellular processes that increase the inflammation observed in respiratory disease. 
Thus, nitric oxide may be considered a secondary mediator of inflammation 
produced by the effector tissue.
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Cytokines
Cytokines are extracellular signalling protein or peptides that act as a local mediator 
in cell-cell communication via activation of signalling pathways (which will be 
described in detail later) and thus play a pivotal role in the regulation of 
inflammation. TNFa and IL-lp can upregulate production of secondary mediators 
such as IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), 
and insulin-like growth factor-1 (IGF-1).
The tumour necrosis factor protein was identified in 1975 and named after its ability 
to kill tumour cells (Carswell et al., 1975). Subsequently, it was found to refer to 
two closely related cytokines, TNFa and TNFp (or lymphotoxin-a) which share 













Figure 1.2. M ajor TNF mediated cellular responses (M acEwan, 2002)
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TNFa is a member of a larger family of related ligands and is an immediate early 
gene. Its gene characteristics are outlined below:
• Multiple response elements in its promoter. These include binding sites for 
nuclear factor kB (NFkB), activating protein (AP)-l, AP-2, specificity 
protein-1 (Spl) and cAMP response element (CRE) and there is evidence of 
combinatorial activation as with COX-2.
• The presence of AREs in the 3'-UTR allowing post-transcriptional regulation 
via control of mRNA stability and translational rate.
• Expression in monocytes and macrophages, B and T lymphocytes and also 
lung epithelial cells
• Induced by a large number of diverse stimuli such as cytokines, growth 
factors, bacterial products and irradiation.
TNFa is first synthesised as a transmembrane (26kDa) precursor which can be 
biologically active in a juxtacrine manner. This precursor can then be cleaved by 
TNFa converting enzyme (TACE) into the 17kDa secreted form of TNFa which 
combine into homotrimers to bind to and activate its receptors.
TNFa and airway diseases
Asthma is perceived as a Th2 disease with a particular profile of cytokine release, 
which is thought to include IL-4 and IL-5. Increasing evidence indicates that other 
cytokines which are released are also associated with the inflammatory response that 
charaterizes human asthma. One such mediator is TNFa, which has been implicated 
in asthmatic inflammation by a broad series of subcellular, in vitro, ex-vivo, in vivo
1
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and genetic studies. TNFa is produced by many cells including macrophages, T- 
cells, mast cells and epithelial cells, but the principal source is the macrophage.
Both TNFa and IL-lp increase the expression of ICAM-1 and vascular cell 
adhension molecule-1 (VCAM-1) on respiratory epithelial cells in vitro, and 
eosinophils show increased adherence to these cells after stimulation, although 
blocking experiments suggest that CD11/CD18 (P2) integrins may play an important 
role in this adhesion (Moser et al., 1992; Godding et al., 1995). These effects are 
amplified in the presence of IL-5, perhaps via a CD 18-dependent mechanism 
(Ebisawa et al., 1994). The TNFa induced increase in ICAM-1 also aids in vitro 
binding of activated T lymphocytes to airway smooth muscle cells, which is 
inhibited by cyclic AMP-dependent protein kinases (Ebisawa et al., 1994; Panettieri, 
Jr. et al., 1995). Thus, TNFa is associated with the up-regulation of adhesion 
molecules, and is able to facilitate inflammatory cell migration, particularly 
eosinophils in respiratory diseases (White et al., 1997). Furthermore, TNFa 
increases expression of the adhesion molecule, ICAM-1, levels of which are 
increased in the serum of chronic obstructive pulmonary disease (COPD) patients 
(Riise et al., 1994).
TNFa may activate macrophages to produce matrix metalloproteases (MMP)s 
(Mautino et al., 1997) and also stimulates bronchial epithelial cells to produce 
tenascin, an extracellular matrix glycoprotein (Harkonen et al., 1995). This data thus 
implicates TNFa in airway remodelling and fibrosis. In addition, TNFa appears to 
increase airway smooth muscle cell contractility (Thabut et al., 2002).
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IL-lfl
IL-1 is a highly inflammatory cytokine which can also upregulate host defences and 
act as an immunoadjuvant. It has two isoforms, IL-1 a  and IL-lp, which belong to a 
larger, evolutionarily conserved, family which includes fibroblast growth factor 
(FGF) and IL-18. Both forms of IL-1 are synthesised as 31kDa precursor forms 
which require processing by specific proteases to produce a mature 17kDa secreted 
cytokine. Although the biological activities of IL-1 a  and p are effectively 
indistinguishable, there are important differences between the two molecules.
ProIL-la is secreted by cells when they die and is then cleaved by extracellular 
proteases. It has been demonstrated that IL-1 a  can be secreted in the absence of cell 
death in vitro (Watanabe and Kobayashi, 1994). However, the fact that IL-1 a  is not 
commonly seen in the circulation or in body fluids, except during severe disease, 
means that release during cell death is likely to be the common mode of production 
(Watanabe and Kobayashi, 1994). In contrast IL-lp is released by living cells on 
stimulation and, like TNFa shares many features of an immediate early gene. The 
precursor form lacks biological activity and is converted to the mature form by the 
action of the cysteine protease (or caspase) IL-lp converting enzyme (ICE), 
although other inflammatory proteases may be able to catalyse the conversion in the 
absence of ICE (Fantuzzi et al., 1997).
IL-lp induces leukocytosis by the release of neutrophils from bone marrow, and also 
induces the release of many other cytokines such as IL-1, -2, -3, -4, -5, -6 and -8, 
regulated upon activation normal T-cell expressed and secreted (RANTES), GM-
9
Chapter 1 - Introduction
CSF, interferon y (IFNy), TNF and platelet-derived growth factor (PDGF) from a 
variety of cells. It induces fibroblasts to proliferate, collagenase secretion, and 
increases synthesis of fibronectin and collagen.
IL-1 P has been importantly implicated in driving the inflammatory response and 
resultant changes in airway smooth muscle (ASM) responsiveness in asthma. 
Furthermore, elevated levels of IL-1 p have been detected in the bronchoalvelolar 
lavage of patients with asthma (Broide et al., 1992; Sousa et al., 1996).
Lipid mediators
Lipid mediators, including prostaglandins, leukotrienes, hydroxyeicosatetraenoic 
acids (HETEs) and PAF, are prevalent in inflammatory disease states. Both 
infiltrating inflammatory cells, and the epithelium produce these lipid mediators in 
response to a number of stimuli. In turn, these lipid products act both as primary and 
secondary mediators of inflammation. Of particular importance is the production of 
prostaglandins by the cyclooxygenase pathway, which is therefore discussed in 
greater detail in the following section.
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1.3 Cvclooxygenase pathway
1.3.1. Background
Prostanoids are mediators that have been implicated in all stages of inflammation. 
Indeed, the inhibition of prostanoid formation by non-steroidal anti-inflammatory 
drugs (NSAIDs) is the basis for their therapeutic as well as their side effects. The 
arachidonic acid pathway plays a vital role in production of lipid mediators, such as 
prostaglandins and leukotrienes, many of which are ligands of PPARs (described 
later).
Arachidonic acid liberation from phospholipids is a reaction catalysed by 
phospholipases A, C and D. The phospholipase A2 (PLA2) family of enzymes are 
the most important with respect to prostaglandin production, and can be split into 
secretory or SPLA2 (low MWt 14-18kDa), and cytoplasmic or CPLA2 (high MWt 80- 
110 kDa). They represent a potential point of regulation of eicosanoid production 
and respond to agonist stimulation. There is evidence for some form of coupling 
between phospholipases and cyclooxygenases, although the mechanism for this has 
yet to be elucidated.
Free arachidonic acid can be metabolised by one of three pathways (these pathways 























Figure 1.3. Pathways of Arachidonic Acid metabolism. Schematic representation of the pathways 
involved in arachidonic acid metabolism and generation of eicosanoids. PLA2 phospholipase A2; 
LOX lipoxygenase; COX cyclooxygenase; PG prostaglandin; HPETE hydroperoxyeicosatetraenoic 
acid; HETE hydroxyeicosatetraenoic acid; EET epoxyeicosatetraenoic acid; PGDH, 15-hydroxy-PG 
dehydrogenase
1.3.2. Lipoxygenases
Lipoxygenases insert an oxygen molecule into the twenty carbon ring of arachidonic 
acid and are numbered after the target carbon atom with 5-, 12-, and 15-lipoxygenase 
being the major enzymes relevant to gastrointestinal function. The ultimate products 
of lipoxygenase (LOX) activity are the leukotrienes, lipoxins and hydroxy fatty acids 
such as the hydroperoxyeicosatetraenoic (HPETEs) and hydroxyeicosatetraenoic 
(HETEs) acids.
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1.3.3. Cytochrome p450
The cytochrome p450 pathway of arachidonic acid metabolism represents a reaction 
where a single oxygen atom is inserted resulting in epoxy and (co/co*1) derivatives 
(Capdevila et al., 1981). Less is known about the functional importance of this 
pathway.
1.3.4. Cyclooxygenase-2 (COX-2)
Arachidonic acid can be metabolised by the rate limiting enzyme, COX to 
prostaglandin H2 (PGH2). This is further metabolised by other enzymes to PGs, 
prostacyclin and thromboxane A2 (Vane et al., 1994). COX enzymes catalyse the 
conversion of arachidonic acid to cyclic endoperoxides which serve as intermediates 
in the generation of prostaglandins -  firstly by inserting two oxygen molecules to 
yield PGG2 (cyclooxygenase activity) and then reducing this intermediate to give 
PGH2 (peroxidase activity). PGH2 is subsequently converted to a variety of 
eicosanoids, arachidonate derivatives based around a 2 0  carbon structure (eicosa is 
Greek for twenty), that include the prostaglandins and thromboxane A2 . Which 
eicosanoids are produced is dependent on the environment, as well as the enzymatic 
machinery, of particular cells.
There are two well characterised isoforms of COX, COX-1 and COX-2. COX-1 
which is the constitutive “housekeeping” isoform, COX-2 is an inducible isoform 
that can be upregulated by growth factors, cytokines and lipopolysaccharide in a 
wide variety of cells (Mitchell et al., 1994). Upregulation of COX-2 is a hallmark 
feature of many inflammatory diseases and thus understanding the mechanisms
13
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involved in regulating this enzyme may prove important in identifying potential 
therapeutic targets for inflammatory diseases such as asthma, rheumatoid arthritis 
and inflammatory bowel disease. Recently, a third COX isoform has also been 
described (Botting, 2000). This enzyme is thought to be a variant of COX-2 induced 
by high concentrations of NSAID and was shown to be highly sensitive to inhibition 
by paracetamol. Thus it is thought that COX-3 may be a product of the same gene 
that encodes COX-2, but has different molecular characteristics (Botting, 2000).
COX gene expression
COX-1 is constitutively expressed in many tissues and cells in the animal species. 
The 5’-flanking region of the human COX-1 gene has multiple transcription start 
sites, does not possess a canonical TATA or CAAT box, and is GC-rich (Figure 1.4).
Human COX-1 promoter
AP-2 Myb GATA A P2SplN F-IL 6 Spl
- + - H H 0 I  f - ^ =
-787/-775 -734/-729 -597/-592 -478/-452 -32/-27 1
Human COX-2 promoter
Spl NFkB AP2 NF-IL6 CRE/E box TATA box
- I — I ------------------- M i l '
-270/-265 -223/-214 -132/-124 -59/-53 -31/-25 1
Figure 1.4. Regulatory elements in the human COX-1 and COX-2 promoter.
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These features are consistent with those of a housekeeping gene. The 5’-flanking 
region of the COX-1 gene possesses several putative binding sites for transcriptional 
activators. Spl has been shown to contribute to constitutive expression of COX-1 in 
human umbilical vein endothelial cells by electrophoretic mobility shift assays 
(EMSA) (Xu et al.. 2000). The regulation of COX-2 gene expression can be 
attributed to many regulatory elements, such as the nuclear factor k B  ( N F k B )  site, 
NF-IL6  motif, CRE and E-box (Figure 1.4).
The ATF/CRE has been identified as one of the most essential regulatory elements in 
the COX-2 promoter region. It has been shown that homo- or heterodimers of c-fos, 
c-jun, ATF families of bZIP proteins and the cAMP response element binding 
protein (CREB) can bind to this element and activate the expression of COX-2 (Xie 
and Herschman, 1996). Activation at the NF-IL6  element is most often associated 
with C/EBP transcription factors. There are several members of the C/EBP 
transcription factor family including C/EBPa, C/EBPp and C/EBP8 . Many studies 
on the expression of COX-2 have implicated the transcription factor NFkB in 
signalling (Ghosh et al., 1998).
1.3.5. Prostaglandin E synthases
Specific downstream prostanoid synthases dictate which individual PGs will be 
synthesised following generation of endoperoxides by COX. There is also evidence 
that these prostanoid synthases can couple with either COX-1 or COX-2. One of the 
best known and most well studied prostaglandins is PGE2 which requires the enzyme 
prostaglandin E synathase (PGES) for its synthesis from COX-generated cyclic
15
Chapter 1 - Introduction
endoperoxides. An inducible microsomal PGES (m-PGES) couples predominantly 
with COX-2 (Jakobsson et al., 1999; Murakami et al., 2000), whereas a 
constitutively and widely expressed cytosolic PGES (c-PGES) is thought to be 
coupled to COX-1 (Tanioka et al., 2000). Both these enzyme activities are dependent 
on reduced glutathione (GSH). After treatment with IL-1 p, mPGES-1 protein 
expression has been shown to be induced in A549 cell line (Jakobsson et al., 1999). 
The induction of mPGES-1 expression and PGE2 production stimulated by IL-lp in 
A549 cells has been demonstrated (Thoren and Jakobsson, 2000) to be in concert 
with the induction of COX-2 expression. The large amounts of PGE2 produced at the 
inflammation site by the coupling of COX-2 and mPGES synthase may be involved 
in the progression of inflammation.
1.3.6. Prostaglandins
Prostaglandins are small lipid molecules that regulate numerous processes in the 
body, including kidney function, platelet aggregation, neurotransmitter release and 
modulation of immune function. Once synthesised, prostaglandins cannot be stored 
and act as local paracrine, autocrine or intracrine mediators. They are involved in a 
multiplicity of physiological responses and mediate the effects of COX expression.
As previously mentioned PGE2 is an important mediator of inflammation and is the 
most well studied PGs. PGE2 is produced by many cells and exerts its effects by 
binding to one (or a combination) of its four subtypes of receptors (EPi, EP2 , EP3 
and E P 4 ) .  The receptors are rhodopsin-type receptors containing seven hydrophobic
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transmembrane domains, coupled through their intracellular sequences to specific G 
proteins with different second messenger signalling pathways. The regulation of 
expression of the various subtypes of EP receptors on cells by inflammatory agents, 
or even PGE2 itself, enables PGE2 to affect tissues in a very specific manner (Harris 
et al., 2002a). Recently, several reports have documented the expression of 
functional EP receptors (EPi, EP3 and EP4) on the nuclear membranes of cells (Guan 
et al., 1998; Bhattacharya et al., 1999). For example, EP3 and EP4 have been 
localized to the nuclear envelope of endothelial cells. These receptors are functional, 
because they can modulate transcription, including that of the gene encoding iNOS 
(Bhattacharya et al., 1999). The discovery of nuclear EP receptors provides an 
additional level of complexity to the PGE2 mediated regulation of cells, and further 
study is necessary to determine the processes that govern the expression and function 
of the nuclear-localized receptors.
Other PG membrane receptors include DP, FP, IP and TP, based on their sensitivity 
to the primary other prostanoids PGD2 , PGF2«, PGI2 and TXA2 respectively. The 
molecular cloning of the eight subtypes of prostanoid receptors has enabled the 
homogenous expression of each type of receptor in cultured cells and thus, an 
analysis of their ligand bindings and signal transducing properties. Table 1.2 
summarizes the characteristics of the prostanoid receptors.
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Table 1.2. Summarises the receptors and some biochemical effects of various eicosanoids.
Regulation o f inflammation by cyclopentenones
In contrast to conventional PGs that act on G protein-coupled cell surface receptors, 
cyclopentenone PGs, such as A12-PGJ2 and 15d-PGJ2, have no cell surface receptor. 
The J series of cyclopentenone PGs, once thought to comprise of inactive 
degradation products of PGD2 , is now well established as regulating diverse 
processes, such as adipogenesis, inflammation and tumorigenesis. 15d-PGJ2 is the 
end-product metabolite of PGD2 (Figure 1.5) and is produced by a variety of cells, 
including mast cells, T cells, platelets and alveolar macrophages.
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Figure 1.5. Schematic representation of PGD2 derivatives. This demonstrates the metabolism of 
PGD2 to both the J series of cyclopentenone prostaglandins, as well as the conversion to the stable 
methoximated derivative
The exact mechanism of entry of 15d-PGJ2 into cells is unknown, but it is possible 
that 15d-PGJ2 enters by an active transport system similar to those described by 
Narumiya et al. (1 9 8 6 )  group for other cyclopentenone prostaglandins (e.g. A-  
12PGJ2). Alternatively, once synthesised 15d-PGJ2 may act within the same cell. An 
additional cryptic mechanism allows transport of the cyclopentenone prostaglandins 
into the nucleus, where they affect gene transcription and thus exert a variety of 
biological actions including induction of stress response, inhibition of cell-cycle 
progression, suppression of viral replication, cell differentiation and development. 
Although it has never been shown directly that 15d-PGJ2 uses these transporters, its 
similar structure to the other PGs makes this mechanism feasible. It is possible that
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locally produced PGD2 could enter a cell by an anionic transporter molecule and 
then be degraded to 15d-PGJ2 once inside the cytoplasm.
Gilroy et al. (1999), presented evidence that suggested that COX-2 may have anti­
inflammatory properties. This study demonstrated that COX-2 may be pro- 
inflammatory during the early phase of a carrageenin-induced pleurisy, dominated 
by PMN cell-dominated phase, but may aid resolution by generating an alternative 
set of anti-inflammatory PGs (Gilroy et al., 1999).
1.4. Signalling pathways
Signalling pathways are vital components in inducing functional effects downstream 
of receptor binding. This next section will introduce the main signalling pathways 
which have been investigated in this thesis and that have been known to be activated 
downstream of cytokine receptors and have been shown to be important in the 
induction of COX-2. These include the phosphoinoitide 3-kinase (PI3K), the 
mitogen-activated protein kinase (MAPK) and transcriptional pathways (NFkB and 
AP-1).
1.4.1. Phosphoinositide 3-kinase (PI3K)
PI3K mediates the formation of D-3 phosphoinositide lipids by transferring the 
terminal phosphate of ATP to the D-3 position of the inositol head group of 
phosphoinositide lipids (Figure 1.6).
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Figure 1.6. Transfer of terminal phosphate of ATP to D-3 position of the inositol head group of 
phosphoinositide lipids.
PI3K can thus potentially produce three products: phosphatidylinositol (3)-phosphate 
[PtdIns(3)P], phosphatidylinositol (3,4)-bisphosphate [PtdIns(3 ,4 )P2] and 
phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3 ,4 ,5 )P3] (Figure 1.7) (DuBois et 
al., 1998; Vanhaesebroeck and Waterfield, 1999).
Figure 1.7. Formation of phosphoinositide lipids by PI3K.
PI(3)P is constitutively present in eukaryotic cells and its levels are largely unaltered 
upon cellular stimulation. In contrast, PtdIns(3 ,4 )P2 and PtdIns(3 ,4 ,5 )P3 are 
generally absent from resting cells, but their intracellular concentration rises 
markedly upon stimulation via a variety of receptors suggesting a second messenger
P tdlns P td ln s(4)P  P td ln s(4 ,5 )P 2
P h osp h oin ositid e  3 -k in a se
P td ln s(3 )P  P td ln s(3 ,4 )P 2 P td ln s(3 ,4 ,5 )P 3
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function. There are multiple isoforms of PI3K in mammalian cells and these are 
subdivided into three classes on the basis of the in vitro lipid substrate specificity, 
structure (Figure 1.8) and likely mode of regulation (Koyasu, 2003).
Class IA
pi 10 a, p, 8 Ras-B C2 PIK Catalytic domain
SH3 3r BH Pr SH2 Inter-SH2 SH2
Pr SH2 Inter-SH2 SH2
Pr sm Inter-SH2 SH2
SH3 BH Pr SH2 Inter-SH2 SH2
Pr SH2 Inter-SH2 SH2
p85 a  
p55 a  
p50 a
p85 p
p5 5  7
Class IB pi 10 7 Ras-B C2 PIK Catalytic domain
plOl
Class II C2a, p, 7 Ras-B C2 PIK Catalytic domain PX C2
Class III Vps34p C2 PIK Catalytic domain
Vpsl5p (p i50)
Figure 1.8. Structural characteristics of the PI3K  family. The PIK is a helical domain that is found 
in lipid kinases but not protein kinases. C2 domains bind phospholipids in a calcium-dependent and -  
independent manner; those of PI3Ks do so in a calcium-independent fashion and recruit PI3Ks to the 
membrane. The SH2 domain of p85a, p55a, p50a, p85(3 and p55y constitutively interacts with the N- 
terminal domain of p i 10a, P, 8. Dual SH2 domains bind to tyrosine-phosphorylated adaptor proteins, 
leading to activation of the kinase activity of the p i 10 subunits. plOl specifically interacts with the N- 
terminal domain of p i 10y. PX domains are known to bind PI(3)P and PI(3,4)P2 and may recruit the 
class II PI3K to the membrane. Functions of the Ras-binding domain (Ras-B), SH3 and Bcr domains 
and the praline-rich regions (Pr) are not fully understood. Vps34p, the class III PI3K, forms a 
complex with a serine/threonine kinase Vpsl5p.
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Class I
The Class I PI3K phosphorylate Ptdlns, PtdIns(4)P and PtdIns(4 ,5 )P2 , resulting in 
the formation of PtdIns(3)P, PtdIns(3 ,4 )P2 and PtdIns(3 ,4 ,5 )P3 in vitro, whereas 
PtdIns(4 ,5 )P2 is the main substrate in vivo. They also interact with Ras and form 
heterodimeric complexes with adaptor proteins that link them to different upstream 
signalling events. The prototypical class IA PI3K is a heterodimer consisting of the 
85kDa regulatory subunit (responsible for protein-protein interactions either via 
protein tyrosine phosphate-binding SH2 domains or SH3 domains and/or proline- 
rich regions) and a catalytic llOkDa subunit. Mammals have three genes for the 
pi 10 subunits, which encode pi 10a, pllOp and pi 108. The existence of multiple 
isoforms of both components, which do not appear to preferentially associate, means 
that there is considerable scope for specific variation between tissues and with 
association to different receptor tyrosine kinases. The class IB PI3K are stimulated 
by G protein py subunits and do not interact with the SH2-containing adaptors that 
bind class IA PI3K. Instead, the first identified member of this family, pllOy, 
associates with a unique p i 0 1  adaptor molecule.
Class II and Class III
Class II PI3Ks are large proteins that have a catalytic domain that is 45-50% 
homologous to Class I PI3K. Class II PI3K also have a C-terminal region that has 
homology to the C2 domains that mediate calcium/lipid binding in classical protein 
kinase C isoforms (Cantrell, 2001). Class II PI3K preferentially phosphorylate 
Ptdlns and PtdIns(4)P in vitro, whereas the Class III PI3K utilise only PI as a
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substrate. The mammalian homologue of Class III PI3K is likely to be the main 
source of PtdIns(3)P.
Phosphatases
The PI3K family mediate various biological effects through the action of the D-3 
phosphorylated phosphoinositides second messengers. The levels of the second 
messenger are regulated by PTEN (phosphatase and tensin homolog) and SHIP (Src- 
homology-2 containing inositol 5’-phosphatase) that can specifically hydrolyze the 
D-3 and D-5 phosphates respectively from the lipid products and thus control the 
level of PtdIns(3,4)P2 and PtdIns(3,4,5)P3.
Downstream targets and functions
A number of proteins have been identified that directly bind PtdIns(3,4,5)P3 and/or 
PtdIns(3,4)P2 via pleckstrin homology (PH) domains, which are lipid binding 
domains, including protein kinase B (PKB/Akt), PtdIns(3,4,5)P3-dependent protein 
kinase-1 (PDK-1), Bruton’s tyrosine kinase, various PLC isoforms and exchange 
factors for the ADP-ribosylation factor family of GTP-binding proteins (Figure
1.15). Moreover, the D-3 phosphoinositide lipids have been linked to the triggering 
of a diverse array of cellular responses including cell survival, mitogenesis, 
membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, 
superoxide production as well as actin polymerisation and chemotaxis (Figure 1.9).
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Figure 1.9 Downstream targets and functions of PI3K. Phosphatidylinositol (3,4,5)-trisphosphate 
[PtdIns(3,4,5)P3] produced by class I PI3Ks recruits proteins that contain a pleckstrin homology (PH) 
domain, including protein kinase B (PKB), phosphoinositide-dependent kinase 1 (PDK1), guanine 
nucleotide exchange factors (GEFs), protein tyrosine kinases of the Tec family [e.g. Bruton’s tyrosine 
kinase (Btk)], phospholipase Cy (PLC-y) and many more. PI3K exerts control on most cellular 
processes and lthough this control is central, the signalling pathways depicted intersect with parallel, 
non-PI3K-dependent mechanisms (not shown) (Wymann et al., 2003). Abbreviations: 4E-BP1, 
eukaryotic initiation factor 4E binding protein 1; Glc, glucose; GLUT4, glucose transporter 4; IkB, 
inhibitor of NFkB; NFkB, nuclear factor kB; TSC1, hamartin; TSC2, tuberin.
PKB
Of these downstream effectors of PI3K, PKB is of particular interest. PKB is also 
known as Akt and is the prototype of a family of kinases that includes three known 
members, PKB a, PKBp and PKBy. It is a serine/threonine kinase that is itself 
activated by two distinct phosphorylation events, and which probably both involve 
the upstream kinase PH domain-containing kinase PDK-1. The binding of 
PtdIns(3 ,4 ,5 )P3 to PKBa PH domain brings this kinase to the plasma membrane, 
where it is phosphorylated on Thr308 in the kinase activation loop and on Ser473 in
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a hydrophobic region of the C-terminus. The upstream kinase that targets Thr308 is a 
ubiquitously expressed kinase, PDK1 (Alessi et al., 1997a; Alessi et al., 1997b; 
Stephens et al., 1998). Three models have been proposed for the phosphorylation of 
the hydrophobic motif in PKB (Figure 1.10). Phosphorylation of Thr308 and Ser473 
residues on PKB leads to its activation.
PKB has now been demonstrated to phosphorylate a number of proteins, particularly 
those involved in regulating glucose metabolism and cell survival, such as GSK-3. 
In particular, PDK-1 and PKB as well as the PI3K homologue, mammalian target of 





Figure 1.10. Three models for the phosphorylation o f the hydrophobic m otif in Akt/PKB. Left 
panel, Ser473 in the hydrophobic motif o f Akt/PKB is regulated by autophosphorylation as a 
consequence o f the PDK-1 step (i.e. Thr308 phosphorylation). Middle panel, a putative PDK2 
functions as a heterologous kinase for Ser473 phosphorylation. Right panel, interaction of proteins 
(e.g., PRK2) with PIF-containing sequences with the PIF-binding pocket in PDK-1, converts PDK-1 
into a Ser473 kinase (Toker and Newton, 2000). KD, kinase domian; PDF, PDK1 interacting factor; 
PRK2, protein kinase C-related kinase 2.
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Approaches utilised to dissect PI3Kfunction
There are three approaches by which the role of PI3K in functional responses can be 
defined-
1. Pharmacological- Wortmannin and the structurally unrelated inhibitor 
LY294002 have high selectivity for PI3Ks (Arcaro and Wymann, 1993; 
Vlahos et al., 1994) and have facilitated experiments on the role of PI3K in 
various cellular responses in vitro (Walker et al., 2000), but it has been 
difficult to study the function of this enzyme family in vivo. The first in vivo 
evidence for the role of PI3Ks in the immune system came from studies in 
which rats were exposed to wortmannin. These studies indicated that 
wortmannin is a potent immune suppressor, but that it is also highly toxic 
(Gunther et al., 1989a; 1989b). Since wortmannin and LY294002 cannot 
discriminate between different isoforms of PI3K, and as PI3Ks are crucial for 
all organ systems, genetic approaches based on gene-manipulated mouse 
systems has provided a breakthrough in elucidating the in vivo role of the 
individual PI3K enzymes.
2. Molecular approaches- There are other methods of inhibiting PI3K such as 
molecular methods like micro-injection of antibodies or transferring 
dominant negative forms of PI3K into cells (Benistant et al., 2000; Sasaki et 
al., 2000; Stein and Waterfield, 2000; Weaver and Ward, 2001). Similar 
transfer methods can be used to manipulate PI3K by causing its over­
expression, and these may be placed under the control of an environmental 
agent such as an antibiotic in the culture media (Craddock et al., 1999).
3. Genetic approaches- the analysis of transgenic and gene-targetted mice that 
have modifications that interfere with or enhance PI3K activation has shed
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considerable new light onto the role of PI3K. Table 1.3 summarises the
different approaches employed and their outcome.
| E S ^
p llO a Die in utero Important in Cell 
growth/survival
(Bi et al., 1999)
p iio p Die in utero Important in Cell 
growth/survival




Grow normally Distinct roles in fetal 
development
(Bi et al., 2002)
p i 105 Grow normally (Sasaki et al., 
2000; Laffargue 
et al., 2002; Jou et 
al., 2002; 
Okkenhaug et al., 
2002)
pllOy Grow normally (Sasaki et al., 
2000; Laffargue 
et al., 2002; Jou et 
al., 2002; 
Okkenhaug et al., 
2002)
p85 deficient mice 
expressing p55a 
and p50a
Viable (Suzuki et al., 
1999; Terauchi et 
al., 1999)
p85a/p55a/p50a Die after birth p55a and p50cx have 
an essential role in 
vivo
(Fruman et al., 
1999)
p850 viable No apparent defects (Ueki et al., 2002)
SHIP Bom-but have a 
shorter life span 
than wild-type
(Helgason et al., 
1998; Liu et al., 
1999)
PTEN Embryonic lethal (Di Cristofano et 
al., 1998; Suzuki 
et al., 1998)
Class II Not yet generated
Class III Not yet generated
Table 1.3. Summaries of the different genetic approaches employed to identify the role of PI3K 
isoforms and their outcome (Koyasu, 2003)
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1.4.2. Mitogen-activated protein kinase (MAPK)
The MAPKs are a major group of pathways which transduce extracellular signals to 
intracellular responses. All subfamilies participate in three tier protein 
phosphorylation cascades (shown in Figure 1.11) that serve to mediate diverse 
cellular processes in response to extracellular signals. The members of the MAPK 
pathways share core features concerning their consitutent kinases:
1. All MAP kinases are activated via phosphorylation of both Thr and Tyr 
in a Thr-Xxx-Tyr motif.
2. This activation is catalysed by a dual specificity serine-threonine MAP 
kinase kinase (MAPKK) which, in turn, is phosphorylated and activated 
by an upstream MAP kinase kinase kinase (MAPKKK)
3. Once activated all MAP kinases can phosphorylate and activate other 
kinases or transcription factors, in the presence of ATP, to exert their 
biological effects.
There are three main categories of MAPK -  extracellular-regulated protein kinase 
(ERK or p42/44), p38 MAP kinase and c-Jun NH2-terminal kinase (JNK or p46/54) 
-  and these shall be considered in turn below.
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MAP kinase kinase kinase Raf-1 MEKK1-4 MEKK,others
1 1 1
MAP kinase kinase MEK 1/2 MKK 4,7 MKK 3,6
I 1 i
MAP kinase ERK 1/2 JNK 1/2 d38 a-5
1  1 1
Transcription factors Elk-1, Fos Jun ATF2
Figure 1.11. MAP kinase superfamily of serine/threonine kinases. Each MAP kinase family 
member-ERK, JNK and p38- is activated by successive activation of a MAP kinase kinase kinase and 
MAP kinase kinase.
ERK
Extracellular-regulated protein kinase (ERK) was the initial classical MAPK and is 
activated in response to proliferation and differentiation factors, mediated by 
receptor tyrosine kinases, heterotrimeric G protein-coupled receptors, cytokine 
receptors and integrins. Receptor ligand interaction promotes the recruitment of the 
small guanosine triphosphatase (GTPase) Ras, which then activates the serine- 
threonine kinase raf, which can activate members of the MAPK /ERK kinase (MEK) 
family. ERK1 (p44) and ERK2 (p42) are activated by phosphorylation at residues
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Thr202 and Try204 by MEK1 and MEK2 which are acting as MAPKKs. In this 
context raf is acting as a MAPKKK.
Downstream of ERK activation are its effectors, which include regulatory molecules, 
the transcription factors ATF2 and Elk, and the MAP kinase activated protein 
kinases (MAPKAPKs) 1 and 5. Thus, ERK2 is a crucial element for maintenance of 
cell homeostasis in response to changes in extracellular environment. Study of the 
cellular effects of ERKs has been made possible by the use of small specific 
MEK1/2 inhibitors such as PD90859 (Alessi et al., 1995).
p38
The p38 MAP kinase is often grouped with c-Jun NH2-terminal kinase (JNK) as the 
stress activated protein kinases. They are both involved in regulating the cells 
responses to stress, inflammation and also apoptosis pathways. The p38 MAP 
kinase isoforms (a, p, P2, y and 6 ) share a Thr-Gly-Tyr motif and are preferentially 
activated by pro-inflammatory cytokines (TNFa and IL-1), UV light, as well as heat 
and osmotic shock. There is some confusion over the precise details of the 
activating pathways for p38 MAP kinase which stems from the convergence of many 
upstream kinase dependent pathways (Herlaar and Brown, 1999; Ichijo, 1999). 
However p38 is activated by the MAPKKs, MKK3 and MKK6 , which act as points 
of convergence for MAPKKK pathways.
The effects of p38 activation are mediated by activation of transcription factors such 
as ATF2 and Elkl as well as activating MAPKAPKs 2, 3 and 5. The study of the
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functional consequences of its activation is assisted by the use of specific inhibitors 
of the pyridinyl imidazole family, such as SB203580 (Young et al., 1997; Davies et 
al., 2000) and SB202190.
JNK
There are many similarities between p38 MAP kinase and JNK. They are both 
activated by similar cellular stresses and have similar functional consequences. 
JNKs are phosphorylated on their common Thr-Pro-Tyr motif by MKK4 and MKK7 
which, as with p38, integrate a wide variety of triggering stimuli.
Downstream of JNK activation, and mediating its effects, is activation of the 
transcription factors API, ATF2 and Elkl. The functional consequences of this are 
believed to be similar to p38 activation. Again, the study of cellular effects of JNK 
have been made possible by the use of newly available JNK inhibitors such as 
SP600125- a reversible ATP-competitive inhibitor (Bennett et al., 2001). A cell- 
permeable, biologically active peptide consisting of a carboxyl terminal sequence 
derived from the JNK binding protein and an amino terminal peptide containing the 
HIV-TAT 48-57 sequence has also been developed. This peptide diminishes JNK 
signalling by blocking the activation of the transcription factor c-jun. This effect 
appears to be due to inhibition of phosphorylation of the activation domains of JNK 
(Bonny et al., 2001; Barr et al., 2002)
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1.4.3. Transcription factors 
Nuclear factor kB (NFkB)
NFkB is an inducible transcription factor first described as a B cell-specific factor 
that binds to a lObp motif in the Ig k  light chain intronic enhancer (Sen and 
Baltimore, 1986a; Sen and Baltimore, 1986b). NFkB is present in all cells in a 
resting state in the cytoplasm; only when it is activated and translocated to the 
nucleus is the usual sequence of events generated. Currently, NFkB consists of a 
family of Rel homology domain (RHD)-containing proteins: Rel A (p65), Rel B, c- 
Rel, p50 (NFkBI), and p52 (NFkB2) (Figure 1.12). NFkBI and NFkB2 are 
synthesized as large precursors of 105 (p i05) and lOOkDa (plOO) respectively. 
These are partially proteolysed by the proteasome (termed processing), to produce 
the active NFkBI p50 and NFkB2 p52 subunits. RelA and c-Rel both have C- 
terminal transactivation domains in their RHDs and can strongly activate 
transcription from NFkB binding sites in target genes. RelB also contains a 
transactivation domain in its RHD and can function as an NFkB activator when 
complexed with p50 or p52. However, RelB/RelA heterodimeric complexes are 
inhibitory, since they cannot bind DNA (Marienfeld et al., 2003). NFkBI p50 and 
NFkB2 p52 lack a transactivation domain, and can only promote transcription when 
heterodimerized with a transactivating Rel subunit (Li and Verma, 2002). 
Homodimers of p50 and p52 function as transcriptional repressors, but can stimulate 
transcription when bound to the hcB-like nuclear protein BCL-3 (Franzoso et al., 
1992; Bours et al., 1993; Fujita et al., 1993).
33
Chapter 1 -  Introduction




















o o o o o o o







0 0 0 0 0 — 317 
0 0 0 — 0 0 0 — * 1  
o o o o o o o -----------
-O O O O O O  5“
-607
< X X X X X X X = > - 446
Figure 1.12. The family of mammalian NFkB/REL and IkB proteins (acquired from (Chen and 
Greene, 2004). The amino-terminal portion of the RHD is responsible for both backbone and 
sequence-specific contacts within the major groove of the kB enhancer. The carboxy-terminal portion 
of the RHD mediates dimerization with other NFicB/REL-family members and forms the site for 
physical docking to the IkBs (Baeuerle, 1998). The p i05 and p i00 proteins contain ankyrin repeats 
(indicated by pink circles), as well as glycine-rich regions (GRRs). The GRRs are important for co- 
translational processing of pl05 to p50 (Lin et al., 1998) and post-translational processing of plOO to 
p52 (Senftleben et al., 2001; Xiao et al., 2001; Claudio et al., 2002; Coope et al., 2002). 
Phosphorylation of RELA at serines (S)276, S311, S529 and/or S536 is required for optimal NFkB 
transcriptional activity. Acetylation of RELA at lysines (K)122, K123, K218, K221 and K310 
regulates distinct functions of NFkB, including DNA binding, IicBa association and RELA-mediated 
transactivation. The leucine zipper (LZ) of RELB is required for transactivation by RELB. NFkB 
action is linked to the biology of its inhibitory proteins, the IkBs (see part b of the figure). A hallmark 
of these IkB proteins is an ankyrin-repeat domain, which mediates the assembly with REL proteins. 
When bound by IkBoi, the nuclear localization signal (NLS) of RELA is masked, and RELA cannot 
localize to the nucleus or bind to DNA. Phosphorylation of two serine residues (SS) at the amino- 
terminal region of IicBa triggers polyubiquitylation and proteasome-mediated degradation of hcBa 
(Chen and Greene, 2004).
In unstimulated cells, NFkB dimers are inactive, since they are sequestered in the 
cytoplasm by interaction with inhibitory proteins termed IkBs (inhibitors of NFkB) 
(Ghosh et al., 1998). In response to stimulation with agonists, IkBs are 
proteolytically degraded by the proteasome, releasing associated NFkB dimers to
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translocate into the nucleus and modulate gene expression (Figure 1.13). The 
transcriptional activity of certain NFkB dimers is additionally regulated by 
phosphorylation, providing an extra level of control of NFkB activation (Chen and 
Greene, 2004).
Stimulu
W W W M  ? 9 9 9 9 9 <Dx5xnxDx?
i *
O phosphorylation ubiquitination
Figure 1.13. Model of generic NFkB activation pathway. Various stimuli induce the 
phosphorylation and subsequent polyubiquitination of IkBs, which are then targeted for degradation. 
Associated NFkB dimers are thereby released to translocate into the nucleus, where they bind to the 
promoter regions of NFkB responsive genes to modulate their expression. The transactivating 
capacity of nuclear NFkB dimmers can also be regulated by phosphorylation.
The Ik B s  comprise a family of ankyrin-domain-containing proteins that keep N F k B  
in its inactive state within the cytoplasm by masking nuclear localization signal 
domains (Siebenlist et al., 1994; Miyamoto and Verma, 1995). This family includes 
IkBoc, IkB |3 , iKBy, Ik B e , bcl-3, pl05 and plOO (Figure 1.12). IkB oi interacts only 
weakly with p50 homodimers, and does not efficiently prevent their translocation to 
the nucleus (Siebenlist et al., 1994)
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Classical (canonical) N F kB  pathway
The prototype NFkB heterodimer is composed of the RelA (p65) and NFkB 1 (p50)
subunits. This combination, which is the component of the NFkB canonical
(classical) pathway, is the most potent gene activator among the NFkB family
(Figure 1.14).
Canonical p i 05 Alternative (p100)
TNFrt,IL-1 TNFa.lL-1. LTa.LTfl
LP3, IP S  CD40L,
CD40L 8AFF,
RANKL
J(MEKK3.TAK1) J  MAP3-K? I NIK
NEMO NEMO f




Figure 1.14 Three NFkB pathways. The canonical pathway (left) is activated by a large number of 
agonists, a few of which are listed. Activation of this pathway depends on the IKK complex (IKK1 
IKK2-NEMO), which phosphorylates LdBa to induce its rapid degradation. (IkBP and IkBe are 
similarly regulated by IKK.) This pathway is essential for immune responses, inflammation and 
promoting cell survival. The alternative NFkB pathway (right) is activated a limited number of 
agonists and is important for secondary lymphoid organogenesis, maturation of B-cells and adaptive 
humoral immunity. This pathway requires NIK and IKK1 and induces the slow processing of p i00 to 
p52, resulting in nuclear translocation of p52/RelB heterodimers. The pl05 pathway (centre) is 
specifically involved in immune and inflammatory responses. Agonist activation of this pathway 
induces phosphorylation of the p i05 PEST region by the classical IKK complex. This triggers p i05 
polyubiquitination and subsequent degradation, releasing p50 homodimers which undergo nuclear 
translocation and positively or negatively regulate gene transcription (Beinke and Ley, 2004).
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The prototypical IkB protein is IkBoc, which binds to the p65 subunit of NFkB in the 
cytoplasm of unstimulated cells keeping it in an inactive state. Pro-inflammatory 
cytokines such as TNFa triggers the activation of a complex of IKK, which includes 
the scaffold protein NFkB essential modulator (NEMO; also named IKKy) 
(Yamaoka et al., 1998), EKKcc and IKKp kinases (Zandi et al., 1997). Once 
activated, the IKK complex phosphorylates the Ser32 and Ser36 residues of IkB cx. 
This step initiates the degradation, by ubiquitination, of IkBoc which allows the 
release of free NFkB. This reveals its nuclear translocation signal resulting in 
transportation to the nucleus and NFkB dependent gene transcription. Among the 
many genes with a NFkB response element is the gene for IkBoc and p i05 which is 
subsequently resynthesised (Cogswell et al., 1993; Ito et al., 1994) after activation. 
Increased production of inhibitory units presumably helps trap NFkB in the 
cytoplasmic compartment, and downregulates activated NFkB, thus terminating new 
cytokine transcription and limiting the inflammatory response by negative feedback. 
An interesting effect of increased production of p i05 is that p50 homodimer 
formation is also increased, which may diminish NFKB-mediated responses to 
subsequent stimuli. Since p50 homodimers do not bind efficiently to IkB, and lack 
transcription-activation domains, they can translocate to the nucleus and function as 
inhibitors of NFkB mediated gene expression by competing with other Rel proteins 
for access to NFkB binding sites.
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Figure 1.15. Regulation of NFkB (RelA/p50) activation following cell stim ulation with TNF-a 
IL -lp , or endotoxin (LPS). Binding of these agents at the cell surface signals phosphorylation and 
addition of ubiquitin (Ub) to the inhibitory unit ( I k B - oi or p i05). These events lead to recognition and 
proteolysis o f the inhibitor, exposing the nuclear localization signal (NLS) on p50 and RelA. 
RelA/p50 heterodimers bind to specific motifs in the promoter regions o f cytokine genes, and initiate 
transcription. Cytokine mRNA is translated into proteins, which are secreted by cells. TNF-a and IL- 
lp  can act locally to amplify NFkB activation. Nuclear binding of NFkB also stimulates production 
of IxB-a and p 105, which inhibit further activation of NFkB. Increased p 105 production favors the 
formation of p50 homodimers, which can inhibit NFkB action by entering the nucleus and competing 
for NFkB binding sites (Blackwell and Christman, 1997).
Positive feedback may occur through extracellular mechanisms that serve to amplify 
inflammatory signals. NFkB activation enhances the transcription of TNFa and IL- 
lp, and both of these cytokines are in turn known to activate NFkB. Both negative 
and positive feedback control of NFkB is outlined in F igure 1.15.
All members of the IkB family do not follow the same paradigm as iKBa. IkBP is 
not regulated by NFkB and does not have this intrinsic negative feedback resulting
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in persisting activation. Furthermore there is evidence of post-translational 
modification of RelA phosphorylation state providing an alternative mechanism of 
regulating NFkB (Egan et al., 1999).
Alternative NFkB pathway
In contrast to this canonical pathway which is activated by multiple stimuli, an 
alternative NFkB activation pathway has been described and is NEMO-independent 
(Figure 1.14). This pathway is activated by B cell-activating factor receptor, 
lymphotoxin-P receptor, CD40, and latent membrane protein-1 of the Epstein-Barr 
virus (Cao et al., 2001; Dejardin et al., 2002). This signalling pathway relies on the 
recruitment of TRAF proteins to the membrane and on the NFKB-inducing kinase 
(NIK) (Xiao et al., 2001), which activates an IKKa homodimer-the substrate of 
which is p i00. Once phosphorylated p i00 is ubiquitinated and cleaved to generate 
the NFkB protein p52, which moves as a heterodimer with RelB into the nucleus.
plOS NFkB pathway
Cellular levels of pi 05 are regulated by two distinct proteolytic mechanisms which 
are mediated by the proteasome. Processing of p i05 to generate p50 occurs 
constitutively, resulting in similar levels of p i05 and p50 in most cell types (Karin 
and Ben Neriah, 2000). By contrast, agonist stimulation predominantly triggers 
complete degradation of p i05, which releases associated Rel subunits to translocate 
into the nucleus, p i05 can retain RelA, c-Rel and p50, but not RelB, in the 
cytoplasm (Rice et al., 1992; Mercurio et al., 1993; Solan et al., 2002). However,
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genetic studies in mice suggest that p i05 is only essential for cytoplasmic retention 
of p50 (Ishikawa et al., 1998). It is unclear whether p i05 binds directly to p50 
homodimers or p50 monomers which subsequently dimerize upon release. IkB a  
binds inefficiently to p50 homodimers (Liou et al., 1992), but can bind to p50, which 
is heterodimerized with other Rel subunits, such as RelA (Figure 1.14).
Regulation o f genes by NFkB pathway
Activated NFkB transcriptionally regulates a large number of genes including many 
immediate early (IE) genes. These include iNOS, IL-8 , RANTES, TNFa, IL-lp, IL- 
6 , ICAM-1 and COX-2. With regard to COX-2, its induction has been shown to be 
NFkB dependent in A549 lung epithelial cells (Newton et al., 1997). The genes 
which are transcriptionally activated by NFkB are generally pro-inflammatory and 
include cytokines that activate NFkB allowing potential amplification of the 
inflammatory response that needs to be tightly regulated. Furthermore, NFkB often 
functions in cooperation with other transcription factors, such as AP-1 and C/EBP, 
that are also involved in regulation of inflammatory and immune genes (Stein and 
Baldwin, Jr., 1993; Stein et al., 1993)
Role o f NFkB in the resolution o f inflammation?
In contrast to the well-documented pro-inflammatory role of NFkB, Lawrence et al., 
(2001) described an active role for NFkB in the resolution of inflammation (Figure
1.16).
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Figure 1.16. Hypothetical model of an alternative anti-inflammatory pathway of NFkB 
activation. Broad-spectrum nuclear factor-tcB (NFkB) inhibitors that target the proteasome or 
undefined upstream signalling events could block potentially beneficial anti-inflammatory pathways 
of NFkB activation (Lawrence et al., 2002). For example, they might block the processing of pl05 to 
p50 and the assembly of p50-p50 homodimer complexes, which negatively regulate pro- 
inflammatory gene expression and might coordinate the expression of an alternative set of NFkB  
target genes through interaction with distinct co-activators. The specificity of cyclopentenone 
prostaglandins (cyPGs) for inhibitor of NFkB kinase-[3 (IKK0) might prevent undesirable side effects 
of inhibitors through the inhibition of other IKKs or IKK-independent pathways for NFkB activation. 
Anti-oxidants have been shown to inhibit many stages of the NFkB pathway, including the activation 
of upstream IKK kinases and IkB kinase activity. P, phosphate; Ub, ubiquitin.
This involved the recruitment of alternative DNA-binding complexes that lack 
transactivation domains, such as p50-p50 homodimers. Broad-spectrum inhibitors of
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the N F kB pathway, such as antioxidants and proteasome inhibitors, had the expected 
anti-inflammatory actions during the initiation of inflammation; however, when they 
were administered after the onset of inflammation, these inhibitors prevented the 
resolution of inflammation, which was associated with the inhibition of leukocyte 
apoptosis. The authors hypothesize that this alternative N F kB  pathway promotes 
leukocyte apoptosis by the transactivation of pro-apoptotic target genes with co­
ach vating factors. Alternatively, active N F kB  DNA binding complexes that lack 
transactivation domains might act as dominant-negative inhibitors of anti-apoptotic 
gene expression (Figure 1.16). CyPGs might repress the activation of IKKp, leading 
to a predominance of anti-inflammatory signalling pathways that are regulated 
independently of IKK or by an alternative IKK complex that is not sensitive to 
inhibition by cyPGs (Lawrence et al., 2002)
Activating protein-1 (AP-1)
AP-1 is a heterodimer of Fos and Jun, and is a member of the basic leucine zipper 
(bZIP) transcription family, characterized by a basic leucine-rich area that is 
involved with dimerization with other transcription factors (Figure 1.17).
Heterodimer of Fos/Jun proteins 













Figure 1.17. Activator protein (AP)-l is a heterodim er of Fos and Jun proteins
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AP-1 is a collection of related transcription factors belonging to the Fos (cFos, FosB, 
Fral, Fra2) and Jun (c-Jun, JunB, JunD) families that dimerize in various 
combinations through their leucine zipper region. Fos/Jun heterodimers bind with the 
greatest affinity and are the predominant form of AP-1 in most cells, whereas 
Jun/Jun homodimers bind with a low affinity.
AP-1 may be activated via PKC and by various cytokines, including TNFa and IL- 
lp  via several types of protein tyrosine kinase and MAPK, which themselves 
activate a cascade of intracellular kinases (Karin, 1995; Karin et al., 1997). Both 
TNFa and IL-ip activate TRAF, which subsequently activates MAP kinases (Eder,
1997). Recent studies suggest that there may be interactions between the AP-1 
activating pathway and NFkB pathways (Eder, 1997).
AP-1 activation in human lung after stimulation with PMA, TNFa and IL-lp has 
been demonstrated (Adcock et al., 1994a; Adcock et al., 1994b). There is evidence 
for increased expression of c-Fos in epithelial cells in asthmatic airways (Demoly et 
al., 1992), and many of the stimuli relevant to asthma that activate NFkB will also 
activate AP-1. AP-1 like NFkB, regulates many of the inflammatory and immune 
genes that are overexpressed in asthma. Indeed, many of these genes require the 
simultaneous activation of both the transcription factors that work together 
cooperatively.
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1.4.4. Signalling pathways downstream of cytokine receptors
Many signalling pathways are activated downstream of cytokine receptors. Although 
the cytokines TNFa and IL-lp have been introduced in terms of their biology, this 
next section describes TNFa and IL-ip receptors and how they couple to the 
signalling pathways described above.
TNFa receptors and signalling
There are two distinct TNFa receptors which are also part of a larger family of 
related receptors. These receptors, TNFR1 (p55 or CD 120a) and TNFR2 (p75 or 
CD 120b), are expressed simultaneously on most cell types and it is therefore 
difficult to assign distinct signalling functions to each receptor (Narumiya and 
Fukushima, 1986; Orlinick and Chao, 1998) However experiments using TNFa-/- 
and TNFR1-/- knockout mice have similar phenotypes with markedly reduced 
sensitivity to LPS after D-galactosamine priming (Pfeffer et al., 1993; Pasparakis et 
al., 1996). Furthermore the TNFa-/- phenotype can be restored to that of wild type 
mice by the preparation of a transgenic mouse with human TNFa which can only 
bind TNFR (Pasparakis et al., 1996). Such studies indicate a central role for TNFR1 
in TNFa signaling. The role of TNFR2 appears to be more complex. Evidence 
shows that the intracellular signals that couple TNFR1 include an intracellular signal 
protein termed TNF receptor-associated death domain (Hsu et al., 1995). Upon 
engagement of TNFR1, this intracellular signal protein acts as an adapter by 
recruiting the downstream transducer TNF-receptor associated factor (TRAF)-2, 
which stimulates NFkB (Hsu et al., 1995; Hsu et al., 1996)
44
Chapter 1 - Introduction
Receptor-mediated multimerization of TRAFs has been found to activate multiple 
signalling pathways (Figure 1.18). The best described of these are the JNK and 
NFkB pathways which play a major role in the biological functions elicited by 
TNFR family members. In addition to these two pathways, reports have also 
documented TRAF-mediated activation of the ERK, p38 and PI3K pathways.
The TNFa promoter itself contains NFkB and AP-1 binding sites and is subject to 
positive autoregulation, a property that is important for the amplification of 
inflammatory responses. Once in the nucleus, NFkB transcriptional activity can be 
modulated further through phosphorylation by various protein kinases that are TNFa 
responsive, such as the p38 subgroup, providing a point for cross-talk with other 
signalling pathways. AP-1 is a heterogeneous collection of dimeric transcription 
factors comprising Jun, Fos and ATF subunits (as outlined above), whose activity is 
regulated by multiple mechanisms, including phosphorylation by various MAPK 
(Karin et al., 1997). JNKs are particularly relevant to TNFa-mediated induction of 
AP-1 activity, although the p38 MAPKs also affect AP-1 activity ( Han et al., 1997; 
Karin et al., 1997)
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Figure 1.18 Signalling pathways activated by TRAFs. This model depicts a partial view of the 
known pathways activated by TRAF proteins. TRAFs activate the JNK, p38, ERK, PI3K and the 
types 1 (classical) and 2 (atypical) NFkB pathways. TRAF-mediated activation of the JNK and NFkB 
pathways has been studied extensively and these pathways are depicted in detail (Dempsey et al., 
2003).
IL-1 receptors and signalling
The IL-1R1 is the IL-1 receptor mediating functional responses and shares a 45% 
homology with the Drosophila Toll gene. When the membrane bound form binds to 
IL-1 a  or (3 it associates with the IL-lRAcP to form a signalling complex which lacks 
any intrinsic kinase activity. It does however have a binding site at amino acids 513-
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520 for IL-1R1 associated kinase (IRAK) which can phosphorylate a lOOkDa 
substrate and is partly responsible for downstream activation of NFkB, MAP 
kinases, and activation of the AP-1 transcription factor. However there is also 
evidence that IL-1 can activate PI3K and, as with TNFa, activation of NFkB may be 
PI3K dependent (Reddy et al., 2000).
1.4.5. Role of signalling pathways in respiratory diseases 
PI3K and asthma
Although reversible airway narrowing leading to wheeze, cough and shortness of 
breath are hallmark features of asthma, patients with longstanding and severe disease 
can develop fixed airways obstruction that is associated with structural changes 
within the airway wall. The most prominent feature of the remodelling airway is an 
increase in airway smooth muscle (ASM). It is clear from a number of diverse 
approaches that the PI3K pathway plays an important role in regulating progression 
cell cycle control and thus airway remodelling (Walker et al., 1998; Krymskaya et 
al., 1999). In addition, p70S6K, a downstream target of PI3K/PKB, has been shown to 
be an important mediator in human ASM cell mitogenesis (Krymskaya et al., 1999).
PI3K is thought to contribute to the pathogenesis of asthma by effecting the 
recruitment, activation and apoptosis of inflammatory cells. The role of Class LA 
PI3K in antigen-induced airway inflammation and hyperresponsiveness has been 
investigated by i.p. administration of Ap85 protein, a dominant negative form of
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p85a, fused to HIV-TAT (TAT-Ap85) into mice (Myou et al., 2003). These authors 
showed that PI3K has a regulatory role in Th2-cell cytokine secretion, airway 
inflammation and airway hyperresponsiveness in mice (Myou et al., 2003).
PI3K and neutrophils
Neutrophils are recruited to the lungs in many respiratory disease states including 
fatal asthma. They cause tissue damage by their capacity to release toxic oxygen 
radicals (generated by the NADPH oxidase complex), the exocytosis of granules 
containing highly histotoxic compounds such as elastase and collagenases, and the 
elaboration and release of additional pro-inflammatory cytokines. PI3K have been 
shown to be key regulators of both neutrophil recruitment and activation. In mice 
lacking the catalytic subunit of the myeloid restricted PI3Ky, neutrophil migration to 
the inflamed peritoneum was severely compromised (Hirsch et al., 2000; Sasaki et 
al., 2000). The accumulation of PtdIns(3 ,4 ,5 )P3 also correlated precisely with 
respiratory burst activity, in that neutrophil priming by agents such as TNFa 
markedly enhanced both the size and the duration of the release of superoxide anions 
and the accumulation of PtdIns(3 ,4 ,5 )P3 (Condliffe et al., 1998). In these cells PI3K 
inhibitors abolish the production of oxygen radicals induced by physiological 
agonists; neutrophils from PI3Ky knockout mice exhibit a diminished respiratory 
burst, with residual activity most probably attributed to the action of remaining Class 
IA PI3K.
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PI3K and eosinophils
Eosinophils accumulate in the bronchial tree and lung parenchyma in a number of 
disease states including asthma. Toxic eosinophil-derived mediators such as 
eosinophil cationic protein, major basic protein and oxygen radicals can damage the 
airway epithelium and are thought to contribute significantly to airway 
hyperresponsiveness. The migration of eosinophils to a number of chemoattractants 
seems to be sensitive to wortmannin (Dunzendorfer et al., 1998). The role of PI3K in 
eosinophil degranulation is not known, but these enzymes are required for activation 
of the eosinophil NADPH oxidase complex (Hofmann et al., 2000).
PI3K and macrophages
Alveolar macrophages undertake a number of key host defence functions within the 
lung. These include the phagocytosis of inhaled particles and respiratory pathogens, 
antigen presentation, and the generation of inflammatory cytokines. Additionally, 
they may be important in the resolution of acute inflammation by the ingestion of 
apoptotic neutrophils. So far, although few studies have addressed the role of PI3K 
in the alveolar macrophage, such data are available for monocyte-derived 
macrophages, macrophage cell lines and murine peritoneal macrophages. Murine 
PI3Ky-null macrophages show decreased migration towards a variety of chemotactic 
agents, and greatly diminished recruitment to the inflamed peritoneum (Hirsch et al., 
2000). The induction of cytokine gene expression in monocytes stimulated by 
formylated peptide has also been shown to be sensitive to PI3K inhibition (Pan et al., 
2000). More importantly, the consequence of excessive PI3K activation has also 
been explored; mice deficient in SHIP suffer from lethal infiltration of the lungs by
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myeloid cells, principally macrophages (Helgason et al., 1998). As with neutrophils 
and eosinophils, it seems that one or more of the PI3Ks is required for macrophage 
recruitment to the lung and for at least a subset of activation responses.
PI3K and epithelial cells
Although comparatively little is known about the function of the PI3Ks in other 
pulmonary cells, several reports have indicated the global importance of this 
signalling pathway in other settings in the lung. For example, PI3K has been 
reported to mediate lung epithelial cell differentiation and surfactant protein 
expression in fibroblasts induced by growth factor-2 (Matsui et al., 1999), although 
subsequent reports have suggested that PI3K inhibits surfactant secretion from type 
II alveolar cells (White and Strayer, 2000). The activation of PI3K by the pro- 
inflammatory Thl cytokine TNFa has been shown in a number of cell systems, 
including epithelial cells (Hanna et al., 1999; Pastorino et al., 1999).
In apparent conflict with the pro-inflammatory role of PI3K in inflammation outlined 
previously, is the activation of PI3K in intestinal epithelial cells by the Th2 cytokine 
IL-13 which in some settings is thought to be regarded as being anti-inflammatory 
(Wright et al., 1997). This is supported by work in other systems demonstrating the 
activation of PI3K by IL-13 and other Th2 cytokines including IL-4 and IL-10 
(Mirmonsef et al., 1999; Ceponis et al., 2000). In the intestinal epithelium the 
activation of PI3K by IL-13 was shown to be the mechanism mediating the 
inhibition of iNOS by this cytokine (Wright et al., 1997).
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MAPK and asthma
The ERK pathway in addition to the PI3K pathway appear to be key positive 
regulators of airway smooth muscle mitogenesis. Bronchoalveolar lavage fluid from 
asthmatic airways has been shown to increase ERK activation (Naureckas et al.,
1999). Cui et al. (2002), suggested the role of both ERK1/2 and p38 MAP kinase in 
eotaxin-induced cytokine production in bronchial epithelial cells. Thus these 
observations suggest the MAPK pathway plays a role in asthma.
Overstretching the airways during positive pressure mechanical ventilation or attacks 
of acute severe asthma are associated with important biologic responses(Oudin and 
Pugin, 2002). These authors showed that the MAPK pathway, and p38 in particular, 
are proximal and key intracellular signaling molecules mediating cell activation in 
response to cyclic stretch, a mechanical strain similar to that applied to lung 
epithelial cells during mechanical ventilation.
Since the MAPK pathways play a crucial role in the activation of transcription 
factors it is not surprising that these pathways therefore are important in the 
induction of pro-inflammatory mediators in respiratory diseases. The MAPK cascade 
is one of the most important signalling pathways involved in expression of COX-2 
gene expression and PG biosynthesis, and contributes to the induction of COX-2 
gene concertedly or independently (Su and Karin, 1996). Once activated, MAPKs 
can phosphorylate and activate transcription factors which regulate gene expression. 
IL-ip rapidly activates JNK/SAPK and p38 MAPK and also induces COX-2 
expression (Guan et al., 1998). The COX-2 gene is an important Ras target.
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Furthermore, studies suggest induction of COX-2 by some mitogens requires 
activation of Ras/Racl/MEKKl/JNKkinase/JNK and/or the activation of 
Ras/Rafl/MAPKK/ERK signal transduction pathway.
The ERK pathway has also been shown to be of particular importance in the 
induction of cyclin D l, IL-1 p, IL-5R, IL-6 , IL-8 , eotaxin, and RANTES. In addition, 
the p38 pathway has been shown to be involved in the induction of IL-6 , IL-8 , 
eotaxin, and RANTES (Gerthoffer and Singer, 2003).
1.5. Peroxisome proliferators activated receptors
PPARy ligands have shown been shown to modulate inflammation via regulation of 
COX-2. Furthermore the COX-2 promoter is thought to have a peroxisome 
proliferator response element (PPRE) (Meade et al., 1999). This next section 
describes PPARs and in particular PPARy and gives an overview of how this 
receptor is thought to regulate the inflammation and the signalling mechanisms 
currently known to be involved.
1.5.1. Background
As previously mentioned there are three isoforms of PPAR- PPARa, PPAR8  
(previously known as PPARP) and PPARy. The PPARy 1 and PPARy2 subisoforms 
differ only in that y2 has 30 additional amino acids at its N terminus due to 
differential promoter usage within the same gene and subsequent alternative RNA
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processing. All isoforms have been cloned and characterized by their distinct 
expression pattern, different ligand binding specificity and metabolic functions.
Structure
PPARs have a similar structural organization to other nuclear hormone receptors 
(Figure 1.19).
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Figure 1.19. Structure of nuclear hormone receptors.
The N-terminal A/B domain contains a ligand independent trans-activation domain, 
termed activation function 1 (AF-1). This domain plays an important role in 
regulating PPAR activity through both phosphorylation by MAPK and interdomain 
communication (Hu et al., 1996; Shao et al., 1998; Juge-Aubry et al., 1999). This 
region is followed by the C domain which encodes the DNA binding domain that 
includes two zinc fingers. The C domain is responsible for the binding of PPAR 
receptor to PPRE in the promoter region of target genes. The D hinge region, which 
follows the C domain, is a docking domain for cofactors (Guan and Breyer, 2001). 
At the carboxyl terminus is a dimerization and ligand binding domain, which has a 
key ligand dependent trans-activation function called AF-2 (Nolte et al., 1998a;
53
Chapter 1 - Introduction
Guan and Breyer, 2001), critical for both ligand-binding and recruitment of PPAR 
cofactors.
PPAR isoforms share a high degree of amino acid sequence similarity, both within 
their DNA- and ligand-binding domains (Kliewer et al., 1994) (Figure 1.20). This is 
reflected in functional similarities in that the receptors are activated by structurally 
related compounds and bind as heterodimers with a retinoid X receptor partner to a 
PPRE. Nevertheless, the three PPAR subtypes appear to serve different roles in vivo. 
They exhibit markedly different tissue distributions (Jones et al., 1995; Braissant et 
al., 1996), have differing affinities for different PPREs (Brun et al., 1996), and are 
activated to different extents by different activators/ligands (Kliewer et al., 1994; 













Figure 1.20. PPAR isoforms share a common domain structure. Human PPAR5, PPARa, and 
PPARy are represented in linear fashion to display a conserved domain structure with a DNA binding 
domain (DBD) and ligand binding domain (LBD). Amino acid numbers are above each receptor, 
whereas percent identity at the amino acid level is displayed within each domain. PPARyl and 
PPARy2 are distinguished by 30 extra amino acids at the N terminus of PPARy2 (adapted from 
(Rosen and Spiegelman, 2001))
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Heterodimerization
PPARs regulate gene expression by forming a heterodimer with a retinoid X receptor 
(RXR). RXRs are members of the nuclear hormone superfamily that are activated 
following the binding of 9-cis retinoic acid (RA) (Murphy and Holder, 2000). Like 
PPARs, RXR subfamily consists of three isoforms, RXRa, RXR(3 and RXRy 
(Mangelsdorf et al., 1992). It is not known whether any one of the RXR isoforms 
preferentially binds one or more of the PPAR isoforms (Clark, 2002). However 
synthetic RXR agonists can activate the complex and thereby obtain antidiabetic 
outcomes similar to those seen with PPAR agonists in mouse models of type 2 
diabetes (Mukherjee et al., 1997).
Figure 1.21. Heterodimerization of PPAR and binding to PPRE
Following ligand binding to PPAR, the conformation of PPAR is altered and 
stabilized such that a binding cleft is created and heterodimerization occurs (Berger 
and Moller, 2002), the PPAR:RXR heterodimer binds to specific response elements 
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of the hexameric DNA consensus AGGTCA arranged as a direct repeat spaced by 
one nucleotide. Such a sequence, or similar one, has been found in numerous PPAR- 
inducible genes including acyl-CoA oxidase and adipocyte fatty acid-binding 
proteins (Wahli et al., 1995). Binding of the heterodimer to the PPRE can thus 
regulate gene expression (Figure 1.21).
Co-activators and co-repressors
PPAR-regulated transcriptional activation is made more complex by the involvement 
of co-activators and co-repressors. Several cofactor proteins, coactivator, and 
corepressors that mediate the ability of nuclear receptors to initiate (or suppress) the 
transcription process were recently identified (Xu et al., 1999b). High-affinity 
complexes are formed between the PPAR-RXR heterodimer and nuclear receptor co­
repressor protein, in the absence of ligand (Murphy and Holder, 2000). These 
prevent transcriptional activation by sequestering the nuclear receptor heterodimer 
from the promoter. As a consequence of the conformational change induced by 
binding of ligand, the co-repressors dissociate and coactivators interact with nuclear 
receptors in an agonist-dependent manner through conserved LXXLL motif (where 
X is any amino acid) (Heery et al., 1997; Torchia et al., 1997). This coactivator 
domain is oriented by a “charge clamp” formed by residues within helix 3 and the 
AF-2 of helix 12 of the LBD. It can then bind to a hydrophobic cleft in the surface of 
the receptor formed by helices 3, 4, and 5 and the AF-2 helix (Nolte et al., 1998b). 
Several coactivators, including CBP/p300 and steroid receptor coactivator (SRC)-l 
(Zhu et al., 1996), possess histone acetylase activity that can remodel chromatin 
structure. A second group of co-activators represented by members of the 
DRIP/TRAP complex such as PPAR binding protein (PBP)/TRAP220 (Zhu et al.,
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1997), form a bridge between the nuclear receptor and the transcription initiation 
machinery. The precise role of a third group, including PPARy co-activator-1 (PGC- 
1) (Puigserver et a l, 1998), receptor interacting protein 140 (RIP140) (Miyata et al.,
1998), and androgen receptor associated protein 70 (ARA70) (Heinlein et al., 1999), 
is not well understood at the molecular level. At its most simple, a sequence of 
events can be envisioned in which coactivators with histone acetylase activity 
complex with PPRE-bound activated PPAR/RXR receptors, disrupt nucleosomes, 
and “open up” chromatin structure in the vicinity of the regulatory region of a gene. 
Complexes such as DRIP/TRAP are then recruited and provide a direct link to the 
basal transcription machinery. As a result, initiation of transcription is induced.
Ligands
PPARs are able to bind several structurally diverse natural and synthetic ligands due 
to their large ligand binding pocket (Table 1.4). The structures of these ligands are 
illustrated in Figure 1.22 (exogenous compounds) and Figure 1.23 (endogenous 
compounds). PPARa is an important regulator of lipid metabolism a number of 
fatty acids and their derivatives bind and activate PPARa- these include palmitic 
acid, oleic acid, linoleic acid, arachidonic acid (Gottlicher et al., 1992) and the 
lipoxygenase products LTB4 and 8 -S-HETE. The non-steroidal anti-inflammatory 
drugs (NSAIDs) indomethacin, fenoprofen, ibuprofen and flufenamic acid also act as 
ligands as well as the fibrate class of hypolipidaemic drugs which exert their 
therapeutic effect via this mechanism (Lehmann et al., 1997). Fatty acids are also 
thought to bind and activate PPARS although with a lower affinity than that to 
PPARa. Synthetic agonists for PPARS include GW501516 and L-165041.
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Some fatty acids and their derivatives can bind PPARy with relatively low affinity; 
however it is believed that their relevant concentrations in the nuclei of target cells 
are likely to be too low for them to be bona fide ligands. Certain eicosanoids have 
been shown to bind and activate PPARy with higher affinity (Yu et al., 1995; 
Reginato et al., 1998) such as 15-deoxy-A12,14-prostaglandin J2 (15d-PGJ2), the 
prostaglandin D2 (PGD2) metabolite. However 15d-PGJ2 has not been definitively 
proven to exist in vivo, nor are its effects specific to PPARy (Li et al., 2001; Wilmer 
et al., 2 0 0 1 ).
Several key observations made in the mid-1990s regarding thiazolidinedione (TZD) 
antidiabetic agents have allowed researchers to determine their primary molecular 
site of action. Such compounds have been developed over the preceding years on the 
basis of their insulin-sensitizing effects in pharmacological studies in animals. TZDs 
were found to induce adipocyte fatty acid-binding protein aP2 (Kletzien et al., 1992; 
Harris and Kletzien, 1994). Independently, Tontonoz et al. (1994), reported that 
PPARy interacted with a regulatory element within the 5’ flanking region of the aP2 
gene that controlled its adipocyte-specific expression. These seminal observations 
were the precursor to additional experiments, which determined that TZDs such as 
rosiglitazone, pioglitazone, englitazone and ciglitazone were, in fact, PPARy ligands 
and agonists (Lehmann et al., 1995; Berger et al., 1996; Willson et al., 1996). Such 
characterization of these anti-diabetic agents also demonstrated a definite correlation 
between the in vivo PPARy binding and agonist activities of these compounds and 
their in vivo insulin-sensitizing actions. (Berger et al., 1996; Willson et al., 1996).
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TZDs were developed primarily to improve the antidiabetic actions of the fibrate 
hypolipidemic agents. Several TZDs including troglitazone have insulin-sensitizing 
and antidiabetic activity in humans with type 2  diabetes or impaired glucose 
tolerance (Willson et al., 1996). Other synthetic ligands include NSAIDs and aryl- 
tyrosine derivatives.
PPAR
Ligands a 8 r Reference
Exogenous compounds
W Y-14,643 +++ + ++ (Desvergne and Wahli, 1999)
Troglitazone - - +++ (Willson et al., 2000)
Rosiglitazone ' ' +++ (Willson et al., 2000)
Ciglitazone +++ (Yang and Frucht, 2001)
Pioglitazone - - +++ (Willson et al., 2000)
Indomethacin + - +++ (Lehmann et al., 1997)
Ibuprofen + - + (Lehmann et al., 1997)
Endogenous activators 
Palmitic acid +++ ++ (X ueta l., 1999a)
Linoleic acid +++ ++ + (X uetal., 1999a)
Arachidonic acid +++ ++ +++ (X uetal., 1999a)
PGA! + ++ + (Yu et al., 1995)
p g d 2 ++ + ++ (Yu et al., 1995)
p g j 2 + +/- +++ (Yu et al., 1995)
15-Deoxy-A1214-PGJ2 + +/- +++ (Desvergne and Wahli, 1999)
8(S)-HETE +++ - - (Desvergne and Wahli, 1999)
15-HETE ? ? +++ (Nagy et al., 1998)
l t b 4 +/- ? ? (Desvergne and Wahli, 1999)
9-HODE ? ? +++ (Nagy et al., 1998)
13-HODE ? ? +++ (Nagy et al., 1998)
Table 1.4. Activity of peroxisome proliferator-activated receptor ligands for receptor subtypes
(symbols are: +, activator; not an activator; +/-, possible activator; ?, not determined). Abbreviation: 
HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid.
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Figure 1.22. S tructu re  of exogenous PPAR ligands
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l t b 4 9-HODE 13-HODE
Figure 1.23. S tructure of endogenous PPAR ligands
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Expression
PPARa is predominantly expressed in the liver and to a lesser extent in the heart and 
muscles. In comparison PPAR8 is abundantly expressed throughout the body but is 
at low levels in the liver (Evans et al., 2004). PPARy is expressed in numerous 
metabolically active tissues including liver, kidney, heart, skeletal muscle, colon, 
small and large intestine, pancreas, spleen and brown fat. It is also present in 
monocytic, vascular endothelial and vascular smooth muscle cells (Berger and 
Moller, 2002). In relation to subtype distribution, PPARy2 is much less abundant in 
all tissues in comparison with PPARyl, the predominant form (Fajas et al., 2001). 
PPARy3 mRNA expression is restricted to macrophages and the large intestine 
(Fajas et al., 1998). Consistent with their expression profiles, the PPARs carry out 
unique functions in the regulation of energy metabolism.
Ubiquitination
Proteasomes act on proteins that have been specially marked for destruction by the 
covalent attachment of a small protein called ubiquitin. Ubiquitin exists in cells 
either free or covalently linked to proteins. Most ubiquitinated proteins have been 
tagged for degradation. Different ubiquitin-dependent proteolytic pathways employ 
structurally similar but distinct ubiquitin-conjugated enzymes that are associated 
with recognition subunits that direct them to proteins carrying a particular 
degradation signal. The conjugation enzyme adds ubiquitin to a lysine residue of a 
target protein and thereafter adds a series of additional ubiquitin moieties, forming a 
multiubiquitin chain that is thought to be recognized by a specific receptor protein in 
the proteasome. Recent data demonstrate that the ubiquitin-proteasome degradation
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system affects the activity of several nuclear receptors. This degradation pathway is 
implicated in the regulation of many short-lived proteins involved in essential 
cellular functions, including cell cycle control, transcription regulation and signal 
transduction (Mimnaugh et al., 1999). Ligand-activation of PPARy results in the 
degradation of this nuclear receptor via this pathway (Hauser et al., 2000). 
Interestingly, interaction with co-repressor proteins protect PPARy from degradation 
whereas interaction with co-activators leads to enhanced degradation (Hauser et al.,
2000). It has been postulated that ligands regulate PPAR degradation in a timely 
manner. In a first stage, the ligand may protect PPAR from degradation in order to 
increase the ligand effect, whereas in a second stage, agonist-induced AF-2 
repositionning and cofactor recruitment may lead to PPAR ubiquitination and 
degradation as a mechanism to arrest transcriptional activation (Figure 1.24).
*  PPARs










Figure 1.24. Possible mechanisms of PPAR degradation by the ubiquitin-proteasome system. 
PPAR proteins are degraded by the ubiquitin-proteasome pathway. This system controls the PPAR 
proteins level in cells and thus the intensity of the response to the ligand. However, first the ligand 
stabilizes the PPAR proteins by decreasing its ubiquitination and then the ligand induces the 
degradation of the PPAR proteins as the consequence of the cofactors recruitment and in order to stop 
the response (Blanquart et al., 2003).
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Extracellular signals which activate intracellular phosphorylation pathways can also 
influence the degradation process, as shown for PPARy (Floyd and Stephens, 2002). 
Treatment of cells with an inhibitor of MEK kinases inhibits the degradation of 
PPARy. Thus PPAR degradation by the ubiquitin-proteasome pathway may be an 
important mechanism in the regulation of PPAR transcriptional activity by 
controlling cellular PPAR protein levels.
1.5.2. Role of PPARa and PPAR5 in inflammation
PPARa plays a crucial role in controlling fatty acid oxidation. In a variety of mouse 
models, PPARa agonists lower plasma triglycerides, reduce adiposity and improve 
hepatic and muscle steatosis, consequently improving insulin sensitivity (Chou et al., 
2002; Kim et al., 2003). In terms of inflammatory responses once activated, PPARa 
has been shown to inhibit the pro-inflammatory enzyme, COX-2 via a NFkB 
dependent pathway and has been hypothesised as having an anti-inflammatory action 
(Staels et al., 1998). In contrast the potent PPARa ligand, WY-14,643, induced 
COX-2 protein in a breast epithelial cell line demonstrating the lack of consensus in 
this area (Meade et al., 1999).
Genetic studies and recently developed synthetic PPAR5 agonists have helped reveal 
the role of PPAR5 as a powerful regulator of fatty acid catabolism and energy 
homeostasis (Peters et al., 2000; Barak et al., 2002). Little is known of the 
physiological role of PPAR5 in terms of inflammation, although it has been shown 
to act as a receptor for the COX-2 product PGI2 in a model of blastocyst
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implantation ( Lim et al., 1999; Meade et a l, 1999). It is also emerging as having a 
potential role in colorectal carcinogenesis (DuBois et al., 1998) where its mRNA is 
seen to co-localise with that for COX-2 although the full implications of this finding 
are yet to become clear. The role of PPARy in inflammation has recently become of 
interest and is the focus of this thesis, thus the next section will introduce PPARy and 
inflammation in more detail.
1.5.3. Role of PPARy in inflammation 
PPARy and anti-inflammatory effects
In vitro effects
An involvement of PPARy in inflammatory processes was first suggested by the 
antagonism between the activities of the proinflammatory cytokine TNFa on the one 
hand and PPARy on the other hand (Peraldi et al., 1997). Consistent with this were 
observations that PPARy agonists seem to inhibit macrophage activation (Ricote et 
al., 1998a) and limit the production of cytokines (Jiang et al., 1998) and chemokines 
(Marx et al., 2000), suggesting an inhibitory role in both inflammation and migration 
of immune cells. PPARy expression is dramatically up-regulated in macrophages and 
T cells during inflammatory responses, and can be induced by IL-4 and other 
immunoregulatory molecules (Ricote et al., 1998b; Huang et al., 1999; Daynes and 
Jones, 2002). In addition, airway inflammation and alterations in cellular turnover 
are histopathologic features of asthma and PPARy expression is augmented in the
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bronchial submucosa, airway epithelium and smooth muscle of steroid-untreated 
asthmatics, as compared with control subjects (Benayoun et al., 2001).
PPARy ligands have shown to inhibit production of many pro-inflammatory 
mediators such as TNFa, IL-6, IL-ip and monocyte chemoattractant protein (MCP)- 
1 expression in monocytes (Jiang et al., 1998; Zhang et al., 2001); iNOS, gelatinase 
B and scavenger receptor-A expression in macrophages (Colville-Nash et al., 1998; 
Ricote et al., 1998b); IFN-inducible protein 10, monokine induced by interferon 
gamma, interferon gamma inducible T-cell alpha chemoattractant, endothelin-1, IL-8 
and MCP-1 expression in endothelial cells (Delerive et al., 1999b; Lee et al., 2000; 
Marx et al., 2000); IL-2 in T lymphocytes (Yang et al., 2000); IL-8 in colonic 
epithelial cells (Su et al., 1999) and iNOS and IL-8 in airway epithelial cells (Wang 
et al., 2001).
Expression of PPARy has also been shown to be robustly upregulated upon the 
differentiation of monocytes into macrophages (Chinetti et al., 1998). Down 
regulation of immunity can be induced by apoptosis, and ligand activation of PPARy 
has been shown to result in apoptosis of nonactivated and activated macrophages 
(Chinetti et al., 1998).
Furthermore, the chemokine RANTES is a potent chemoattractant for eosinophils. 
RANTES is produced by lung epithelial cells during eosinophil-rich inflammatory 
diseases such as asthma. In A549 cells, IL-ip and TNFa induce mRNA expression, 
endogenous RANTES protein secretion, and promoter activity, which have been
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shown to be inhibited by TZDs. This raises the possibility that TZDs might be of 
therapeutic value in diseases such as asthma (Momoi et al., 1999).
In vivo effects
Several studies have investigated the role of PPARy ligands in modifying animal 
models of autoimmune diseases. Su et al. (1999), showed that in a mouse model of 
inflammatory bowel disease, TZDs markedly reduced colonic inflammation. 
Kawahito et al. (2000), demonstrated that intraperitoneal administration of PPARy 
ligands ameliorated adjuvant-induced arthritis with suppression of pannus formation 
and mononuclear cell infiltration in rats. 15d-PGJ2 exerts potent anti-inflammatory 
effects in the carrageenan-induced pleurisy and collage-induced arthritis models of 
acute and chronic inflammation, respectively (Cuzzocrea et al., 2003). 15d-PGJ2 and 
PPARy ligands have also been shown to inhibit inflammation in models of ischemia- 
reperfusion injury (Nakajima et al., 2001). Although in many of these studies, when 
more selective ligands (e.g. TZDs) were used, high concentrations (far exceeding 
those required to bind the receptor) were necessary to achieve the results described 
(Chawla et al., 2001). In addition, PPARy has been shown to inhibit inflammation in 
a mouse model of atherosclerosis (Li et al., 2000a). Woerly et al. (2003), 
demonstrated that PPARy was expressed by eosinophils and that PPARy agonists 
were able to inhibit eosinophil chemotaxis and antibody-dependent cellular 
cytotoxicity reactions in vitro. Furthermore, in a murine model of asthma, treatment 
with a PPARy agonist also inhibited the development of allergic inflammation, 
including pulmonary eosinophilia and airway hyperresponsiveness. However, target
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cells for PPARy agonists within the airways and the mechanisms by which they 
inhibit allergic inflammation were poorly characterised (Woerly et al., 2003). 
Moreover, Mueller et al. (2003), not only showed that PPARy ligands reduce the 
immunological symptoms of allergic asthma, such as reduced lung inflammation and 
mucus production, in a murine model of this disease, but that T cells from these 
ciglitazone treated mice also produce less IFNy, IL-4 and IL-2 upon rechallenge in 
vitro with the model allergen.
PPARy and pro-inflammatory effects
Despite extensive evidence suggesting the anti-inflammatory effects of PPARy 
ligands, they have also been found to stimulate the expression of the 
proinflammatory receptors CD 14 and CD 1 lb/CD 18 and to increase expression of 
class B scavenger receptors (CD36 and SR-B1) (Nagy et al., 1998; Tontonoz et al., 
1998; Chinetti et al., 2000). 15d-PGJ2 can induce expression of the proinflammatory 
mediators type II secreted phospholipase A2 and COX-2 in smooth muscle and 
epithelial cells, respectively (Couturier et al., 1999; Meade et al., 1999). The 
regulation of COX-2 by PPARy ligands will be outlined in more detail further on in 
this section. 15d-PGJ2 can also stimulate the production of proinflammatory 
mediators, such as IL-8 and MAPK, in some systems (Wilmer et al., 2001; Zhang et 
al., 2001; Fu et al., 2002). Thus, it is clearly evident that PPARy ligands, but in 
particular, 15d-PGJ2, possess both anti-inflammatory and pro-inflammatory 
functions in vitro (which are summarised in Table 1.5). In addition, plasma TNFa 
levels following challenge with LPS (Thieringer et al., 2000) or the development of 
arthritis (Wiesenberg et al., 1998) were not affected by PPARy ligand treatment.
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Therefore further investigation is required in order to identify the complex role of
PPARy ligands in the regulation of inflammation.
Monocvtes i  TNFa, IL-6, IL-lp and MCP-1
(Jiang et al., 1998; Zhang et al., 
2001)
t  IL-8 (Wilmer et al., 2001; 
Zhang et al., 2001; Fu et al., 
2002)
Macrophages i  iNOS (inducible nitric oxide), 
gelatinase B and scavenger 
receptor-A (Colville-Nash et al., 
1998; Ricote et al., 1998a)
T expression of the 
proinflammatory receptors 
CD14 and CDllb/CD18 and 
class B scavenger receptors
(Nagy et al., 1998; Tontonoz et 
al., 1998; Chinetti et al., 2000) 
IL-8 and MAPK (Wilmer et 
al., 2001; Zhang et al., 2001;
Fu et al., 2002).
Endothelium I IFN-inducible protein 10, 
monokine induced by interferon 
gamma, interferon gamma 
inducible T-cell alpha 
chemoattractant, endothelin-1, 
IL-8 and MCP-1 expression 
(Delerive et al., 1999b; Lee et al., 
2000; Marx et al., 2000)
T-lvmnhocvtes 1 IL-2 (Yang et al., 2000)
Colonic 
epithelial cells
i  IL-8 (Su et al., 1999)
Airwav 
epithelial cells
i  iNOS, IL-8 and RANTES
(Wang et al., 2001).
t  COX-2 (Meade et al., 1999)
Tablel.5. Summary of the anti- and pro-inflammatory effects of PPARy in vitro
1.5.4. Molecular mechanisms of the anti-inflammatory effects of PPARy 
ligands
PPARy- dependent mechanisms
The molecular mechanisms by which PPARy regulates inflammatory response genes 
are not yet fully understood. In addition to the classical mechanism of gene
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regulation (described above), PPARy can inhibit NFicB-driven transcription by 
physically interacting with both p65 (Chung et al., 2000) and p50 (Cemuda- 
Morollon et al., 2001). Using endothelin-1 promoter as a model, it has been 
demonstrated that PPARy inhibits AP-1 transcriptional activity by reducing AP-1 
DNA binding and thus the production of endothelin-1 (Delerive et al., 1999b). This 
inhibition is likely due to a direct interaction between PPARy and c-jun as previously 
reported for PPARa (Delerive et al., 1999a). Law et al. (1996), reported that TZDs 
inhibit c-fos transcription in vascular smooth muscle cells. In a model of cardiac 
ischemia reperfusion, rosiglitazone significantly reduced c-jun-NTL-terminal kinase 
(JNK) activation in vivo (Delerive et al., 2001). Previous reports suggested that 
nuclear receptors may regulate AP-1 activation by modulating JNK function (Caelles 
et al., 1997; Srivastava et al., 1999). However little is known about the molecular 
mechanisms of kinase inhibition by nuclear receptors.
A model for PPARy-mediated inhibition of iNOS transcription was proposed by Li 
et al. (2000b). In this model, it was suggested that PPARy inhibits STAT1, AP-1 and 
NFkB transcriptional activities by targeting coactivators such as CBP through direct 
interaction with its N-terminal domain and via SRC-1-like bridge factors (Li et al., 
2000b). Such a model of competition for limiting amounts of co-activators to inhibit 
transcriptional activation has already been proposed for other nuclear receptors 
(Kamei et al., 1996; Sheppard et al., 1998). However, this hypothesis of 
transrepression is not supported by recent reports (De Bosscher et al., 2000; McKay 
and Cidlowski, 2000). Finally, Yang et al. (2000), showed that PPARy activation 
results in a reduction of IL-2 secretion in T lymphocytes, which is due to a ligand
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dependent interaction between the transcription factor nuclear factor of activated T- 
cells (NFAT) and PPARy. Figure 1.25 outlines the molecular mechanism of anti­
inflammatory effects of PPARs.
IL-1 p, TNFa and 




Inhibition of other 
transcriptional 
pathways e.g.
|— ► STAT, and NFAT^
Figure 1.25. Hypothetical model of PPARy-dependent and independent inhibition of the 
inflammatory response genes (modified from (Delerive et al., 2001). 15d-PGJ2 may inhibit 
transcription of inflammatory response genes independent of PPARy (shown by red lines) by 
inhibiting the IKK complex and thereby preventing activation of NFkB and subsequent transcription, 
or by directly inhibiting NFkB (p65/p50). 15d-PGJ2 and TZDs may also prevent transcription in a 
PPARy dependent mechanism (shown by green lines), by directly inhibiting NFkB or binding to and 
competing for cofactors required by NFkB mediated transcription. TZD and 15d-PGJ2 may also cause 
inhibition of other transcriptional pathways, such as ST AT, NFAT, JNK or p38.
PPARy independent mechanisms
Many studies have indicated that 15d-PGJ2 may not be specific for PPARy (Petrova 
et al., 1999; Hortelano et al., 2000; Tsubouchi et al., 2001). In contrast to the results
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described above, PPARy ligands, with the exception of 15d-PGJ2, do not inhibit 
LPS-induced cytokine production in cultured macrophages and diabetic db/db mice 
treated in vivo (Thieringer et al., 2000). Chawla et al. (2001), recently utilized 
murine PPARy null macrophages to demonstrate that previously reported inhibitory 
actions of PPARy agonists on macrophage cytokine production occur via a receptor- 
independent mechanism. 15d-PGJ2 has been shown to suppress the production of 
iNOS in activated microglia and astrocytes by a mechanism independent of PPARy 
activation (Petrova et al., 1999). This was shown by the fact that 15d-PGJ2 could not 
stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected 
PPARy in these cells. These pharmacological discrepancies suggested that 15d-PGJ2 
may act through PPARy-independent pathways. Reports indeed demonstrate that, in 
the absence of PPARy expression, 15d-PGJ2 also negatively regulates the 
inflammatory response (Petrova et al., 1999).
There is abundant evidence implicating NFkB as a major target for receptor- 
independent gene repression by 15d-PGJ2 (Castrillo et al., 2000; Straus et al., 2000; 
Boyault et al., 2001). It has been demonstrated that 15d-PGJ2 can directly inhibit and 
modify the IKK2 subunit of IKK. This, in turn, prevents the phosphorylation of the 
inhibitory IkB proteins thus preventing the activation of NFkB (Castrillo et al., 
2000; Rossi et al., 2000). 15d-PGJ2 has also been shown to directly inhibit binding of 
NFkB to target DNA sequences (Straus et al., 2000) (Figure 1.25). Both mechanisms 
for inhibition of NFkB activity involve the alkylation of specific cysteine residues in 
target proteins. Furthermore, Chinetti et al. (1998), demonstrated that rosiglitazone 
induced apoptosis of cultured macrophages by altering NFkB signalling at
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concentration that paralleled its known affinity for PPARy. This ligand has also been 
shown to block inflammatory cytokine synthesis in colonic cell lines by inhibiting 
activation of the NFkB pathway (Su et al., 1999). This latter observation offers a 
possible mechanistic explanation for the observed anti-inflammatory actions of 
TZDs in rodent models of colitis (Su et al., 1999)
1.5.5. PPARy and the COX-2 pathway
Negative feedback regulation ofprostaglandin synthesis via PPARy and NFkB 
15d-PGJ2 may function as a physiological negative feedback regulator of 
prostaglandin synthesis and inflammatory response. As previously outlined, 15d- 
PGJ2 is present in the inflammatory fluids during the resolution phase of 
inflammation (Gilroy et al., 1999). PPARy is expressed at high levels in activated 
macrophages, making these cells likely targets for receptor-dependent actions of 
15d-PGJ2 (Ricote et al., 1998b). Finally, 15d-PGJ2 represses the synthesis of COX-2 
and inhibits the production of PGE2 by macrophages, consistent with the hypothesis 
that it can act as a negative feedback regulator of prostaglandin synthesis (Straus et 
al., 2000). Thus 15d-PGJ2 participates in a physiological negative feedback loop by 
repressing a number of inflammatory response genes (e.g. iNOS and TNFa) as well 
as the synthesis of the inflammatory mediator PGE2 via inhibition of NFkB (Figure 
1.26).
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Figure 1.26. Model for mechanisms by which 15d-PGJ2 exerts negative feedback regulation of 
prostaglandin biosynthesis and inflammatory gene expression. During an inflammatory response, 
COX-2 produces prostaglandins from arachidonic acid. Many of these prostaglandins are involved in 
inflammation. PGD2 can be dehydrated to produce the metabolite 15d-PGJ2 which can then inhibit 
further COX-2 expression by various mechanisms (AA-arachidonic acid).
COX-2 and PPAR
The PPARy ligand and metabolite of COX-2 product, 15d-PGJ2, has been shown to 
suppress LPS-induced expression of COX-2 in macrophage-like differentiated U937 
cells (Inoue et al., 2000); COX-2 induction in astrocytes (Janabi, 2002); and PMA 
induced COX-2 expression and PGE2 synthesis in human epithelial cells 
(Subbaramaiah et al., 2001). In contrast PPARy ligands have also been shown to 
increase TNF-a induced COX-2 expression in human colonic epithelial cells (Ikawa 
et al., 2001).
PPARy activated by its ligands can block both AP-1 and NFkB mediated COX-2 
gene expression (Inoue et al., 2000). The mechanism of suppression by PPARy is a
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consequence of inhibition of c-jun expression and competition for limiting amounts 
of the general coactivator CREB-binding protein (CBP)/p300. Binding of a PPARy 
ligand enhances the interaction between CBP/p300 and PPARy (Mizukami and 
Taniguchi, 1997; Gelman et al., 1999). This results in less CBP/p300 being available 
for AP-1 mediated induction of the COX-2 gene.
NSAIDs are widely used in the treatment of inflammation, and their efficacy is 
considered to be a result of their inhibitory effects on COX-2. However, NSAIDs 
have recently been identified as ligands of PPARs. Paik et al. (2000), reported that 
the NSAID, flufenamic acid, showed two opposing effects on COX-2 expression; it 
induces COX-2 expression in colonic epithelial cells and macrophages; conversely, 
it inhibits TNFa or LPS-induced COX-2 expression, and similar effects were also 
seen with 15d-PGJ2. These results indicated that NSAIDs inhibit mitogen-induced 
COX-2 expression while they induce COX-2 expression (Paik et al., 2000).
Due to the disparate effects seen on COX-2 expression in different systems, it is 
difficult to fully dissect out the regulatory mechanisms of PPARy on COX-2 
expression.
1.5.6. PPARy and signalling pathways 
PI3K and PPAR
Insulin is a strong activator of PI3K/PKB dependent pathway, and TZD drugs are 
clinically used to treat type 2  diabetes since they can increase insulin sensitivity. 
Rieusset et al. (2001a;2001b), demonstrated that the gene of p85aPI3K is a likely
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target of PPARy in normal human adipocytes and PPARa in human muscle cells. 
However, p85 k/o are more susceptible to hypoglycaemic have increased insulin 
sensitivity (Fruman et al., 2000; Ueki et al., 2002). Furthermore, the PI3K/PKB 
pathway has been shown to be involved in downstream signalling of PPARy ligands 
in various pathways such as the cell migration of human umbilical vein endothelial 
cells (Goetze et al., 2002). In addition, PKB has been linked to the regulation of 
NFkB and/or Rel family transcription factors that are essential for the induction of 
cytokine gene expression (Kane et al., 1999). Thus TZD and other PPARy ligands 
may induce PI3K isoforms in human lung epithelial cells and may affect PPARy 
mediated transcription of pro-inflammatory cytokines. 15d-PGJ2 has been shown to 
suppress inflammatory response by inhibiting NFkB signaling at multiple steps as 
well as by inhibiting the PI3K/Akt pathway independent of PPARy in primary 
astrocytes (Giri et al., 2004). 15d-PGJ2 induction of HO-1 gene expression in human 
lymphocytes was also shown to involve the PI3K signaling pathway (Alvarez- 
Maqueda et al., 2004).
MAPK and PPAR
15d-PGJ2 and members of the TZD class of drugs have recently been shown to 
activate the MEK/ERK pathway in vascular smooth muscle cells (Takeda et al., 
2001), in astrocytes and preadipoctyes (Lennon et al., 2002) and human mesangial 
cells (Wilmer et al., 2001). Lennon et al. (2002), also showed the activation of the 
p38 and JNK MAPK pathways following stimulation with ciglitazone in astrocytes 
and preadipocytes. All these cells express PPARy, however, the effects described 
above on ERK induction may possibly be mediated independently of PPARy since
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the time courses for the activation of ERK are too rapid to encompass the classical 
transcriptional mechanism (Takeda et al., 2001).
Recently, it has been demonstrated that the transcriptional activities of PPARs are 
regulated by post-translational mechanisms including phosphorylation and 
ubiquitination. In 1996, Zhang et al., showed that insulin treatment increases the 
ligand-independent transcriptional activity of PPARy and synergizes with a PPARy 
ligand to enhance its transcriptional activity. Moreover, the authors demonstrated 
that PPARy is phosphorylated by the MAPK pathway in vivo (Zhang et al., 1996). In 
contrast, it has been shown that phosphorylation of mouse PPARy by activators of 
MAPK induces an inhibition of its transcriptional activity (Hu et al., 1996). This 
result was confirmed in 1997 in a study by Adams et al., in which it was shown that 
serine 84 of human PPARy 1 is phosphorylated by the MAPK ERK2 and JNK 
(Adams et al., 1997). Furthermore, mutation of this serine increases the AF-1 
transcriptional activity of PPARy. Camp et al. (1999), demonstrated that mouse 
PPARy 1 is also regulated by MAPK phosphorylation at a site located on serine 82. 
Moreover these authors demonstrated that JNK, a MAPK, phosphorylates PPARy2 
and decreases its ligand-dependent transcriptional activity. Han et al.(2002), 
demonstrated that treatment of macrophage with TGFpl and 2 can inhibit PPARy 
ligand-induced expression of CD36 via activation of the MAPK pathway.
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1.6. Aim of the study
For many years COX-2 has been a therapeutic target for the development of anti­
inflammatory drugs for various diseases. COX-2 is generally regarded as a pro- 
inflammatory enzyme and thus regulating it can reduce inflammation. Furthermore 
PPARy ligands are thought to be anti-inflammatory and have been shown to regulate 
COX-2 in other systems, thus the aim of this work was to investigate the 
mechanisms involved in the regulation of COX-2 by PPARy ligands in lung 
epithelial cells and to assess whether PPARy may be benefical in the treatment of 
inflammatory lung diseases such as asthma and COPD. It was hypothesed that the 
PI3K pathway plays an important role in the regulation of COX-2.
The first results chapter investigates the signalling pathways activated by cytokines 
(TNFa and IL-ip) and the involvement of these pathways in COX-2 regulation in 
the human lung epithelial cell line, A549. These cytokines were utilised since they 
have been shown to be important in inducing inflammatory responses as previously 
outlined. In order to investigate the role of PI3K pathway, pharmacological methods 
were employed. Previous work has shown that PI3K inhibitors, LY294002 and 
wortmannin, are poor inhibitors of recombinant PI3K-C2a (Domin et al., 1997). 
Thus the sensitivity of PI3K isoforms to LY294002 and wortmannin was first 
characterised. It was important to dissect out the mechanisms and pathways involved 
in the regulation of COX-2 expression by cytokines since the second aim was to 
investigate the effects of PPARy ligands on cytokine induced events.
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Despite extensive studies utilizing PPARy ligands, the mechanism of action of these 
compounds is not only ambiguous but varies from system to system. The next aim 
was to clarify the signalling pathways activated by PPARy ligand in the A549 cell 
line and to investigate the involvement of these pathways in the regulation of COX- 
2, a known downstream target for activated PPARy in other cell types. 
Understanding the mechanisms of action of these ligands in this cell line may reveal 
important therapeutic targets for inflammatory lung diseases.
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2 . METHODS & MATERIALS
2.1 Cell Culture Conditions
2.1.1 A549 cells
The human lung epithelial cell line A549 was obtained from the European Collection 
of Animal Cell Cultures (ECACC). A549 cells are human lung epithelial 
adenocarcinoma cells isolated from a 58 year old Caucasian male (ECACC). A549s 
were routinely cultured in 175cm2 tissue culture flasks in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with penicillin (10 u/ml), streptomycin (lOpg/ml), 
lOmM L-glutamine, 20mM HEPES buffer and 10% v/v FBS (referred to as complete 
medium). Cultures were maintained at 37°C in an atmosphere of 5% CO2 . The 
medium was changed every 2-3 days.
To subculture confluent monolayers, the medium was removed and the cells were 
washed twice with PBS (w/o Ca2+ and Mg2+). Cells were then washed with a 3ml 
Trypsin-EDTA mixture of 0.05% (w/v) Trypsin and 0.02% (w/v) EDTA. The 
excess solution was removed and the cells were incubated for approximately 5 mins 
at 37°C until the cells had detached from the flask. The action of trypsin/EDTA was 
inhibited by the addition of complete DMEM medium and the cell suspension was 
centrifuged at 1500g for 5 min. The cell pellet was resuspended in complete 
medium and cell counting and viability were checked in a Neubauer 
haematocytometer after mixing 50 pi of cell suspension with 50 pi of Trypan Blue 
(Sigma). Dead cells stained blue, due to the uptake of Trypan Blue. Cell viability 
was always greater than 95%. Cells were counted and then seeded into 24-well
80
Chapter 2 - Methods e£ Materials
plates for luciferase assays; 6  well plates or 35mm petri dishes for western and 
ELISA protocols; 6 cm (diameter) petri dishes for in vitro lipid kinase assays and 
nuclear extractions; and into 175 cm2 for further culture. Flasks and plates reached 
confluency after approximately 3-4 days.
2.1.2 Jurkat cells
The human leukaemic T-cell line Jurkat was obtained from Imperial Cancer 
Research Fund. Jurkat were routinely cultured in 175cm2 tissue culture flasks in 
RPMI 1640 medium supplemented with penicillin (10 u/ml), streptomycin (lOpg/ml) 
and 10% v/v foetal calf serum (FBS) (referred to as complete medium). Cultures 
were maintained at 37°C in an atmosphere of 5% CO2 . Fresh medium was added 
every 2-3 days and confluent flasks were split into 3 175cm flasks with fresh 
medium. Prior to cell stimulations, cells were washed three times in RPMI, counted, 
resuspended at a density of 2 X 107 cells per 500pl for in vitro lipid kinase assays in 
FBS-free RPMI.
2.1.3. HT-29 cells
The human colonic epithelial cell line HT-29 was obtained from the European 
Collection of Animal Cell Cultures (ECACC). HT-29 cells are human colon 
adenocarcinoma grade II cells isolated from a primary tumour in a 44 year old 
Caucasian female. HT-29 colonic epithelial cells were routinely cultured in 80cm 
tissue culture flasks in McCoy’s medium supplemented with penicillin (10 u/ml), 
streptomycin (10 pg/ml), fungizone (0.5 pg/ml), and 10% (v/v) FBS (referred to as 
complete medium). Cultures were maintained at 37°C in an atmosphere of 5% CO2 .
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The medium was changed every 2-3 days and cells were subcultured in a similar 
manner to A549 cells (described above).
2.1.4. Freezing and Thawing of cells
For storage, cells were resuspended at 4 x 106 cells/ml of freeze medium. The freeze 
medium contained 10% of dimethylsulphoxide (DMSO) (Sigma) and 90% FBS. The 
cell suspension was transferred to cryotubes (Nunc) at 1 ml/tube, gradually cooled in 
vapour phase of liquid nitrogen overnight and then stored in liquid nitrogen tanks. 
For resuscitation of cells from liquid nitrogen, cells were rapidly defrosted at 37°C in 
a water bath, washed in with their appropriate medium, resuspended in complete 
medium and A549 and Jurkat cells from 1 cryotube were seeded into 75cm tissue 
culture flasks in complete DMEM and RPMI medium respectively. Tissue culture 
was then continued as above.
2.2. Experimental Protocol
A549 epithelial cells were cultured in the container appropriate to the planned 
experiment, as described above (Table 2.2.1).
Assay Culture Vessel Cell Number A549
Luciferase assays 24 well plates 3.5 xlO6 cells
Western analysis 6  well plates (6 hr plus time points) 
35mm dishes (up to 2 hr time points) 
60mm dishes for nuclear extracts
1 0 7 cells
ELISAs 6  well plates 1 0 7 cells
In vitro lipid 
kinase assays
60mm dishes
Table 2.1 Outline of the culture vessels used for various experimental protocols.
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Prior to the experiment the confluent monolayers of A549 cells were washed and 
cultured in FBS-free medium overnight. Growth arrested cultures were then treated 
with fresh FBS-free medium and stimulated with the appropriate concentrations of 
either drugs, or cytokines, or vehicle controls for the times described in the results 
section. Supernatants for ELISAs were collected, centrifuged to remove cellular 
debris and stored at -80°C until assayed. Cellular and nuclear proteins were 
extracted as described below for Western analysis and for NFkB p65 activation 
assays. Cell counting and viability were routinely checked at the beginning and the 
end of the experiment, by phase microscopy and by trypan blue exclusion, using 
representative wells. Cell viability was always greater than 95%. Recipes for buffers 
and solutions are listed in the appendix.
2.3. Immunoblotting
2.3.1. Overview
Western analysis is a technique of assaying the relative amounts of specific proteins 
within cells. Once the cells have been incubated in the appropriate conditions the 
cells are lysed and the whole cell proteins are extracted and quantified. The whole 
cell extracts can then be run in a current through a polyacrylamide gel to separate the 
proteins according to their molecular weight. The proteins can then be transferred to 
a membrane which can be incubated with a primary antibody specific for the protein 
to be assessed. A second incubation with a labelled secondary antibody against the 
primary antibody is then carried out. The membrane is then washed and the relative 
amount of the labelled secondary antibody is then assessed, usually by using a horse
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radish peroxidase tag on the secondary antibody to catalyse a reaction which can 
then be visualised.
From the point of view of the primary antibodies that are used, they can be specific 
for certain conformations of the protein to be assayed. In particular they can be 
directed to a phosphorylated form of the protein where phosphorylation indicates a 
change in function such as activation. Such an antibody can then be used to assess 
relative changes in the amount of this phosphorylated form of the protein, and by 
inference is a surrogate marker of any associated change in function. To ensure that 
the total amount of the specific protein is unchanged the results from these 
phosphorylated antibodies are compared to results using an antibody against all 
forms of the specified protein, referred to as a pan antibody.
2.3.2. Collecting samples
Attached monolayers of A549 cells were stimulated and incubated at 37°C as 
described. Stimulations were terminated at the appropriate times with aspiration of 
the supernatant and then the addition of 2 0 0  pi ice cold lysis buffer ( 1 % (v/v) 
Nonidet P-40, 150nM NaCl, 50mM Tris pH 7.5, 5mM EDTA, lOmM sodium 
fluoride, ImM phenylmethylsulfonyl fluoride, lOpg ml' 1 leupeptin, lOpg ml' 1 
aprotinin, lpg ml' 1 soybean trypsin inhibitor, lpg ml' 1 pepstatin A, ImM sodium 
orthovanadate, 1 mM sodium molybdate). Cells were solubilised using a cell scraper 
and the resulting lysates were transferred to 1.5ml plastic tubes and rotated at 4°C for 
10 mins. The samples were then centrifuged at 13,000 rpm for 10 mins at 4°C and
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the protein containing supernatant was transferred to a fresh eppendorf tube. 
Samples could be frozen at -80°C at this point.
2.3.3. Protein assay
Total protein per lysate was estimated using the Bio-Rad Protein Assay. This assay 
is based on the Bradford dye-binding procedure. Known concentrations of bovine 
serum albumin (BSA) diluted in lysis buffer were used as a standard curve. 5pl of 
sample was diluted in 1 ml of 20% Bradford solution. 100 pi of Bradford samples 
was transferred into 96-well plate and read at 595nm on a Dynatech MR5000 
platereader. The protein concentrations were calculated by linear regression from 
the standard curve.
2.3.4. Whole cell extracts
50pl of 5X SDS sample buffer (5% SDS, 50% glycerol, 200mM Tris-HCl pH 6 .8 , 
bromophenol blue, 5% 2-mercaptoethanol) was added to each protein sample. 
Samples were then vortexed briefly, boiled for 5 mins and spun down before loading 
onto a gel. Samples could be frozen at -80°C at this point.
2.3.5. Separation of cellular proteins by electrophoresis
Proteins were analysed by one dimensional gel electrophoresis, which under 
reducing conditions separates proteins based on molecule size. Sodium Dodecyl 
Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out
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essentially as described by Laemmli (1970). Proteins were separated by SDS-PAGE 
using the Bio-Rad Mini Protean II.
Minigels of the appropriate percentage were prepared as described in buffers and 
solutions section. The resolving gel was poured into the gel equipment and overlaid 
with MilliQ water. After 20 mins the resolving gel set and the water was removed. 
The stacking gel was poured on the top of the running gel and set with a 10 or a 15 
lane comb inserted. When the stacking gel was set the comb was removed, the wells 
were washed thoroughly with MilliQ water followed by running buffer. Then 25 pg 
of sample was loaded per lane (~1 0 -2 0 pl) alongside a molecular weight marker. 
Gels were run at room temperature at 80 volts, until the bromophenol blue tracking 
dye entered the running gel. The voltage was then increased to 180 volts. Gels were 
run until the bromophenol blue band had reached the bottom of the resolving gel. 
Gels were then placed into transfer buffer.
2.3.6. Semi-dry transfer of proteins to nitrocellulose
The graphite electrodes of the semi-dry transfer apparatus (Pharmacia-Biotech 
Multiphor II) were dampened with semi-dry transfer buffer (39mM glycine, 48mM 
Trizma base, 0.0375% SDS, 20% (v/v) methanol, MilliQ water). This was followed 
by placing a sandwich of four pieces of 3MM Whatman paper cut to the size of the 
gel, one piece of nitrocellulose membrane, the gel and another four pieces of 3MM 
Whatman paper, all soaked in transfer buffer. Each layer was rolled gently to expel 
air bubbles. The transfer was run for one hour at 0.8mA/cm2 of membrane (~40mA
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per gel). The membrane was then stained with Ponceau S to check for transfer and 
equal loading of the samples and also to confirm the location of the molecular 
weight markers. The stain was removed by washing the membrane in distilled water 
for 2 mins, followed by a 10 mins wash in Tris buffered saline (TBS; 20mM Tris- 
HC1 pH 7.5, 150mM NaCl, MilliQ water).
2.3.7. Immunoblotting of nitrocellulose bound protein
Non-specific binding sites on the nitrocellulose were blocked by 1 hour incubation of 
the membrane with the appropriate blocking buffer at room temperature on a rocking 
platform. The nitrocellulose membrane was washed for 10 mins in TBS-Tween 0.1% 
and then incubated with the primary antibody made up in TBS-Tween 0.1% overnight. 
Blocking buffer was added to some primary antibodies; see section 6.2 for specific 
probing conditions. The membrane was then washed five times for 5 mins each on a 
rocking platform at room temperature with TBS-Tween 0.1%. The membrane was then 
incubated for 1 hour with the appropriate secondary antibody diluted in TBS-Tween 
0.1% Tween. After this incubation washings were repeated as previously described, 
before a final wash for 5 mins in TBS. 5ml of Enhanced Chemiluminescent Lumigen 
(ECL) reagent was added for 1 min and the membrane was then exposed to X-ray film 
for 2 sec -  30 mins. The film was developed using an RGII Fuji X-ray film developer.
2.3.8. Membrane stripping
Where appropriate, blots were stripped of bound antibody and reprobed with a 
different primary antibody. After the ECL procedure described above, the
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membrane was washed once in TBS for 10 mins and then placed in 50ml of stripping 
buffer (62.5mM Tris-HCl pH 6 .8 , 2% (w/v) SDS lOOmM 2-mercaptoethanol, 
MilliQ) water in a sealed sandwich box and incubated at 60°C for 30 mins with 
regular mixing. After extensive washing in at least three changes of TBS-Tween 
0.1.% followed by a TBS wash, the membrane would be reblocked in the appropriate 
blocking buffer before the addition of the new primary antibody.
2.4. Nuclear extract preparation
Cells were washed with PBS and 400pl of Buffer 1 (lOmM HEPES, lOmM KC1, 
lOOpM EDTA, lOOpM EGTA, ImM sodium molybdate, ImM sodium vanadate, 
lOmM sodium fluoride, MilliQ water) was added to cells. Adherent cells were 
carefully scrapped off the Petri dishes with a rubber scrapper and were transferred 
into plastic tubes. Cells were put on ice for 15 mins followed by the addition of 15 pi 
of 10% NP-40 which lyses the cell membrane. Samples were then centrifuged at 
13,000g for 5 min to pellet the nuclei. The supernatant, which contains the cytosolic 
proteins, was transferred to new tubes. The nuclei pellet was then washed in Buffer 1 
and resuspended in 50pl Buffer 2 (lOmM HEPES, 400mM NaCl, lOOpM EDTA, 
lOOpM EGTA, ImM sodium molybdate, ImM sodium vanadate, lOmM sodium 
fluoride). Samples were rotated for 30 mins at 4°C. Finally, the samples were 
centrifuged at 13,000g for 5 min and the supernatant, containing the nuclear extracts 
were retained. Bradford assay was carried out to determine protein concentration. 
Samples could be frozen at -80°C at this point.
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Nuclear extracts were utilised for the assessment of transcription factor activation by 
aid of Trans AM NFkB kits (Active Motif, Belgium). 5 X SDS sample buffer was 
added to an aliquot of both cytosolic and nuclear extracts and samples were boiled 
for 5 mins before being loaded onto polyacrylamide/sodium dodecyl sulphate gels to 
determine PPARy expression or IkB degradation. Western blot analysis was then 
carried out as described above.
2.5. In vitro lipid kinase assay
2.5.1. Overview
PI3K activity can be measured directly by an in vitro lipid kinase assay. This assay 
detects the transfer of radiolabeled y-phosphate of ATP to the D-3 position of Ptdlns, 
resulting in the formation of (32P)-labelled PtdIns(3)P.
2.5.2. Immunoprecipation and reaction
Cells were stimulated and lysates were pre-cleared with either 20 pi protein A or G 
sepharose beads for 1 hour at 4°C with constant rotation. Samples were then spun at 
13,000g and supernatants were transferred into clean tubes. Proteins were then 
immunoprecipated, by the addition of lp l of the antibody against the protein of 
interest, and were rotated at 4°C for one hour. 40 pi 50% (v/v) suspension of the 
protein-A or G sepharose beads were then added, and the samples were again rotated 
for 1 hour at 4°C. The beads were captured by centrifugation at 12,000g for 1 minute 
at 4°C. The beads were then extensively washed as follows-
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3 x in wash buffer A (PBS, 1% NP-40, lOOpM sodium vanadate)
3 x in wash buffer B (lOOmM Tris, pH 7.4, 5mM LiCl, lOOpM sodium 
vanadate)
2 x TNE buffer (lOmM tris, pH 7.4, 150mM NaCl, 5mM EDTA, lOOpM 
sodium vanadate).
Between each wash the beads were spun down at 12-14,000g for 15 seconds. After 
the removal of the final wash pre-treatment with inhibitors (made up in 50 pi TNE 
buffer) was carried out where appropriate. Control samples were treated with 50 pi 
TNE for the same period of time. Following pre-treatment, 10 pi (20pg) PI (Ptdlns) 
and lOpl lOOmM MgCh were added to each pellet of beads. The reactions were 
started by adding 5 pi of ATP reaction buffer (0.88 mM ATP, 20 mM MgCL, and 5- 
10 pCi (y P)-ATP) and were allowed to proceed for 10 minutes. Reactions were 
terminated by the addition of 20 pi 5N HC1 and 160pl chloroform/methanol (1:1). 
Samples were briefly vortexed and phases were separated by centrifuging for 10 
min. 50pl of the lower chloroform phase was removed and spotted onto 1% 
potassium oxalate-treated thin-layer chromatography (TLC) plates. The lipids were 
resolved by TLC in chloroform:methanol:water:ammonium hydroxide 
(60:47:11.3:2). (32P)-labelled lipids were visualised by autoradiography at -80°C. 
TLC plates were iodine stained to confirm equal loading.
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2.6. N F kB L u c ife ra se  re p o r te r  assay
2.6.1. Overview
Genetic reporters are commonly used to study gene expression. Firefly luciferase is 
widely used as a reporter for the following reasons:
1) Reporter activity is available immediately upon translation since the protein 
does not require post-translation processing.
2) The assay is very sensitive
3) The assay is rapid, reliable and easy to perform
Firefly luciferase is a 61kDa monomer that catalyzes the mono-oxygenation of beetle 
luciferin (reaction shown below Figure 2.1.) Beetle luciferin is a relatively stable 
molecule found only in luminous beetles (which include fireflies). The enzyme uses 
ATP as a cofactor, although most of the energy for photon production comes from 
molecular oxygen. The gene encoding firefly luciferase (luc) is a cDNA clone that 
has been incorporated into a number of vectors.
Figure 2.1. Catalyzation of beetle luciferin by firefly luciferase (Prom ega)
2.6.2. Assay procedure
A549-6xBtkluc cell line, obtained from Robert Newton (University of Warwick), is 
a cell line stably transfected with the NFkB luciferase reporter (Newton et al., 1998). 




x o - c r
O-
+ AMP + Ff* + CO^ t Lfcjt
Beetle Lucifer in Qiylucifecin
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sequence 5’-AGC TTA CAA GGG ACT TTC CGC TGG GGA CTT TCC AGG 
GA-3’, which contains two copies of the decameric NFkB site (underlined), up­
stream of a minimal thymidine kinase promoter (positions -105 to +51) driving a 
luciferase gene (Newton et al., 1998). To allow selection of stable transfectants the 
6KBtkluc vector was opened with Pvid and a H indi (blunted- Pvul fragment 
containing the pMClneoPolyA (Stratagene) neomycin gene was inserted in an 
opposite orientation to the luciferase gene to generate 6KBtkluc.neo3. The 
transfection process utilises Tfx50 reagent (Promega) (Newton et al., 1998).
Following cell treatment for the appropriate time with PPARy ligands, cytokines 
and/or inhibitors, Promega Steady Glo buffer/substrate (200 pi) was added to each 
well, mixed thoroughly, and left to stand at room temperature for 10 mins. The 
supernatant was mixed further and 200 pi from each well was transferred to an 
opaque-walled 96-well plate (Costar). Luminescence was measure on a Beckman 
Topcounter with a 5 sec read per well.
2.7, Prostaglandin E? ELISA
2.7.1. Overview
This assay to measure PGE2 concentration uses a kit from R&D Systems (Abingdon, 
UK). It is based on the competitive binding technique in which PGE2 present in the 
sample competes with a fixed amount of alkaline phosphatase-labelled PGE2 for 
sites on a mouse monoclonal antibody (Figure 2.2).
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Q  Cell Culture PGE2 
Alkaline Phosphatase-labelled PGE2 as assay reagent 
Y Fixed Goat anti-mouse antibody 
r  Mouse anti-PGE2 monoclonal antibody as assay reagent
Figure 2.2 Schematic representation of prostaglandin ELISAs. This demonstrates the competitive 
binding technique used in the ELISAs for PGE2 in this work. See text for full explanation
During the incubation, the mouse monoclonal antibody becomes bound to the goat 
anti-mouse antibody coated onto the microplate. Following a wash to remove excess 
conjugate and unbound sample, a substrate solution is added to the wells to
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determine the bound enzyme activity. The intensity of the colour generated is 
inversely proportional to the concentration of PGE2 in the sample.
2.7.2. Assay procedure
Known concentrations of a PGE2 standard were diluted in cell culture medium and 
used for a standard curve (39 pg/ml to 5000 pg/ml). 100 pi of standard or diluted 
(1:5) cell culture supernatant sample were placed in microplates coated with goat 
anti-mouse antibody. To each was added 50 pi of PGE2 conjugate (conjugated to 
alkaline phosphatase) and 50 pi of PGE2 antibody solution (mouse monoclonal). 
The plates were covered and incubated on a shaking platform for two hours at room 
temperature. After this incubation the wells were aspirated and washed with 200 pi 
wash buffer using a multi-channel pipette. This was repeated to give a total of three 
washes and after the last wash the microplates were inverted and blotted against 
clean paper towelling. 200 pi of pNPP substrate was then added to all wells and 
incubated at room temperature without agitation. The optical density at 405nm was 
determined immediately using a Dynatech MR5000 plate reader. The PGE2 
concentrations were calculated by comparison to the sigmoid standard curve using 
BioLinx software and dilution factors were taken into consideration.
2.8. Microarrav
2.8.1. Overview
Microarrays can be used to analyse the expression of tens of thousands of genes 
simultaneously. Microarrays are miniature devices containing thousands of DNA
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sequences stuck on at different positions (addresses). Hybridization to complex 
mixtures of labelled DNA molecules, prepared from cellular RNA, shows the 
relative expression levels of thousands of genes (see below Figure 2.3). This can be 
used to compare gene expression levels within a sample or look at differences in the 
expression of specific genes across different samples.
Figure 2.3. Gene chip showing relative expression levels
2.8.2. RNA isolation
RNA was isolated from A549 cells using Trizol following cell stimulation in 10 cm 
petri dishes. After the removal of cell culture supernatant, 2 ml of Trizol was added 
to the cells for 1 minute, resulting in cell lysis. The sample was solubilised by 
passing the lysate through a pipette several times. The samples were then placed in 
two 1.5 ml plastic tubes and frozen at -80°C. When thawed 200 jliI of chloroform was 
added to each tube and the samples were shaken vigorously for 15 seconds. They were 
then incubated at room temperature for 3 minutes before being centrifuged at 12,000g 
for 15 mins at 4°C. The DNA and proteins were in the interphase and organic phase 
while the aqueous phase contained the RNA which was carefully pipetted off into a 
new eppendorf. 500 ml of isopropanol was then added to the aqueous phase and the 
samples stored at room temperature for 10 mins. They were then centrifuged at 
12,000g for 10 mins at 4°C and an RNA pellet was subsequently visible at the bottom
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of the tube. The supernatant was removed and the pellet washed with 1ml cold 75% 
ethanol, centrifuged at 7500g for 5 mins at 4°C. The supernatant was removed and the 
pellet was air-dried. Each pellet was resuspended in 45 pi of RQI buffer and the RNA 
from both pellets combined. RNA samples were incubated at 37°C for 30 mins, put 
through QLAGEN RNeasy columns and eluted in 30 pi RNase-free water. RNA was 
then quantified and lOOng per well was run on RNA chips on Agilent 2100 
Bioanalyzer.
RNA samples were processed for hybridisation on Affymetrix HG U133A 
(Affymetrix Inc, Santa Clara, US) gene chip by the Genomics Factory EU 
(Novartis), following standard procedures. The Gene chip Human Expression Array 
HG U133A contains approximately 22,000 probe sets representing more than 20,000 
transcripts derived from approximately 17,000 well substantiated human genes. This 
design uses sequences selected from GenBank, dbEST and RefSeq. The sequence 
clusters were created from the Unigene database (Build 133, April 20, 2001).
2.8.3. M icroarray analysis
Data analysis was performed either in Genespring 5 (Silicon Genetics, Redwood 
city, US) or Excel (Microsoft). The default normalisation, recommended by 
Genespring was applied. It consisted of two steps (1) per chip normalisation (global 
normalisation) and (2) per gene normalisation. This resulted in transforming 
Affymetrix MAS5 gene expression data to a normalised constant value of 1 in 
Genespring. The genes were subsequently filtered by setting a minimal expression 
value (the smallest value any gene is allowed to have, here 20) to be met in at least
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50% of the conditions. This restriction was applied to raw data. The reason for this 
trimming was to discount gene expression values which can not be distinguished 
from background noise, and therefore may account for false positives.
2.9. TransAm NFkB kit
2.9.1. Overview
Trans AM™ method, developed by Active Motif, introduced the first ELISA-based 
kits to detect and quantify transcription factor activation. TransAM NFkB kits 
contain a 96-well plate to which oligonucleotide containing the NFkB consensus 
binding site (5’GGGACTTTCC-3’), have been immobilized. The active form of 
NFkB p65 contained in cell extract specifically binds to this oligonucleotide. The 
primary antibody used to detect NFkB recognizes an epitope on p65 that is 
accessible only when NFkB p65 is activated and bound to its target DNA. Addition 
of a secondary antibody conjugated to horseradish peroxidase (HRP) provides 
sensitive colorimetric readout that can be quantified by spectrophotometry. Figure 
2.4 outlines the assay procedure.
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Add nuclear «trac t Add pmrary antibody








Figure 2.4. Outline of the TransAM  NFkB assay procedure
2.9.2. Assay procedure
Sample (20 pi; containing 7.5-10 pg protein) was diluted in complete lysis buffer 
was added in duplicate to wells containing 30 pi binding buffer. Appropriate blank 
and positive controls were carried out. The plate was then covered and incubated at 
room temperature with mild agitation for one hour. The wells were washed 3 times 
with 200 pi of IX washing buffer. For each wash, the plate was flicked over a sink 
to empty wells, and then the inverted plate was trapped three times on absorbent 
paper towels. Diluted p65 NFkB antibody (100 pi; 1:1000 dilution in IX antibody 
binding buffer) was added to wells of the Trans AM NFkB kit. The plate was cover 
and incubated for one hour at room temperature without aggitiation, followed by 
three washes as described above. 100 pi diluted anti-rabbit (1:1000 dilution in IX 
antibody binding buffer) was then added to each well. The plate was covered and
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further incubated for one hour at room temperature without agitation, followed by 
four washes as described above. 100 pi of room-temperature developing solution 
was added to wells and incubated for 10 minutes protected from direct light. Finally 
a 100 pi of stop solution was added and the absorbance on a spectrophotometer was 
read at 450 nm.
2.10, Statistics
One way ANOVA test with Bonferroni Correction was carried out to test for 
statistical significance of ELISA and NFkB activation data. A statistical cut-off of a 
P value of 0.05 was used. In order to derive differentially expressed genes from the 
microarray analysis, a Welch t-test (parametric, not assuming equal variances) was 
used with a statistical cut-off of a P value of 0.05. No multiple testing corrections 
were applied and fold change filtering was also performed in Genespring. The 
average expression value per gene from three separate experiments was used to 
define the fold change as a ratio. The fold regulation cut-off used was a >2 fold up or 
downregulation.
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2.11. M aterials
(32P)v-ATP Amersham International, (UK)
2-Mercaptoethanol Sigma, Poole (UK)
15d-PGJ2 Calbiochem (UK)
Absolute Ethanol BDH, Poole (UK)
Acrylamide/bis acrylamide Bio-Rad, (UK)
Adenosine triphosphate Sigma, Poole (UK)
Ammonium persulphate BDH, Poole (UK)
BADGE Tocris, Avonmouth (UK)
Bovine serum albumin (BSA) Sigma, Poole (UK)
Bromophenol blue BDH, Poole (UK)
Cell culture plastics Nunc, (UK)
Chloroform Fisons, Loughborough (UK)
Anti-COX-1 Ab (C-20; sc-1752) Santa Cruz, (USA)
Anti-COX-2 Ab Alexis (Nottingham, U.K.).
Chloroform Fisons, Loughborough (UK)
Dimethyl sulphoxide (DMSO) Sigma, Poole (UK)
I Dulbecco’s Modified Eagle Medium Gibco BRL, Paisley (UK)
Enhanced chemiluminescence detection kit for Amersham International, (UK)
Western blotting (ECL)
Anti-ERKl/2 polyclonal Ab (sc-93) Santa Cruz, CA (USA)
Anti-ERK 1 a 1 polyclonal Ab (cat. no. 9101) Cell signalling (UK)
Ethylenediaminetetraacetic acid (EDTA) Sigma, Poole (UK)
Foetal bovine serum (FBS) Gibco BRL, Paisley, (UK)
Formaldehyde BDH, Poole (UK)
Glycerol Sigma, Poole (UK)
Glycine Sigma, Poole (UK)
Goat anti-rabbit peroxidase conjugate DAKO, Glostrup, Denmark
GW9662 Tocris, Avonmouth (UK)
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HEPES (1M liquid) Gibco BRL, Paisley, (UK)
Hydrochloric acid BDH, Poole (UK)
Anti-lKB Ab (C-15; sc-203) Santa Cruz, CA (USA)
IL-la: human recombinant; specific activity 5x10 
U/mg
Peprotech, London (UK)
L-glutamine Gibco BRL, Paisley, (UK)
Leupeptin Sigma, Poole (UK)




Methanol Fisons, Loughborough (UK)
Molecular weight markers Bio-Rad, Hertforshire (UK)
Anti-mPGES polyclonal Ab Alexis (Nottingham, U.K.).
Anti-NFKB p65-276Ser polyclonal Ab (cat. no. 3037) Cell signalling, Hitchin, (UK)
Nitrocellulose BDH (UK)
NP40 Sigma, Poole (UK)
Anti-PI3K-pl 10 Ab (sc-7177) Santa cruz, CA (USA)
Anti-PI3K-p85 Ab Gift from J. Domin, (Imperial 
College, London, U.K)
PD98059 Alexis (Nottingham, U.K.)
Penicillin/ Streptomycin Gibco BRL, Paisley, (UK)
PGE2 ELISA kit R & D Abingdon (UK)
Phosphate buffered saline Gibco BRL, Paisley, UK
Phosphatidylinositol Sigma, Poole (UK)
Anti-PI3K- C2a Ab Gift from J. Domin (Imperial 
College, London, U.K)
Anti-PI3K- C2|3 Ab Gift from J. Domin (Imperial 
College, London, U.K)
Anti-PKB-a 473Ser, polyclonal Ab (cat. no. 9271) New England Biolabs, USA
Anti-PKB-a, polyclonal Ab (sc-1618) Santa Cruz, CA (USA)
101
Chapter 2 - Methods &  Materials
PMSF Sigma, Poole (UK)
Ponceau S Sigma, Poole (UK)
Anti-PPARy polyclonal Ab Alexis (Nottingham, U.K.)
Promega Steady Glo luciferase buffer Promega, Southampton, (UK)
Propan-l-ol Fisons, Loughborough (UK)
Propan-2-ol Fisons, Loughborough (UK)
Protein G beads Amersham (UK)
Ro-32-0432 Alexis (Nottingham, U.K.)
RPMI 1640 Gibco BRL, Paisley, (UK)
Sodium azide Sigma, Poole (UK)
Sodium chloride Sigma, Poole (UK)
Sodium dodecyl sulfate (SDS) Sigma, Poole (UK)
Sodium fluoride Sigma, Poole (UK)
Sodium hydroxide Sigma, Poole (UK)
Sodium molybdate Sigma, Poole (UK)
Sodium orthovanadate Sigma, Poole (UK)
TEMED Sigma, Poole (UK)
Thin layer chromatography plates Whatmann (UK)
Tissue culture reagents Gibco BRL, Paisley, UK
TNF-a: human recombinant; specific activity 6xl07 
U/mg
Peprotech, London (UK)
Trans AM™ NFkB kits Actif Motif, Rixensart, Belgium
Trizma base Sigma, Poole (UK)
Troglitazone Alexis (Nottingham, U.K.)
II Trypan Blue Sigma, Poole (UK)
Trypsin EDTA Gibco BRL, Paisley, (UK)
Tween-20 Sigma, Poole (UK)
Wortmannin Sigma, Poole (UK)
X-OMAT film Amersham International, UK
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3. RESULTS I
3.1. Selectivity of PI3K inhibitors to Class IA and Class IIPI3K
3.1.1. Background
This thesis investigates the role of the PI3K pathway in regulation of COX-2 
expression by cytokines and PPARy ligands in A549 cell line. In the first section of 
this chapter the involvement of the PI3K pathway was evaluated by the use of two 
distinct pharmacological inhibitors of PI3K, LY294002 and wortmannin. 
Wortmannin is derived from a metabolite of the fungus Penicillium fumiculosum 
thorn and LY294002 is derived from quercetin.
Previous work has shown that LY294002 and wortmannin are poor inhibitors of 
recombinant PI3K-C2a (Domin et al., 1997). Thus the selectivity of LY294002 and 
wortmannin to PI3K isoforms was investigated by in vitro lipid kinase assays. The 
well characterised Jurkat cell line, which have high basal PI3K activity due to the 
lack of lipid phosphatases SHIP and PTEN, was initially utilised as a positive control 
and have the additional advantage that they grow rapidly and therefore supply a large 
number of cells which is required in order to carry out in vitro lipid kinase assays.
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3.1.2. Results
Expression of PI3K isoforms
It was necessary to first identify the expression of different isoforms of PI3K in 
A549 cell line, in order to evaluate which isoforms may be involved in PPARy 
mediated signal transduction (investigated in the next chapter). Jurkat whole cell 
extract was used as a positive control since they have been shown to express Class 
1A p85 regulatory subunit. This is known to be tightly coupled to p i 10 a , p and 5 
catalytic isoforms which are not thought to exist on their own in the cytoplasm. 
Hence, p85a is an indirect maker of pi 10 catalytic subunit expression; although it 
does not tell us which Class IA pi 10 isoforms are expressed. Jurkat cells also 
express Class IB PI3K, PI3K-C2a and PI3K-C2p.
A549 cells showed increasing expression of the regulatory p85 domain of Class LA 
PI3K isoforms, as well as a  and p isoforms of the Class II PI3Ks (Figure 3.1) when 
increasing amounts of protein were loaded onto the SDS-page gel. As expected, 
these cells did not express the Class IB PI3K catalytic subunit pllOy, which has 
expression predominantly restricted to cells of haematopoietic lineage 
(Vanhaesebroeck and Waterfield, 1999). Expression of all four isoforms investigated 
were seen in the Jurkat positive control.
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  150kDa anti-C2P-PI3K
Figure 3.1 The A549 cell line express PI3K isoforms.
3.2 x 106 grow-arrested, confluent A549 cells were lysed with lysis buffer to obtain 
whole cell lysates (WCL). Positive control lysates whole cell lysate of Jurkat (J6) cell 
line for PI3K isoforms were also collected. Proteins were quantified by Bradford assay 
and boiled with 5 x sample buffer, resolved by SDS-PAGE (20|ig of protein was 
loaded for the positive control), transferred to nitrocellulose membranes and 
immunoblotted, as described in Methods and Materials, with Ab raised against 
specific PI3K isoforms (B; anti-p85, anti-pl 10y, PI3K-C2a and PI3K-C2P). Proteins 
were visualized with ECL. Data is representative of three experiments.
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Effect of PI3K inhibitors on Class IA and Class II PI3K isoforms in Jurkat cell 
line
Anti-p85 antibody was used to immunoprecipate Class IA PI3K catalytic subunits 
which are associated with the regulatory p85 subunit. Anti-PI3K-C2a antibody was 
utilised to immunoprecipate Class Hot PI3K and similarly anti-PI3K-C2p antibody 
was used to immunoprecipate Class lip PI3K isoform.
The activities of Class IA PI3K, PI3K-C2a and PI3K-C2p were sensitive to 
LY294002 (Figure 3.2A, 3.2B and 3.2C respectively; left panels) although at varying 
degrees in the Jurkat cell line. In comparison, wortmannin inhibited Class IA PI3K 
and PI3K-C2P (Figure 3.2A and 3.2C respectively; right panels), but had little effect 
on PI3K-C2a activity (Figure 3.2B; right panel). Densitometry was carried out and 
utilised to calculate IC50 values of the inhibitors to PI3K activity. The rank order of 
sensitivity of LY294002 was Class IA PI3K (ICso= 6.5 pM) > PI3K-C2a (ICso= 7.3 
pM) > PI3K-C2p (IC5o=23.1 pM) (calculated from Figure 3.2D). Whereas, the rank 
order of sensitivity of wortmannin was Class IA PI3K > (ICso= 8.7 nM) > PI3K-C2p 
( IC 5 o= 5 1 .2  nM)>PI3K-C2ot (ICso= > 500 nM) (calculated from Figure 3.2E).
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Figure 3.2 Sensitivity of PI3K isoforms to LY294002 and Wortmannin in 
Jurkat cell line. Whole cell lyates from unstimulated cells were immunoprecipated 
(I.P.) for Class lA-p85 associated PI3K (A), PI3K-C2oc (B), and PI3K-C2p (C) and 
assayed for in vitro lipid kinase activity in the presence of increasing concentration of 
LY294002 (pre-treatment for 30mins prior to initiation of reaction), as indicated (left 
hand panels) or pre-treated Wortmannin for 10 mins, as indicated (right hand panels). 
Reactions were carried out in the presence of Mg2+ buffer. Reaction products were 
extracted, fractionated by thin layer chromatography, and examined by 
autoradiography. Data is representative of three experiments. Results were quantified 
by densitometry, a dose response curve created and IC50 values calculated (D and E). 
Error bars illustrate standard deviation.
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Effect of PI3K inhibitors on Class IA and Class IIPI3K isoforms in A549 cell 
line
Next it was investigated whether the same differential sensitivity of the PI3K 
inhibitors was also seen in A549 cell line. As demonstrated in Jurkat cell line, the 
activities of Class IA PI3K, PI3K-C2a and PI3K-C2p were sensitive to LY294002 
(Figure 3.3A, 3.3B and 3.3C respectively; left panels) although at varying degrees in 
A549 cell line. In comparison, wortmannin inhibited Class IA PI3K and PI3K-C2P 
(Figure 3.3A and 3.3C respectively; right panels), but had little effect on PI3K-C2a 
activity (Figure 3.3B; right panel). Again, densitometry was carried out and utilised 
to calculate IC50 values of the inhibitors to PI3K activity. The rank order of 
sensitivity of LY294002 was Class IA PI3K (IC5o= 3.42 pM) > PI3K-C2a (IC5o= 
7.36 pM) > PI3K-C2p (ICso= 19.69 pM) (calculated from Figure 3.3D). Whereas, 
the rank order of sensitivity of wortmannin was Class IA PI3K > (IC5o= 0.219 nM) > 
PI3K-C2p (IC50= 55.73 nM) PI3K-C2a (IC50= > 500 nM) (calculated from Figure 
3.3E).
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Figure 3.3 Sensitivity of PI3K isoforms to LY294002 and Wortmannin in A549 
cell line. Whole cell lyates from unstimulated cells were immunoprecipated (I.P.) for 
Class lA-p85 associated PI3K (A), PI3K-C2a (B), and PI3K-C2p (C) and assayed for 
in vitro lipid kinase activity in the presence of increasing concentration of LY294002 
(pre-treatment for 30mins prior to initiation of reaction), as indicated (left hand panels) 
or pre-treated Wortmannin for 10 mins, as indicated (right hand panels). Reactions 
were carried out in the presence of Mg2+ buffer. Reaction products were extracted, 
fractionated by thin layer chromatography, and examined by autoradiography. Data is 
representative of three experiments. Results were quantified by densitometry, a dose 
response curve created and IC50 values calculated (D and E).
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The table below outlines the differential sensitivity of LY294002 and wortmannin to 
PI3K isoforms in both Jurkat and A549 cell lines.
Jurkat A549 Jurkat A549
Class IA PI3K 6.5 3.4 8.7 0 .2 2
PI3K-C2a 7.3 7.4 >500 >500
PI3K-C2P 23.1 19.7 51.2 55.7
Table 3.1 Comparison of rank order of sensitivity of LY294002 and wortmannin in Jurkat and 
A549 cell lines (Data calculated from Figure 4.2 and 4.3; n =3).
Effect of varying amount of substrate (PI) on the sensitivity of LY294002 to 
PI3K-C2P isoforms
The amount of substrate (PI) used in in vitro lipid kinase assays is thought to play an 
important role in enzyme kinetics and thus may affect the sensitivity of inhibitors. 
Thus I investigated whether the sensitivity of LY294002 to PI3K-C2P could be 
increased by altering substrate concentration. Interestingly, decreasing the amount of 
substrate (down from 20 pg to 2.5 jig) increased the sensitivity of LY294002 for 
PI3K-C2p (from 23.1% inhibition to 77.2%; Figure 3.4A and B).
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Substrate conc. pg 20 15 10 7.5 5 2.5 1.25






Figure 3.4 Sensitivity of PI3K-C2p isoform to LY294002 in the presence of 
decreasing concentration of substrate in the A549 cell line. Whole cell lyates from 
unstimulated cells were immunoprecipated for PI3K-C2P (A) and assayed for in vitro 
lipid kinase activity in the presence or absence of LY294002 10pM (pre-treatment for 
30mins prior to initiation of reaction), in decreasing amounts of substrate as indicated. 
Reactions were carried out in the presence of Mg2+ buffer. Reaction products were 
extracted, fractionated by thin layer chromatography, and examined by 
autoradiography. Data is representative of three experiments. Results were quantified 
by densitometry and the percentage inhibition of LY294002 compared to its respective 
control are illustrated in (B).
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3.2. Regulation of TNFa and IL-lB stimulated signalling and COX-2
expression and activity in A549 cell line
3.2.1 Background
TNFa has previously been shown, in a colonic epithelial cell line, to activate both 
the PI3K-dependent signalling pathway and the MAPK signalling pathway, which in 
turn plays key roles in the regulation of COX-2 expression (Weaver et al., 2001). In 
addition the pro-inflammatory cytokine IL-ip has also been shown to induce COX-2 
expression via these signalling pathways in canine tracheal smooth muscle cells 
(Yang et al., 2002). Thus, the regulatory role of PI3K and MAPK in TNFa and IL- 
lp induced COX-2 expression in the human lung epithelial cell line A549 was 
investigated in this latter section of this chapter. This was of importance for further 
studies, in the next chapter, which investigate the effects of PPARy ligands on 
cytokine induced expression of pro-inflammatory mediators such as COX-2.
3.2.2 Results
TNFa and IL-ip activate the PI3K and MAPK pathways
The recruitment, phosphorylation and subsequent activation of PKB are 
fundamentally dependent on the accumulation of lipid products of PI3K 
(Vanhaesebroeck and Alessi, 2000) thus phosphorylation of PKB was used as an 
indirect marker of PI3K activation. Phosphorylation of ERK was used as a marker of 
activation of the ERK MAPK pathway. TNFa (100 ng/ml) markedly increased PKB
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phosphorylation at 10-30 mins (Figure 3.5A), and ERK phosphorylation at 10 mins 
(Figure 3.5B). Similarly, IL-ip induced activation of PKB (Figure 3.5C) and ERK 
(Figure 3.5D) at 10-30 mins.
Having determined that TNFa and IL-lp can activate both PKB and ERK MAPK in 
a time-dependent manner, the effects of increasing concentrations of these cytokines 
was investigated in order to determine the optimum concentration for further 
experiments. TNFa induced concentration dependent phosphorylation of ERK, 
however a similar effect on PKB phosphorylation was not so evident (Figure 3.6A). 
This may be due to the high basal level of phospho-PKB sometimes seen in A549 
cells. IL-ip induced concentration dependent phosphorylation of PKB and ERK 
(Figure 3.6A and 3.6B respectively). Maximum phosphorylation of ERK with TNFa 
was observed at 100 ng/ml, whereas with IL-lp it was seen at 10 ng/ml and thus 
these concentrations were used for further experiments.
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Figure 3.5 Effect of TN Fa and IL-ip on PKB and ERK phosphorylation
1.2 x 106 growth arrested, confluent A549 cells were stimulated at 37°C (for the 
indicated time points) with TNFa (100 ng/ml) (A) or IL-lp (lOng/ml) (B). Cells 
were lysed with ice-cold lysis buffer, protiens extracted, quantified and boiled with 
5 X sample buffer. Protein (25 |ig) was resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted, as described in Methods and 
Materials, with a phospho-specific PKB Ab with affinity for the active Ser473- 
phosphorylated form of PKB (upper panels A and C) or a phospho-specific ERK 
Ab with an affinity for phosphorylated Thr202/Tyr204 sites (upper panel B and D). 
Proteins were visualized with ECL. Blots were stripped and reprobed with anti- 
PKB or anti-ERK Ab to verify equal loading and efficiency of protein transfer 
(lower panels). Data is representative of three separate experiments.
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Figure 3.6 Effect of increasing concentration of TNFa and IL-1(3 on PKB 
and ERK phosphorylation.
1.2 x 106 growth arrested, confluent A549 cells were stimulated at 37°C (for 10 
mins) with increasing concentrations of TNFa (A) or IL-ip (B). Cells were lysed 
with ice-cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample 
buffer. Protein (25 pg) was resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and immunoblotted, as described in Methods and Materials, with a 
phospho-specific PKB Ab with affinity for the active Ser473-phosphorylated form of 
PKB or a phospho-specific ERK Ab with an affinity for phosphorylated 
Thr202/Tyr204 sites. Proteins were visualized with ECL. Blots were stripped and 
reprobed with anti-PKB or anti-ERK Ab to verify equal loading and efficiency of 
protein transfer. Data is representative of three separate experiments.
115
Chapter 3 -  <RgsuCts I
Next the effect of the PI3K inhibitor-LY294002 and the MEK inhibitor PD98059, on 
TNFa- and IL-ip- induced PKB and ERK phosphorylation were examined (Figure 
3.7 and 3.8 respectively). LY294002 (10 pM) completely abolished TNFa induced 
phosphorylation of PKB, but had no effect on TNFa induced ERK phosphorylation 
at the concentration used (Figure 3.7A). Pretreatment with PD98059 (20 pM; an 
inhibitor of MEK) had no inhibitory effects on TNFa induced PKB phosphorylation, 
and surprisingly it only modestly inhibited TNFa induced ERK phosphorylation 
(Figure 3.7B). Similar effects on IL-lp- induced PKB and ERK phosphorylation 
were seen in the presence of these inhibitors (Figure 3.8A and 3.8B).
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Figure 3.7 Effect of PI3K and MEK inhibitors on TNFa induced signalling 
events
1.2 x 106 growth arrested, confluent A549 cells were pre-treated with LY294002 (10 
pM) for 30 mins (A) or with PD98059 (20 pM) for 1 hour (B) prior to stimulation at 
37°C (for the indicated time points) with TNFa (100 ng/ml). Cells were lysed with ice- 
cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample buffer. 
Protein (25 pg) was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted, as described in Methods and Materials, with a phospho-specific 
PKB Ab with affinity for the active Ser473-phosphorylated form of PKB or a phospho- 
specific ERK Ab with an affinity for phosphorylated Thr202/Tyr204 sites. Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-PKB or anti-ERK Ab 
to verify equal loading and efficiency of protein transfer (lower panels). Data is 
representative of three separate experiments.
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Figure 3.8 Effect of PI3K and MEK inhibitors on IL-lp induced signalling 
events
1.2 x 106 growth arrested, confluent A549 cells were pre-treated with LY294002 (10 
jliM) for 30 mins (A) or with PD98059 (20 |iM ) for 1 hour (B) prior to stimulation at 
37°C (for the indicated time points) with IL-lp (10 ng/ml). Cells were lysed with ice- 
cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample buffer. 
Protein (25 jig) was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted, as described in Methods and Materials, with a phospho-specific 
PKB Ab with affinity for the active Ser473-phosphorylated form of PKB or a phospho- 
specific ERK Ab with an affinity for phosphorylated Thr202/Tyr204 sites. Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-PKB or anti-ERK Ab 
to verify equal loading and efficiency of protein transfer (lower panels). Data is 
representative of three separate experiments.
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Induction of COX-2 by TNFa and IL-ip
It is commonly reported that COX-2 is inducible in other cell lines by stimulation 
with a variety of pro-inflammatory cytokines, bacterial products, tumour promoters 
and other mitogens. Therefore the pro-inflammatory Thl cytokines TNFa and IL- 
lp  were initially chosen in an attempt to induce COX-2 in human lung epithelial 
cells.
TNFa (100 ng/ml) induced COX-2 protein expression in a bi-phasic manner (Figure 
3.9A). The first peak in COX-2 expression was seen at 4 hours, expression then 
decreased between 6 and 12 hours and a second, more prominent peak in the 
induction of COX-2 was seen at 24-48 hours post-stimulation. COX-1 expression 
was unaltered as expected. Production of PGE2 depends on COX-2 activity 
generating prostaglandin endoperoxide substrates, which are then subsequently 
converted to PGE2 by microsomal PGES (mPGES). An inducible mPGES couples 
predominantly with COX-2 (Jakobsson et al., 1999; Murakami et al., 2000), whereas 
a constitutively and widely expressed cytosolic PGES (cPGES) is thought to be 
coupled to COX-1 (Tanioka et al., 2000). Expression of the inducible mPGES 
increased in a time dependent manner (Figure 3.9A; middle column lower panel). IL- 
lp  (10 ng/ml) induced COX-2 expression more robustly than TNFa (Figure 3.9A; 
right column upper panel). This effect also appeared to be bi-phasic in nature, with 
the first peak seen at 6 hours followed by a second peak in COX-2 expression at 24- 
48 hours. Furthermore, IL-ip also induced mPGES expression at 48 hours (Figure 
3.9A; right column lower panel). Untreated cells showed minimal induction of COX- 
2 expression at 48 hours, but no effect on mPGES was seen (Figure 3.9A; left
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column). On the whole neither cytokine affected COX-1 expression; however a 
modest effect on COX-1 expression was seen following TNFa and IL-lp stimulation 
at 48 hours. TNFa and IL-lp induced COX-2 expression was shown to be 
concentration dependent at 6 hours (Figure 3.9B). The 6 hour time-point was chosen 
as this was a time-point at which COX-2 induction can be seen clearly but is not 
maximal, thus ensuring a large window for detection of upregulation or 
downregulation of the enzyme.
Having established that TNFa and IL-ip induced COX-2 expression, the effects of 
these cytokines on COX-2 activity was determined by measurement of PGE2 , a 
downstream product of COX-2. TNFa and IL-ip induced PGE2 production in a 
time-dependent manner which peaked at 12-24 hours post-stimulation (Figure 3.9C). 
Again, IL-lp showed a more robust induction of PGE2 than TNFa.
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Figure 3.9 Effect of TN Fa and IL-lp on COX-2 and mPGES expression and 
PGE2 production.
1.2 x 106 growth arrested confluent A549s were stimulated at 37°C with either TNFa 
and IL-lp over a time course (2-48 hrs) (A and C). Controls were carried out for each 
time point. 1.2 x 106 growth arrested confluent A549s were stimulated at 37°C for 6  
hours with increasing concentrations of TNFa and IL-lp (B). Cells were lysed with 
ice-cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample buffer. 
Protein (25 jug) was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted, as described in Methods and Materials, with an anti-COX-2 Ab or 
anti-mPGES Ab (A and B; upper and lower panels respectively). Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-COX-1 or anti-PKB 
Ab to verify equal loading and efficiency of protein transfer (middle panels). Prior to 
lysing of cells, supernatants were collected and analysed for PGE2 production by 
ELISA (C). Samples were assayed in duplicate and results are expressed as mean. Data 
is representative of three separate experiments.
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Role of PI3K pathway in cytokine induced COX-2 and PGE2 production
The role of PI3K pathway in TNFa induced COX-2 expression and PGE2 production 
was next investigated by means of two previously characterised PI3K inhibitors, 
wortmannin and LY294002. COX-2 expression and PGE2 production were markedly 
upregulated in response to TNFa (Figure 3.10A and 3.1 OB) which was sensitive to 
LY294002 in a concentration dependent manner with a 58% inhibition seen at 10 
pM. In comparison, TNFa induced COX-2 and PGE2 production was relatively 
insensitive to wortmannin (up to lOOnM) (Figure 3.10C and 3.10D). Neither 
inhibitor affected COX-1 expression (Figure 3.10A and 3.10C lower panels).
Role of MAPK pathway in cytokine induced COX-2 and PGE2 production
Since TNFa induced activation of the ERK MAPK pathway, the role the ERK 
MAPK and also the p38 MAPK pathway in TNFa induced COX-2 expression was 
investigated. This was carried out by use of two MAPK inhibitors, firstly the MEK 
inhibitor PD98059 and secondly the p38 inhibitor SB202190. PD98059 (2-20 pM) 
partially inhibited TNFa induced COX-2 expression in a concentration dependent 
manner, with 53 % inhibition seen at 20 pM (Figure 3.11 A). Furthermore, a more 
profound effect was seen on PGE2 production, where complete inhibition of COX-2 
activity was demonstrated with PD98059 at concentration of 10-20 pM (Figure
3.1 IB). SB202190 (1-10 pM) showed a more marked inhibition of TNFa induced 
COX-2 expression, with a maximum inhibition of 63 % (Figure 3.11C). Again, a 
concentration dependent inhibition of PGE2 production was seen, with a maximal 
effect being seen at 10 pM (Figure 3.1 ID).
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Figure 3.10 Effect of PI3K inhibitors on TNFa induced COX-2 expression and 
PGE2 production
1.2 x 106 growth arrested confluent A549 cells were pretreated for 30 mins with 
LY294002 (1-10 pM) (A) and for 10 mins with another PI3K inhibitor wortmannin 
(100 nM) (B) prior to stimulation with TNFa 100 ng/ml for 6 hours. Cells were lysed 
with ice-cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample 
buffer. Protein (25 pg) was resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and immunoblotted with an anti-COX-2 Ab (upper panels). Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-COX-1 Ab to verify 
equal loading and efficiency of protein transfer (lower panels). Densitometry was 
carried out on COX-2 blots in order to quantify results and values are graphically 
represented below the respective blot. Data is representative of three separate 
experiments. 1.2 x 106 growth arrested confluent A549 cells were pretreated for 30 
mins with LY294002 (1-10 pM) (C) and for 10 mins with another PI3K inhibitor 
wortmannin (10-100 nM) (D) prior to stimulation with TNFa 100 ng/ml for 24 hours. 
Supernatants were collected and analysed for PGE2 production by ELISA. Samples 
were assayed in duplicate and results are expressed as mean. Data is representative of 
three separate experiments.
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Figure 3.11 Effect of MEK and p38 inhibitors on TNFa induced COX-2 
expression and PGE2 production
1.2 x 106 growth arrested confluent A549 cells were pretreated for 1 hour with 
PD98059 (2-20 pM) (A) and for 1 hour with SB202190 (1-10 juM) (B) prior to 
stimulation with TNFa 100 ng/ml for 6 hours. Cells were lysed with ice-cold lysis 
buffer, proteins extracted, quantified and boiled with 5 X sample buffer. Protien (25 
pg) was resolved by SDS-PAGE, transferred to nitrocellulose membranes and 
immunoblotted with an anti-COX-2 Ab (upper panels). Proteins were visualized with 
ECL. Blots were stripped and reprobed with anti-COX-1 Ab to verify equal loading 
and efficiency of protein transfer (lower panels). Densitometry was carried out on 
COX-2 blots in order to quantify results and values are graphically represented below 
the respective blot. Data is representative of three separate experiments. 1.2 x 106 
growth arrested confluent A549 cells were pretreated for 1 hour with PD98059 (2-20 
pM) (C) and for 1 hour with SB202190 (1-10 pM) (D) prior to stimulation with TNFa 
100 ng/ml for 24 hours. Supernatants were collected and analysed for PGE2 
production by ELISA. Samples were assayed in duplicate and results are expressed as 
mean. Data is representative of three separate experiments.
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Role of PKC pathway in cytokine induced COX-2
Previous studies have indicated the involvement of the PKC pathway in cytokine 
induced COX-2 expression (Chen et al., 2000). The involvement of this pathway in 
this system was investigated with the aid of the PKC inhibitor Ro-32-4032. 
Surprisingly the Ro-32-4032 (1-10 pM) had no effect on TNFa induced COX-2 
(Figure 3.12A). Ro-32-4032 also had little or no inhibitory effects on TNFa induced 
PGE2 production (Figure 3.12B).
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Figure 3.12 Effect of PKC inhibitors on TNFa induced COX-2 expression and 
PGE2 production
1.2 x 106 growth arrested confluent A549 cells were pretreated for 30 mins with Ro- 
32-4032 (1-10 pM) prior to stimulation with TNFa 100 ng/ml for 6 hours (A) or 24 
hours (B) . A- Cells were lysed with ice-cold lysis buffer, proteins extracted, 
quantified and boiled with 5 X sample buffer. Protien (25 pg) was resolved by SDS- 
PAGE, transferred to nitrocellulose membranes and immunoblotted with an anti-COX- 
2 Ab (upper panels). Proteins were visualized with ECL. Blots were stripped and 
reprobed with anti-COX-1 Ab to verify equal loading and efficiency of protein transfer 
(lower panels). Densitometry was carried out on COX-2 blots in order to quantify 
results and values are graphically represented below the respective blot. Data is 
representative of three separate experiments. B- Supernatants were collected and 
analysed for PGE2 production by ELISA. Samples were assayed in duplicate and 
results are expressed as mean. Data is representative of three separate experiments.
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Involvement of the NFkB pathway in COX-2 regulation by cytokines
The transcriptional NFkB pathway is known to play an important role in downstream 
signalling of cytokines (Chen et al., 2000; Hozumi et al., 2001; Haddad, 2002). The 
COX-2 promoter has NFkB binding sites, and thus NFkB has been shown to play a 
vital role in the regulation of COX-2 in various cell systems, including A549 cell 
line (Newton et al., 1997). There are several ways in which the activation of NFkB 
can be assayed. Firstly, activation of the classical NFkB pathway requires 
degradation of the inhibitory subunit, IkB. This can easily be assessed by Western 
analysis using an antibody specific to IkB and determining whether expression of 
this protein is lost over a time course. Secondly, following IkB degradation the 
NFkB p65 subunit is phosphorylated and this can also be detected by Western
77  ( \analysis with an antibody specific for NFkB p65 phosphoserine . Thirdly, once 
NFkB p65 is phosphorylated it is able to translocate to the nucleus and bind specific 
sites in the promoter region of the target gene, this can be detected by the use of 
ELISA-based EMSA kits. Finally, NFkB gene reporter assays can be utilised to 
evaluate the gene activity of NFkB by measuring luciferase activity. This next 
section employed each of these described assays in order to investigate the role of 
the NFkB pathway in cytokine induced events.
TNFa (100 ng/ml) induced IkB degradation within 10 mins post-stimulation (Figure 
3.13A; upper panel). This effect was maintained until 2 hours, at which point IkB 
expression was restored. Interestingly a second phase of IkB degradation was seen at 
6 hours, and this returned to basal levels by 24 hours. Basal IkB degradation did not 
alter over the time course of the experiment (Figure 3.13A; upper panel). TNFa
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induced marked NFkB p65 phosphorylation at 10 mins post-stimulation, which 
returned to basal levels by 6 hours (Figure 3.13A; middle panels). The effects seen 
on NFkB p65 phosphorylation were supported by NFkB p65 activation, which also 
peaked at 10 mins post-stimulation, was maintained at the same level for 2 hours, 
after which it decline and almost returned to basal by 24 hours (Figure 3.13B). Time 
point controls were also carried out and showed no significant changes.
A549 cell line stably transfected with the NFkB luciferase gene reporter construct 
was utilised to measure reporter activity. TNFa and IL-lp induced NFkB reporter 
activity in a concentration dependent manner at 6 hour time point (Figure 3.14A). 
Maximal reporter activity was seen at 10-100 ng/ml TNFa and at 1-100 ng/ml IL- 
ip. In addition, an increase in reporter activity was still seen at 24 hours post­
stimulation with TNFa 100 ng/ml albeit slightly lower than that seen at 6 hours 
(Figure 3.14B). Next it was investigated whether cytokine induced NFkB activity 
was mediated via PI3K pathway. This was carried out by the use of two PI3K 
inhibitors previously described. Both TNFa and IL-lp induced NFkB gene reporter 
activity was sensitive to LY294002 in a concentration dependent manner (Figure 
3.14C), with a 50% inhibition seen at 10 pM LY294002. In contrast, wortmannin 
had no effect on TNFa and IL-lp induced NFkB gene reporter activity at 
concentrations up to 1 pM (Figure 3.14D).
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Figure 3.13 Effect of TNFa on IkB degradation, NFkB p65 phosphorylation 
and activation.
3.2 x 106 growth arrested confluent A549 cells were stimulated with either TNFa 100 
ng/ml (A) over a time course (10 mins -24 hrs). Nuclear and cytosolic proteins were 
extracted as described in Methods and Materials. Proteins were quantified and 
cytosolic protein samples were boiled with 5 X sample buffer, protein (25 pg) was 
resolved by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted 
with an anti-lKB Ab (upper panels, A) or an anti-phospho-p65 Ab (middle panels, A). 
Proteins were visualized with ECL. Blots were stripped and reprobed with anti-ERK 
Ab to verify equal loading and efficiency of protein transfer (lower panels, A). 
Nuclear extracts (7.5 jig) from the same experiments were assayed for NF-kB p65 
activation/DNA binding by use of a TransAM™ NF-kB p65 kit (B). Samples were 
assayed in duplicate and results are expressed as mean NF-kB p65 activation (A595). 
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Figure 3.14 Effect of TN Fa and IL-ip on NFkB gene reporter activity.
A- 0.2 x 106 growth arrested, confluent A549-KBtkluc cells (A549 cells that have been 
stably transfected with the NF-kB luciferase gene reporter construct) were stimulated 
with TNFa or IL-ip (at the indicated concentration) for 6 hours (A); with TNFa (100 
ng/ml) at 6 and 24 hours (B); and with TNFa (100 ng/ml) or IL-lp (10 ng/ml) for 6 
hours in the presence of 30 min pretreatment with LY294002 (0.3-10 pM; C) or 10 min 
pretreatment with wortmannin (10-1000 nM; D). Promega Steady-Glo luciferase buffer 
was added to cells and left at room temperature for 10 mins. Lysates were then mixed 
and 200 pi sample was then transferred into opaque 96-well plates and luminescence 
was measured on a Beckman Topcount with a 5 sec luminescence program. Results are 
expressed as mean luminescence or as fold change over basal. Data is representative of 
more than three separate experiments.
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3.3. Summary 
Summary of section 3.1
• A549 cells express Class IA p85, PI3K-C2a and PI3K-C2p, but not Class IB 
pi 10y.
• LY294002 and wortmannin show differential selectivity to PI3K isoforms, 
and similar results were obtained in two distinct cell lines.
• Furthermore, the IC50 values obtained in the two cell lines are comparable.
• Interestingly wortmannin is unable to inhibit PI3K-C2a isoforms at 
concentrations up to 500 nM in either the Jurkat or A549 cell line.
• However, the sensitivity of LY294002 PI3K-C2p can be increased when the 
amount of substrate (PI) used in the assay is decreased to a minimum of 2.5 
pg in A549 cell line.
Summary of section 3.2
• TNFa and IL-lp activated the PI3K and ERK MAPK pathways as assessed 
by phosphorylation of PKB and ERK respectively.
• TNFa induced phosphorylation of PKB was sensitive to the PI3K inhibitor 
LY294002 and phosphorylation of ERK was sensitive to the MEK inhibitor 
PD98059.
• TNFa and IL-ip induced COX-2 expression in a concentration dependent 
manner. In addition, both cytokines induced the time dependent production 
of PGE2 , a downstream product of COX-2.
131
Chapter 3 — <R#suCts I
• TNFa induced COX-2 expression and PGE2 production was sensitive to the 
PI3K inhibitor LY294002, but insensitive to another PI3K inhibitor 
wortmannin.
• TNFa induced COX-2 expression and PGE2 was also sensitive to the MEK 
inhibitor PD98059 and the p3S inhibitor SB202190, but was insensitive to 
the PKC inhibitor Ro-32-4032.
• TNFa activated the NFkB pathway, as shown by time dependent IkB 
degradation, NFkB p65 phosphorylation and activation, and concentration 
dependent induction of NFkB gene reporter activity. Furthermore, IL-ip 
induced NFkB gene reporter activity in a concentration dependent manner. 
Both TNFa and IL-lp induced NFkB gene reporter activity was sensitive to 
PI3K inhibitor LY294002, but insensitive to wortmannin.
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3.4. Discussion I
Characterisation of PI3K isoform expression and inhibitor sensitivity
This work looks at the involvement of signalling pathways in the regulation of COX- 
2 expression at the protein and product level by TNFa and IL-lp. Previous reports 
have only shown the expression of pi 10a in A549 cell line (Ahmad et al., 2003). 
This study reports for the first time expression of Class LA PI3K, PI3K-C2a and 
PI3K-C2P in A549 cell line. It was not surprising that the A549 cell line did not 
express pllOy, as this isoform is known to be restricted to haematopoietic lineages 
(Vanhaesebroeck and Waterfield, 1999). The expression of PI3K isoforms has been 
shown to be expressed in many cells associated with lung inflammation. 
Furthermore, studies have shown that PI3K activity increased significantly after 
allergen challenge in a murine model of asthma (Kwak et al., 2003). Administration 
of either wortmannin or LY294002 reduced bronchial inflammation and airway 
hyperresponsiveness. Thus these studies suggest an important role of PI3K in airway 
inflammation.
The study of the role of PI3Ks in cell physiology has been aided by the use of the 
inhibitors wortmannin and LY294002 [2-(4-morpholinyl)-8-phenyl-4//-1 - 
benzopyran-4-one]. Wortmannin is a PI3K inhibitor derived from a metabolite of the 
fungus Penicillium funiculosum Thom (Wiesinger et al., 1974; Park et al., 1997). It 
was first characterized as an inhibitor that is effective at micromolar concentrations 
of myosin light-chain kinase but was later shown to inhibit mammalian PI3Ks at 
nanomolar concentrations (Arcaro and Wymann, 1993; Powis et al., 1994). It
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covalently attaches to the pi 1 0  catalytic subunit and causes irreversible inhibition 
with a Ki of 1-10 nM and a similar IC50. LY294002 is a structurally distinct, 
competitive inhibitor for the adenosine triphosphate binding site of PI3K and has 
been shown to cause specific inhibition with a X, of 1. 6  pM and an IC50 of 1 .4 pM 
(Vlahos et al., 1994),
Domin et al. (1997), demonstrated that wortmannin is a poor inhibitor of PI3K-C2a, 
In this study, it is demonstrated here that PI3K-C2a was refractory to wortmannin in 
both Jurkat and A549 cell line. LY294002 was shown to be less selective towards 
PI3K-C2P compard to the other isoforms investigated and this was in accordance 
with studies carried out by Arcaro et al., (1998). The differential sensitivity of PI3K 
isoforms to LY294002 and wortmannin must therefore be taken into account when 
utilising these inhibitors to evaluate the role of PI3K in various systems.
Another possible explanation for the differential effects of the two inhibitors is that 
wortmannin and LY294002 may not be as specific at inhibiting PI3K as claimed. 
Although there are reports demonstrating the specificity of their actions (Wiesinger 
et al., 1974; Vlahos et al., 1994; Davies et al., 2000), there are isolated reports 
suggesting other actions of these pharmacological compounds. Wortmannin has 
been reported to inhibit phospholipase A2 (Cross et al., 1995), although if this 
resulted in less arachidonic acid as substrate for COX-2 one might expect inhibition 
of PGE2 production rather than potentiation. Reports that wortmannin can inhibit 
PI4K (Nakanishi et al., 1995) are more difficult to interpret, as is the finding that 
LY294002 can inhibit casein kinase (Davies et al., 2000).
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Although disparity between results obtained using wortmannin and LY294002 are 
rare, there is a precedent (Salh et al., 1998). This group were studying PI3K and 
iNOS activation in a macrophage cell line and showed that activation of PI3K by 
LPS was sensitive to both wortmannin and LY294002. However, nitric oxide 
generation was sensitive only to LY294002 and not to wortmannin. They proposed 
a FKBP12-rapamycin-associated protein (FRAP) dependent pathway which was 
more sensitive to LY294002 than to wortmannin. Supporting their proposition is 
evidence from a second group demonstrating that both wortmannin and LY294002 
can inhibit FRAP at higher concentrations than those necessary to inhibit PI3K 
(Brunn et al., 1996).
Interestingly, when the amount of substrate used in the assay was reduced, PI3K- 
C2p activity was more sensitive to LY294002. Since LY294002 is known to act by 
competitively inhibiting the ATP binding site, it can be hypothesised that high 
concentrations of substrate (PI) may somehow be hindering the ability of LY294002 
to bind to this site. Thus these points must be taken into consideration when 
interpreting these results since it is difficult to determine the substrate concentration 
in these cell systems.
To summarise, one must be aware of the potential pitfalls regarding the 
interpretation of the results when using these pharmacological inhibitors of PI3K. 
There are other methods of inhibiting PI3K such as molecular methods like micro­
injection of antibodies or transferring dominant negative forms of PI3K into cells 
(Benistant et al., 2000; Sasaki et al., 2000; Stein and Waterfield, 2000; Weaver and 
Ward, 2001). Similar transfer methods can be used to manipulate PI3K by causing
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its over-expression, and these may be placed under the control of an environmental 
agent such as an antibiotic in the culture media (Craddock et al., 1999). Evidence 
should be gathered from different models using different mechanisms of 
manipulating PI3K and from the resulting evidence a consensus should be drawn. 
Thus more selective assays as well as inhibitors and/or molecular methods would be 
required to fully investigate the role of individual PI3K isoforms in the regulation of 
COX-2 expression in lung epithelial cells.
TNFa and IL-lp mediated signalling
The role of PI3K and MAPK in TNFa and IL-lp signalling has been established 
(Saklatvala et al., 1999; Akira, 2003). The activation of PI3K occurs through an 
interaction of the SH2 domain of the PI3K p85 subunit with a domain in the partner 
cell surface receptor containing the motif YXXM (Saklatvala et al., 1999; Akira, 
2003). A putative PI3K binding site (amino acids 257-260, YKAM) is found in the 
C terminus of MyD88 (molecule myeloid differentiation factor 88), an adaptor which 
links IL-1R with downstream signaling molecules. Activation of the toll-like 
receptor (TLR)4 with LPS or the IL-1 receptor with IL-lp induces the recruitment of 
MyD88. MyD88 in turn recruits two distinct putative serine-threonine kinases. One 
kinase is the IL-1 receptor-activated kinase (IRAK), IRAK then interacts with the 
adaptor molecule, TNF receptor-activated kinase (TRAF6), which links both 
proteins to a second protein kinase NFKB-inducing kinase (NIK). NIK activates the 
IKK that directly phosphorylates IkB. The phosphorylation of IkB initiates its 
ubiquitin-proteasome-mediated degradation, and liberates and activates NFkB. 
Moreover, the TNF-receptor activates TRAF2, but not TRAF6. Downstream
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signalling pathways of LPS, IL-1 and TNF converge at a point distal to TRAF6 and 
TRAF2 (Figure 3.15).
The involvement of the MAPK and NFkB pathway in TNFa and IL-lp signalling 












MEK1/2, MKK 4A7, MKK 3/6
ERK 1/2, JNK, p38
NFkB
C/EBPs ATF/AP1
Figure 3.15. Signalling pathways activated downstream of surface receptors leading to gene 
activation (adapted from (Tanabe and Tohnai, 2002)).
Here it is shown that both the PI3K and ERK MAPK pathways are activated 
following TNFa and IL-lp stimulation in lung epithelial cell line A549. As expected
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the PI3K inhibitor LY294002 completely abolished TNFa and IL-1 p induced PKB 
phosphorylation. In contrast the MEK inhibitor, PD98059, although it showed 
attenuation in the TNFa and IL-lp induced ERK phosphorylation did not completely 
abolish the response.
Activation of the COX-2 pathway by TNFa and IL-ip
Several studies have shown that cytokines such as TNFa and IL-lp can induce 
COX-2 expression in lung epithelial cell lines (Newman et al., 1994; Newton et al., 
1997; Chen et al., 2000; Lin et al., 2000; Chen et al., 2001). Of particular importance 
are reports that show the involvement of various signalling pathways such as NFkB, 
PKC and MAPK in the induction of COX-2 by both TNFa and IL-1 p (Newton et al., 
1997; Chen et al., 2000; Lin et al., 2000; Chen et al., 2001). The PI3K pathway has 
also been shown to play a regulatory role in TNFa induced COX-2 expression in 
colonic epithelial cell lines (Weaver et al., 2001).
There are many signalling pathways involved in COX-2 gene induction some of 
which have already been outline in the above section. c-Jun also appears to play a 
role in COX-2 activation in LPS-treated macrophages. Interestingly, MEKK1 and 
JNK-dependent transcriptional activation of the COX-2 gene in LPS-treated 
macrophages does not require Ras activation. Recently, the adapter protein ECSIT, 
has been identified and shown to link the signalling pathway from the cytoplasmic 
domain of receptors (TLR4 and IL-1 receptor) to MEKK1 (Figure 3.15).
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The A549 cell line used in this study displayed a small amount of constitutive COX- 
2 expression at the protein level which is faintly seen in blots with good sensitivity. 
This is in keeping with results from other groups (Pawliczak et al., 2004; Petkova et 
al., 2004). The small amount of constitutive expression seen is reflected in detectable 
amounts of PGE2 production.
It has been demonstrated here that the pro-inflammatory cytokines TNFa and IL-lp 
can induce COX-2 in the A549 cell line. TNFa (and to a lesser extent IL-ip) induce 
COX-2 expression in a bi-phasic manner. This has also been shown in the 
carrageenin-induced pleurisy model in rats (Gilroy et al., 1999), where COX-2 
protein expression peaked initially at 2 hrs, associated with maximal PGE2 synthesis. 
However at 48 hrs there was a second increase in COX-2 expression. Paradoxically, 
this coincided with inflammatory resolution and was associated with minimal PGE2 
synthesis. In contrast, levels of PGD2 and 15d-PGJ2 were high at 2 hrs, decreased as 
inflammation increased, but were increased again at 48 hrs. The use of a selective 
COX-2 inhibitor and a dual COX-1/COX-2 inhibitor blocked inflammation at 2 
hours but significantly exacerbated inflammation at 48 hrs, which was associated 
with reduced exudate PGD2 and 15d-PGJ2 concentrations, and was also reversed by 
replacement of these PGs. Thus this study suggested that COX-2 may be pro- 
inflammatory during the early phase of a carregeenin-induced pleurisy, but may aid 
resolution at the later phase by generating an alternative set of anti-inflammatory 
PGs (Gilroy et al., 1999). In the A549 cell system PGE2 concentration peaked 
between 12-24 hrs following stimulation with either TNFa or IL-lp. The profile of 
PGE2 production did not follow the same kinetics of COX-2 expression, in that at 
late time points (48 hrs) the level of PGE2 produced was low despite maximal COX-
139
Chapter 3 -  (Discussion I
2 expression. This effect may suggest that the profile of PG produced by COX-2 is 
altered at later time points, reflecting the resolution phase of inflammation as 
described by work done by Gilroy et al., (1999).
COX-1 expression was unaltered following cytokine treatment, consistent with its 
role as the “housekeeping” isoform. mPGES is coupled to COX-2 and thus the 
increase in the mPGES expression was not unexpected since COX-2 expression 
increased following cytokine stimulation. The putative promoter of the human 
mPGES-1 gene is GC-rich, lacks a TATA box, and contains binding sites for C/EBP 
a  and p and AP-1, two tandem GC- boxes, two progesterone receptor and three GRE 
elements (Naraba et al., 2002). Of these sites, the GC boxes are critical for the 
promoter activity, where the transcription factor Egr-1 binds to the proximal GC box 
and triggers mPGES-1 transcription. Stimulus-induced activation of MAPK leads to 
the induced expression of the transcription factor Egr-1 (Guha et al., 2001). 
Furthermore, Egr-1 is phosphorylated and activated by MAPK. In the context of my 
findings, both TNFa and IL-1 p were able to activate MAPK which may induce 
activation of Egr-1. Activated Egr-1 can bind to the proximal GC box in the 
mPGES-1 promoter, leading to transcriptional activation of the mPGES-1 gene 
(Murakami and Kudo, 2004). Although the role of Egr-1 in mPGES induction has 
been documented, the role of NFkB is also thought to be of importance (Catley et al., 
2003). This is of particular interest in this system since results show activation of the 
classical NFkB pathway.
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Involvement of signalling pathways in TNFa induced COX-2 expression
As previously outlined signalling downstream of TNF and IL-1 receptors can 
activate the PI3K pathway. The PI3K pathway lies upstream of TNFa induced 
NFkB signalling (Ozes et al., 1999; Reddy et al., 2000), and since the COX-2 
promoter contains NFkB binding sites it can be hypothesised that these pathways 
may play important roles in cytokine induced gene expression.
P13K pathway
The involvement of the PI3K pathway in TNFa induced COX-2 expression and 
PGE2 production is unclear given that the two PI3K inhibitors utilised showed 
differential effects. LY294002 showed inhibitory effects on TNFa induced COX-2 
expression and PGE2 , whereas wortmannin showed no significant effect on either 
TNFa induced COX-2 expression or PGE2 production. Differential effects of PI3K 
inhibitors on COX-2 expression have previously been demonstrated (Weaver et al.,
2001). However, Weaver et al., showed that wortmannin further enhanced cytokine- 
induced COX-2 expression in colonic epithelial cells, and in comparison LY294002 
enhanced cytokine-induced COX-2 at low concentrations but had an inhibitory effect 
at higher concentration (10 pM) (Weaver et al., 2001). The inhibitory effects of 
LY294002 at higher concentrations in the study by Weaver et al., were suggested to 
be due to non-specific effects or due to disparate effects on different PI3K isoforms. 
The disparate effects seen in my system may be due to the differential sensitive of 
the two inhibitors on activity of different PI3K isoforms. Since PI3K-C2a is 
refractory to wortmannin and has no effect on TNFa induced NFkB reporter activity 
and COX-2, this isoform may be of particular importance in TNFa induced events.
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MAPK pathway
The data presented here also suggests an important role of the MAPK pathway in 
TNFa induced COX-2 expression. Both the MEK inhibitor, PD98059 and the p38 
MAPK inhibitor partially abrogated TNFa induced COX-2 expression. Furthermore, 
TNFa induced phosphorylation of ERK MAPK in A549. These pathways have 
previously been shown to play regulatory roles in COX-2 expression (Yang et al.,
2002). Inflammatory stimuli activate major intracellular signalling pathways such as 
the: NFkB pathway and the MAPK pathways (Ono and Han, 2000; Kracht and 
Saklatvala, 2002; Clark et al., 2003; Kumar et al., 2003). The MAPK are inactivated 
by phosphatases, especially the dual specificity phosphatases. These pathways drive 
transcription of inflammatory genes. The promoter regions of these genes, such as 
COX-2, have binding sites for a limited set of transcription factors: sites for NFkB, 
AP-1, C/EBPp and Ets family members are common. JNKs phosphorylate and 
activate c-jun and ATF2, which are components of AP-1 binding complexes. ERK 
activates C/EBPP and AP-1, and all three MAPKs can phosphorylate Ets 
transcription factors such as Elk-1 and SAP-1 (Kracht and Saklatvala, 2002).
Several transcription factors can be phosphorylated by p38 and the downstream 
kinases might also be involved (Ono and Han, 2000; Kracht and Saklatvala, 2002) in 
the induction of COX-2. The p38 pathway stabilises inflammatory response protein 
mRNAs (Kracht and Saklatvala, 2002; Clark et al., 2003) and promotes their 
translation (Kumar et al., 2003) through AU-rich elements (AREs) in the 3’ 
untranslated region of the mRNAs (Winzen et al., 1999; Lasa et al., 2000). These 
contain repeats of the motif AUUUA, often in a U-rich context, and are present in
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mRNAs of cytokines, inflammatory proteins and oncogenes (Bakheet et al., 2001; 
Kracht and Saklatvala, 2002; Clark et a l, 2003). They were discovered as instability 
elements but, in the case of inflammatory response mRNAs, the instability is 
countered by signalling in the p38 pathway (Winzen et al., 1999; Lasa et al., 2000; 
Frevel et al., 2003). COX-2 mRNA has an ARE in the proximal 3’ untranslated 
region, which has been mapped in detail (Lasa et al., 2000; Sully et al., 2004); it is 
stabilised by MAPKAPK-2. The ARE directs rapid de-adenylation of the 3’-poly A 
tail of the mRNA; this is followed by rapid degradation of the body by the exosome, 
a complex of 3’-> 5’ nucleases. Activation of p38 markedly delays the de- 
adenylation but has little effect on the rate of decay of the de-adenylated message 
(Dean et al., 2003). Thus it is clear that p38 plays an important role in the regulation 
of COX-2 mRNA stability, and thus is vital in the expression of COX-2.
PKC pathway
Despite evidence that suggested the involvement of the PKC pathway in COX-2 
regulation in lung epithelial cell line, NCI-H292 (Chen et al., 2000), this pathway 
was not an obligatory event in TNFa-mediated COX-2 expression in A549 cells.
TNFa induced activation of the NFkB pathway
As outlined in the introduction the NFkB pathway plays a fundamental role in the 
regulation of many inflammatory mediators including COX-2. Previous studies in 
the A549 cell line have shown the importance of the NFkB pathway in COX-2 and 
mPGES expression and PGE2 production following IL-lp stimulation (Catley et al.,
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2003). However, this effect has not been conclusively shown to involve the PI3K 
pathway in this system. The data presented here clearly indicated activation of the 
classical NFkB pathway following cytokine stimulation. TNFa and IL-lp induced 
NFkB gene reporter activity, was sensitive to the PI3K inhibitor LY294002 but 
insensitive to another PI3K inhibitor wortmannin. Again this result can be explained 
due to the differential selectivity of LY294002 and wortmannin on PI3K isoforms. 
The above results suggest that cytokine mediated activation of the NFkB pathway is 
partially dependent on the PI3K pathway. Contrary to the results illustrated here, the 
PI3K pathway has been shown to negatively regulate the NFkB pathway in other 
systems (Weaver et al., 2001).
The bi-phasic induction of COX-2 protein by TNFa and IL-1 p was discussed earlier. 
Interestingly TNFa also induced IkB degradation in a bi-phasic manner. These 
results may therefore suggest that the bi-phasic nature of IkB degradation leads to bi- 
phasic induction of COX-2 since the COX-2 promoter is known to have NFkB 
binding sites. Furthermore, the IkB promoter also has NFkB binding sites and thus 
activation of this pathway has previously been shown to lead to autoregulation 
(Cogswell et al., 1993; Ito et al., 1994; Hoffmann et al., 2002). Figure 3.16 outlines 
the suggested autoregulatory mechanism of the NFkB pathway.
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Figure 3.16. Autoregulation of the NFkB pathway by IkB.
Several studies have shown TNFa stimulation does not induce p i00 processing, 
although it strongly induces hcBa degradation (Coope et al., 2002; Derudder et al., 
2003; Gommerman and Browning, 2003; Muller and Siebenlist, 2003). However, 
TNFa stimulation does increase the expression of both p i00 and RelB, which are 
transcriptional targets of the classical NFkB signalling pathway (Gommerman and 
Browning, 2003; Yilmaz et al., 2003). Thus the classical NFkB pathway is indirectly
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linked to the alternative NFkB pathway and may influence the amplitude and 
duration of its activation.
Mutation analysis of p65 Ser276 has shown the extreme importance of this residue 
for engagement of the cofactor CBP and its paralogue p300 (Zhong et al., 1998). 
MSK1 is a direct target for both p38 and ERK MAP kinases and was first identified 
as a very potent CREB kinase (Deak et al., 1998). Alignment of the CREB sequence 
containing the MSK1 phosphorylation site (Seri 33) and the sequence surrounding 
Ser276 of p65 revealed an unexpectedly high degree of similarity. The fact that 
phosphorylation of CREB and/or p65 is essential for recruitment of CBP/p300 led 
Vermeulen et al., to investigate the role of MSK1 in p65 phosphorylation. Indeed the 
authors showed that MSK1 is involved in Ser276 phosphorylation and subsequent 
gene activation in response to TNF treatment (Vermeulen et al., 2003)
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Figure 3.17. Intracellular signalling pathways thought to mediate COX-2 induction in A549 
cells. A distinct set of upstream kinases including MAPKs can activate transcription factors (NFkB, 
AP-1, C/EBP) which in turn leads to upregulation of COX-2 (adapted from Chun et al., 2004). 
Putative pathways are shown in solid arrows whereas unknown pathways are shown by dashed 
arrows.
Although this chapter has shown that TNFa and IL-lp activate the NFkB pathway, 
the involvement of other transcriptional pathways in the induction of COX-2 cannot
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be ruled out. Figure 3.17 outlines the intracellular signalling pathway that I found to 
be involved in mediating COX-2 induction.
Due to the clear evidence of the role of the MAPK pathway in the induction of COX- 
2 expression it is highly unlikely that NFkB is the sole transcriptional pathway 
involved in the cytokine induced expression of COX-2 in A549 cell line.
3.5. Conclusions
This chapter has outlined some of the signalling pathways involved in the regulation 
of COX-2 expression by cytokines in A549, lung epithelial cell line. The MAPK, 
NFkB and to a certain extent the PI3K pathway all seem to play important roles in 
this process. However in this chapter I have also characterised two PI3K inhibitors 
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4. RESULTS II
4.1 Regulation of signalling and basal COX-2 expression and 
activity by PPARy ligands
4.1.1. Background
PPARy expression is augmented in the bronchial submucosa, airway epithelium and 
smooth muscle of steroid-untreated asthmatics, as compared with control subjects 
(Benayoun et al., 2001), suggesting a role of PPARy in airway inflammation.
PPARy ligands have been shown to inhibit production of many pro-inflammatory 
mediators as outlined in the introduction. Several studies have investigated the role 
of PPARy ligands in modifying animal models of autoimmune diseases and further 
support the hypothesis that PPARy ligands may be beneficial in inflammatory 
responses (Nakajima et al., 2001; Cuzzocrea et al., 2003).
This chapter investigates the effects of PPARy ligands on signalling pathways and 
COX-2 expression, and the effect of PPARy ligands on cytokine induced 
inflammatory responses.
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4.1.2. Results
Expression of PPARy in A549 cell line
PPARy has shown to be expressed in various epithelial cells including colonic 
epithelial cells, mammary epithelial cells and also lung epithelial cells (Benayoun et 
al., 2001; Ikawa et al., 2001; Subbaramaiah et al., 2001). In order to evaluate the role 
of PPARy on the regulation of COX-2 by PPARy ligands, its expression was first 
determined by immunoblotting. Some studies indicate that PPARy, like other nuclear 
receptors, resides in the cytoplasm until activated, and then translocates to the 
nucleus where it can regulate transcription. In contrast, immunofluorescence analysis 
and western blot analysis have shown PPARy to be predominately nuclear localised 
in macrophages (Chinetti et al., 1998) and nuclear localisation of PPARy has been 
shown to be independent of ligand (Dreyer et al., 1993). Thus the localisation of 
PPARy in its inactive state may vary from one cell type to another. It was therefore 
necessary to not only verify the expression of PPARy in A549 cell line, but also to 
determine its localisation within the cell. A colonic epithelial cell line (HT-29) was 
used as a positive control, since this cell line has been shown to express PPARy 
(DuBois et al., 1998; Lefebvre et al., 1999; Galetto et al., 2001; Ikawa et al., 2001; 
Kehrer et al., 2001). Nuclear and cytoplasmic extracts were also compared to whole 
cell lysates obtain with standard lysis buffer. The molecular weight of PPARy is 
around 54 kDa. Figure 4.1 shows the expression of PPARyi and PPARy2 in the 
nucleus of A549 and HT-29 cell lines. In addition the HT-29 cell line shows 
expression of PPARy in whole cell extract.
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Figure 4.1 The A549 cell line express PPARy isoforms.
3.2 x 106 grow-arrested, confluent A549 cells were harvested for nuclear and 
cytosolic protein extraction as described in Methods and Materials. Positive control 
lysates (nuclear extract of HT-29 colonic epithelial cell line for PPARy expression) 
were also collected. Proteins were quantified by Bradford assay and boiled with 5 x 
sample buffer. Protein (25pg) were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted, as described in Methods and 
Materials, with an anti-PPARy Ab (which recognises PPARy, and PPARy2). Proteins 
were visualized with ECL. Data is representative of three experiments.
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Effect of PPARy ligands on PKB and ERK phosphorylation
PPARy ligands have been shown to activate both the PI3K and extracellular 
regulated kinase ERK MAPK pathways in vascular smooth muscle cells (Takeda et 
al., 2001) and the ERK MAPK pathway in murine myoblasts (Huang et al., 2002).
Having established that A549 cells express PPARy, and PI3K isoforms (in Chapter 
3), the involvement of the PI3K pathway in PPARy ligand signalling in A549 cells 
was investigated. PPARy and PI3K pathways have been shown to be involved in the 
regulation of COX-2 expression in other cell lines following stimulation with a 
variety of stimuli (Matsuura et al., 1999; Chen et al., 2000; Weaver et al., 2001; 
Yang et al., 2002; Liu et al., 2003; Luo et al., 2003; Bradbury et al., 2004; Chen et 
al., 2004; Lin et al., 2004). Activation of the PI3K pathway was determined 
indirectly by assessing phosphorylation of PKB.
Both the synthetic PPARy ligand, troglitazone and the naturally occurring PPARy 
ligand 15d-PGJ2 (10 pM) induced transient phosphorylation of PKB which was 
detectable at 15 mins and declined back to basal levels after 60 mins (Figure 4.2A). 
Phosphorylation of PKB by both troglitazone and 15d-PGJ2 was also shown to be 
concentration dependent at 30 mins, (Figure 4.2B). Troglitazone responses were 
detected following 1-100 pM, whilst 15d-PGJ2 responses were detectable following 
10-100 pM. Subsequent experiments were performed with 10 pM of either 
troglitazone or 15d-PGJ2. The competitive PI3K inhibitor LY294002 completely 
abolished the effects of both troglitazone and 15d-PGJ2 on PKB phosphorylation 
(Figure 4.2C and 4.2D respectively). As a comparison, I also investigated the effects
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of troglitazone and 15d-PGJ2 on phosphorylation of ERK since this has also been 
reported to be downstream of PPARy in other settings (Takeda et al., 2001) and as 
shown in Chapter 3 plays a role in induction of COX-2. Troglitazone treatment 
resulted in phosphorylation of ERK 1/2 MAPKs, an event associated with activation 
of these enzymes (Figure 4.2E). Furthermore, PD98059, a MEK inhibitor (Alessi et 
al., 1995), attenuated troglitazone induced ERK activation (Figure 4.2E). 15d-PGJ2 
did not stimulate phosphorylation of ERK (Figure 4.2A)
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Figure 4 .2 T roglitazone stim ulates PI3K  and M E K  dependent phosphorylation o f  PK B  
and ER K  respectively, w hereas 15d-PG J2 only stim ulates PI3K  dependent 
phosphorylation  o f PK B .
1.2 x 106 growth arrested, confluent A549 cells were stimulated (for the indicated times) with 
either troglitazone or 15d-PGJ2 (10 (iM) (A); or with varying concentrations of troglitazone or 
15d-PGJ2 for 30 mins (B); or pretreated with LY294002 10 pM for 30 mins or with PD98059 
20 pM for 60 mins followed by stimulation with troglitazone (10 pM) (C and E); or pretreated 
with LY294002 10 pM for 30 mins followed by stimulation with 15d-PGJ2 (10 pM) (D). Cells 
were lysed with ice-cold lysis buffer, proteins extracted, quantified and resolved by SDS- 
PAGE, Immunoblotting was carried out, as described in Methods and Materials, with a 
phospho-specific ERK Ab with an affinity for phosphorylated Thr202/Tyr204 sites (middle panel 
A and upper panel C) or a phospho-specific PKB Ab with affinity for the active Ser473- 
phosphorylated form of PKB (upper panels A, B, D and E). Proteins were visualized with 
ECL. Blots were stripped and reprobed with anti-PKB or anti-ERK Ab to verify equal loading 
and efficiency of protein transfer (lower panels). Data is representative of three separate 
experiments.
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Effect of PPARy on COX-2 expression and activity.
The effects of troglitazone and 15d-PGJ2 on COX-2 expression were examined over 
times ranging from 2 hours to 48 hours post-stimulation in A549 cells. Untreated 
A549 cells had barely detectable levels of COX-2 expression (Figure 4.3A, left 
panel). However, after 48 hours in the experimental environment COX-2 expression 
was more prominent but this did not correlate with detectable basal production of 
PGE2 , a marker of COX-2 activity (Figure 4.3A, middle panel). Troglitazone (10 
pM) induced COX-2 protein expression in a time dependent manner from 4 hours to 
48 hours while COX-1 levels were unaltered (Figure 4.3A). In addition, troglitazone 
induced COX-2 expression was concentration-dependent at 6 hours (Figure 4.3B). 
The increase in COX-2 expression in response to troglitazone was accompanied by a 
marked increase in production of PGE2 at 48 hours (Figure 4.3C). Troglitazone 
stimulated expression of mPGES, with kinetics similar to those observed for COX-2 
induction (Figure 4.3 A). However, 15d-PGJ2 (10 pM) was unable to alter expression 
of COX-2, mPGES or PGE2 production above levels seen in time matched controls.
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Figure 4.3 Troglitazone, but not 15d-PGJ2, induces COX-2 and mPGES 
expression and PGE2 production in a time-dependent manner in A549 cell line.
1.2 x  106 growth arrested confluent A549s were stimulated at 37°C with either 
troglitazone (10 pM) or 15d-PGJ2 (10 pM) over a time course (2-48 hrs) (A and C). 
Controls were carried out for each time point. 1.2 x 106 growth arrested confluent 
A549s were stimulated at 37°C for 6  hours with increasing concentrations of 
troglitazone or 15d-PGJ2 (B). Cells were lysed with ice-cold lysis buffer, proteins 
extracted, quantified and boiled with 5 X sample buffer. Protein (25 pg) was resolved 
by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted, as 
described in Methods and Materials, with an anti-COX-2 Ab or anti-mPGES Ab (A 
and B; upper and lower panels respectively). Proteins were visualized with ECL. Blots 
were stripped and reprobed with anti-COX-1 Ab to verify equal loading and efficiency 
of protein transfer (middle panels). Prior to lysing of cells, supernatants were collected 
and analysed for PGE2 production by ELISA (C). Samples were assayed in duplicate 
and results are expressed as mean. Data is representative of three separate 
experiments.
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Evaluation of the involvement of PPARy in Troglitazone induced COX-2
I next investigated whether induction of COX-2 by troglitazone was mediated via 
PPARy by use of the two selective PPARy antagonists, GW9662 and bisphenol A 
diglycidyl ether (BADGE). Neither BADGE (1-100 pM) nor the irreversible PPARy 
antagonist, GW9662 (Leesnitzer et al., 2002) (0.1- 10 pM), were able to inhibit 
troglitazone induced COX-2 expression at 6  hours or 24 hours (Figure 4.4A and 
4.4B).
Effect of selective PPAR agonists on COX-2 expression.
To elucidate whether the disparate effects seen with the two ligands were due to 
effects on other isoforms of PPAR, three highly selective PPAR agonists were 
utilised. Neither GW262570 (PPARy/a agonist; Figure 4.5A) or BRL49653 (PPARy 
agonist; Figure 4.5B) induced COX-2 expression. L-165041 (PPARS agonist; Figure 
4.5C) showed slight induction of COX-2 at high concentration (10-30 pM). 
GW262570 has preferred selectivity towards PPARy, BRL49653 is also a PPARy 
selective agonist with an EC50 of 0.04 pM (Lehmann et al., 1995) whereas L-165041 
is PPAR8  selective at low micromolar range EC50 values are shown in the table 
below (Table 4.1).
PPARoc PPARy PPAR8
GW262570 0.4 0.0003 -
BRL49653 (Rosiglitazone) - 0.04 -
L-165041 1 0 5.5 0.5
Table 4.1. EC50  values of three PPAR agonists obtained from cell based assays (obtained from 
Novartis Horsham Research Centre courtesy of Dr. Paul Whittaker, Novartis Horsham Research 
Centre, U.K.).
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Figure 4.4. Troglitazone induced COX-2 expression is insensitive to two 
PPARy antagonist.
1.2 x 106 growth arrested confluent A549 cells were pretreated for 1 hour with 
PPARy antagonist, BADGE (1-100 pM) (A) and for 30 mins with PPARy 
antagonist, GW9662 (0.1-10 pM) (B) prior to stimulation with troglitazone (10 
pM) for 6  hrs (unless otherwise stated). Cells were lysed with ice-cold lysis buffer, 
proteins extracted, quantified and boiled with 5 X sample buffer. Protein (25 pg) 
was resolved by SDS-PAGE, transferred to nitrocellulose membranes and 
immunoblotted with an anti-COX-2 Ab (upper panels). Proteins were visualized 
with ECL. Blots were stripped and reprobed with anti-COX-1 Ab to verify equal 
loading and efficiency of protein transfer (lower panels). Data is representative of 
three separate experiments.
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Figure 4.5 Effect of selective PPAR agonists on COX-2 regulation.
3.2 x  106 growth arrested confluent A549 cells were treated with GW262570 (1 |iM- 
100 |iM) (A), BRL49653 (3 |iM - 300 \iM) (B) or L-165041 (0.3 pM- 30 pM) (C) for 
6  hrs. Cells were lysed with ice-cold lysis buffer, proteins extracted, quantified and 
boiled with 5 X sample buffer. Protein (25 jug) was resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and immunoblotted with an anti-COX-2 Ab 
(upper panels). Proteins were visualized with ECL. Blots were stripped and reprobed 
with anti-PKB Ab to verify equal loading and efficiency of protein transfer (lower 
panels). Data is representative of more than three separate experiments.
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Involvement of PI3K pathway in Troglitazone induced COX-2 expression
Two PI3K inhibitors LY294002 and wortmannin showed differential effects on 
troglitazone induced COX-2 expression (Figure 4.6A and 4.6B). LY294002 showed 
a 33% inhibition of troglitazone induced COX-2 expression at 10 pM (Figure 4.6A). 
In comparison wortmannin showed no ability to attenuate the troglitazone induced 
response (Figure 4.6B). Neither inhibitor affected COX-1 expression.
Effects of ERK and p38 MAPK and PKC inhibitors on Troglitazone induced 
COX-2 expression
The MEK inhibitor, PD98059, showed a concentration-dependent inhibition of 
troglitazone-induced COX-2 (Figure 4.7A) with 40% inhibition seen at 10-20 pM. 
SB202190 also showed a concentration dependent inhibition of troglitazone induced 
COX-2 expression (Figure 4.7B), with a 38% inhibition seen at 10 pM. Furthermore, 
the broad-spectrum PKC inhibitor Ro-32-4032 showed concentration dependent 
inhibition of COX-2 expression (Figure 4.7C), with a 54 % inhibition at 10 pM. As 
expected none of the inhibitors assessed affected COX-1 expression. These results 
suggest that troglitazone-induced COX-2 expression is mediated independently of 
PPARy, but is partially dependent on the PI3K, ERK and p38 MAPK and PKC 
pathways.
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Figure 4.6. Effect of PI3K inhibitors on Troglitazone induced COX-2 
expression
1.2 x 106 growth arrested confluent A549 cells were pretreated for 30 mins with 
PI3K inhibitor, LY294002 (1-10 pM) (A) and for 10 mins with another PI3K 
inhibitor wortmannin (10-100 nM) (B) prior to stimulation with troglitazone (10 
pM) for 6  hrs. Cells were lysed with ice-cold lysis buffer, proteins extracted, 
quantified and boiled with 5 X sample buffer. Protein (25 pg) was resolved by 
SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with an 
anti-COX-2 Ab (upper panels). Proteins were visualized with ECL. Blots were 
stripped and reprobed with anti-COX-1 Ab to verify equal loading and efficiency 
of protein transfer (lower panels). Densitometry was carried out on COX-2 blots in 
order to quantify results and values are graphically represented below the 
respective blot. Data is representative of three separate experiments.
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Figure 4.7 Effect of ERK, p38 MAPK and PKC inhibitors on troglitazone 
induced COX-2 expression.
1.2 x 106 growth arrested confluent A549 cells were pretreated for 1 hr with MEK 
inhibitor, PD98059 (2-20 pM) (A); for 1 hour with the p38 inhibitor SB202190 (1-10 
pM) (B) and for 30 mins with the PKC inhibitor Ro-32-0432 (1-10 pM) (C), prior to 
stimulation with troglitazone (10 pM) for 6  hrs. Cells were lysed with ice-cold lysis 
buffer, proteins extracted, quantified and boiled with 5 X sample buffer. Protein (25 
pg) was resolved by SDS-PAGE, transferred to nitrocellulose membranes and 
immunoblotted with an anti-COX-2 Ab (upper panels). Proteins were visualized with 
ECL. Blots were stripped and reprobed with anti-COX-1 Ab to verify equal loading 
and efficiency of protein transfer (lower panels). Densitometry was carried out on 
COX-2 blots in order to quantify results and values are graphically represented below 
the respective blot. Data is representative of three separate experiments.
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Effects of PPARy agonists on NFkB activation.
Since troglitazone markedly induced COX-2 expression and PGE2 production at 24 
to 48 hours (observed in Figure 4.3), it was next investigated whether the NFkB 
pathway was involved in the induction of COX-2 expression. I first assessed NFkB 
activation indirectly by monitoring degradation of cytosolic IkB, which under resting 
conditions is bound to and inhibits NFkB. Thus induction of the classical NFkB 
pathway firstly requires degradation of IkB. Neither troglitazone nor 15d-PGJ2 
induced IkB degradation at early phase time points (up to 2 hours) (Figure 4.8 A; 
upper panels). Modest IkB degradation was seen with troglitazone at 24 hours 
(Figure 4.8A; upper panels), but neither troglitazone nor 15d-PGJ2 stimulated 
phosphorylation of p65. NFkB activation was next investigated by monitoring 
activation of the binding ability of NFkB p65 to consensus oligonucleotide 
sequences by means of the TransAM NFkB p65 kit. Once again, TNFa induced 
marked activation of NFkB p65 from 10 mins through to 2 hours (Figure 4.8B). 
Troglitazone induced slight activation of NFkB at 24 hours (Figure 4.8B), which was 
consistent with the minimal degradation of IkB observed at 24 hours. 15d-PGJ2 had 
no effect on NFkB p65 activation (Figure 4.8B). A final method for assessing NFkB 
activity was to use an A549 cell line stably transfected with NFkB luciferase gene 
reporter construct. TNFa greatly induced NFkB luciferase gene reporter activity at 
both 6  hrs and 24 hrs (Figure 4.8C). In comparison, neither troglitazone nor 15d- 
PGJ2 activated NFkB luciferase gene reporter activity above basal levels at 6  or 24 
hours (Figure 4.8C).
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Figure 4.8 Neither troglitazone nor 15d-PGJ2 induced, degradation of IkB, NFkB p65 
phosphorylation or activation or NFkB gene reporter activity in comparison to TNFa.
3.2 x 106 growth arrested confluent A549 cells were stimulated with either troglitazone (10 
pM) or 15d-PGJ2 (lOpM) (A) over a time course (10 mins -24 hrs). Nuclear and cytosolic 
proteins were extracted as described in Methods and Materials. Proteins were quantified and 
cytosolic protein samples were boiled with 5 X sample buffer. Protein (25 pg) was resolved 
by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with an anti- 
IkB  Ab (upper panels, A) or an anti-phospho-p65 Ab (middle panels, A). Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-ERK Ab to verify equal 
loading and efficiency of protein transfer (lower panels, A). Nuclear extracts (7.5 pg) from 
the same experiments were assayed for N F kB p65 activation/DNA binding by use of a 
TransAM™ N F kB  p65 kit (B). Samples were assayed in duplicate and results are expressed 
as mean N F -kB  p65 activation (A595). Data is representative of three separate experiments. 
C- 0.2 x 106 growth arrested, confluent A549-KBtkluc cells (A549 cells that have been 
stably transfected with the N F - kB luciferase gene reporter construct) were stimulated with 
troglitazone (10 pM), 15d-PGJ2 (10 pM) or TNFa 10 ng/ml (as a positive control) for 6  and 
24 hours. Promega Steady-Glo luciferase buffer was added to cells and left at room 
temperature for 10 mins. Lysates were then mixed and 200 pi sample was then transferred 
into opaque 96-well plates and luminescence was measured on a Beckman Topcount with a 
5 sec luminescence program. Results are expressed as mean luminescence ± s.e.m. Data is 
representative of more than three separate experiments.
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Next it was investigated whether the modest IkB degradation and NFkB p65 
activation induced by troglitazone at 24 hours was dependent on PPARy. 
Surprisingly, the troglitazone-induced degradation of IkB and p65 activation 
observed at 24 hours were not inhibited by pre-treatment with PPARy antagonist 
GW9662 (Figure 4.9A and 4.9B), thus suggesting that troglitazone can induce IkB 
degradation independently of PPARy.
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Figure 4.9 Minimal activation of NFkB pathway by Troglitazone at 24 hours is 
independent of PPARy
3.2 x  106 growth arrested confluent A549 cells were pretreated for 30 mins with 
GW9662 (1 pM) prior to stimulation with troglitazone (lOpM) for 24 hours. Nuclear 
and cytosolic proteins were extracted as described in Methods and Materials. Proteins 
were quantified and cytosolic protein samples were boiled with 5 X sample buffer. 25 
pg of protein was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted with an anti-IkB Ab (upper panel, A). Proteins were visualized 
with ECL. Blots were stripped and reprobed with anti-ERK Ab to verify equal loading 
and efficiency of protein transfer (lower panel, A). 7.5 pg of nuclear extracts from the 
same experiments were assayed for NFkB p65 activation/DNA binding by use of a 
TransAM™ NFkB p65 kit (B). Samples were assayed in duplicate and results are 
expressed as mean NFkB p65 activation (A595). Data is representative of three separate 
experiments.
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Effect of PGE2 and PGE2 analogue on troglitazone induced COX-2 expression
Previous studies have shown that the COX-2 product, PGE2 , can negatively feedback 
to regulate COX-2 expression (Akarasereenont et al., 1999). Furthermore vast 
amounts of PGE2 were produced following stimulation with troglitazone but only at 
late time point (48 hrs). Thus this next section investigates whether the huge increase 
in PGE2 plays a feedback role and thus may regulate troglitazone induced COX-2. 
The concentration of PGE2 used was 0.05ng/ml to 5ng/ml since the level of PGE2 
produced by stimulated cells is within these concentrations. PGE2 inhibited 
troglitazone induced COX-2 expression in a concentration dependent manner (Figure 
4.10A) at 6  hours, with 47 % inhibition observed at 5 ng/ml. PGE2 can act on all four 
EP receptor subtypes. Next it was investigated whether an EP3 selective agonist, 
sulprostone, would have the same effect as PGE2 . Sulprostone showed little 
inhibition of troglitazone induced COX-2 at 6  hours and no inhibition at 24 hours 
(Figure 4.1 OB).
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Figure 4.10. Regulation of troglitazone induced COX-2 expression by PGE2 and a 
PGE2 analogue.
1.2 x 106 growth arrested confluent A549 cells were co-treated with PGE2 (0.05-5 
ng/ml) and troglitazone (10 pM) (A); or with sulprostone (0.1-10 pg/ml) and 
troglitazone (10 pM) (B) for 6  hours (unless otherwise stated). Cells were lysed with 
ice-cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample buffer. 
Protein (25 pg) was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted with an anti-COX-2 Ab (upper panels). Proteins were visualized 
with ECL. Blots were stripped and reprobed with anti-COX-1 Ab to verify equal 
loading and efficiency of protein transfer (lower panels). Densitometry was carried out 
on COX-2 blots in order to quantify results and values are graphically represented 
below the respective blot. Data is representative of three separate experiments.
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Effect of Troglitazone and 15d-PGJ2on gene activation assessed by microarray 
analysis
RNA microarray analysis was utilised to investigate the regulation of genes by 
troglitaozone and 15d-PGJ2. Table 4.2 shows that 15d-PGJ2 up-regulated only 1 gene 
and downregulated 9 genes, 6  hours post-stimulation. In comparison, troglitazone 
upregulated 31 genes and downregulated 16 genes at the same time point (Table 
4.3). The only similarity in gene regulation by the two ligands was that both 
inhibited ribosomal S2 protein and heat shock protein. This data suggests that in 
addition to disparate effects on signalling pathways, troglitazone and 15d-PGJ2 
manifest different gene expression patterns both in number and the types of genes 
observed. Surprisingly COX-2 expression was not found to be regulated by 
troglitazone, using the criteria for selection.
Upregulated




fasciculation and elongation protein zeta 2 (zygin II) 1.084 0.424 -2.559
TRAF-interacting protein l-TRAF mRNA, complete cds. 1.585 0.707 -2.242
heat shock 70kD protein 9B (mortalin-2) 2.107 0.953 -2.211
clone FLB4941 PR01292 mRNA, complete cds. 1.813 0.820 -2.210
NCK-associated protein 1 (NCKAP1), mRNA. 1.847 0.848 -2.178
ribosomal protein S2 1.510 0.721 -2.095




chromosome 1 open reading frame 28 1.511 0.747 -2.022
Table 4.2. Microarray analysis comparing genes upregulated or downregulated following 
treatment with 15d-PGJ2. 8.8 x 106 growth arrested confluent A549 cells stimulated with 15-dPGJ2 
(10 |iM) for 6 hours. RNA was isolated using Trizol, RNA quantified and lOOng per well was run on 
RNA chips on Agilent 2100 Bioanalyzer. RNA samples were processed and analysed as described in 
Methods and Materials.
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Upregulated
activating transcription factor 4 (tax-responsive enhancer element 
B67) (ATF4), mRNA.
0.840 1.951 2.321
dual specificity phosphatase 1 0.810 1.822 2.250
basic helix-loop-helix domain containing, class B, 2 0.799 1.664 2.081
methylene tetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase (MTHFD2), nuclear gene 
encoding mitochondrial protein, mRNA.
0.934 2.109 2.258
3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR), 
mRNA.
0.940 1.889 2.009
activating transcription factor 3 (ATF3), mRNA. 0.746 1.947 2.608
phosphoenolpyruvate carboxykinase 2 (mitochondrial) (PCK2), 
mRNA.
0.759 1.541 2.032
interleukin 8 (IL8), mRNA. 0.981 2.434 2.483
HIF-1 responsive RTP801 0.932 2.145 2.302
stanniocalcin 2, clone MGC:1881, mRNA, complete cds. 0.876 2.123 2.423
sodium channel, nonvoltage-gated 1 alpha (SCNN1A), mRNA. 0.645 1.427 2.210
transcription elongation factor A (Sll), 2 (TCEA2), mRNA. 0.633 1.323 2.090
mevalonate kinase (mevalonic aciduria) (MVK), mRNA. 0.635 1.439 2.265
hypothetical protein FU10374 (FU10374), mRNA. 0.796 1.616 2.031
S100 calcium-binding protein P (S100P), mRNA. 0.909 1.837 2.022
KIAA0590 gene product (KIAA0590), mRNA. 0.698 1.483 2.124
Asparagine synthetase (ASNS), mRNA. 0.929 2.365 2.545
zinc finger DAZ interacting protein 3 0.860 1.763 2.051
delta sleep inducing peptide, immunoreactor 1.017 3.297 3.243
inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 0.977 1.959 2.006
Adipose differentiation-related protein, clone MGC: 10598, mRNA, 
complete cds.
0.698 2.317 3.319
p8 protein homolog (COM1) mRNA, complete cds. 0.822 1.914 2.329
vascular endothelial growth factor mRNA, complete cds. 0.863 1.777 2.060
lipin 1 0.781 1.949 2.497
DNA sequence from clone RP3-408B20 on chromosome 6 0.820 1.858 2.265
cytochrome b reductase 1 0.592 1.203 2.030
protein kinase domains containing protein similar to 
phosphoprotein C8FW (LOC57761), mRNA.
0.854 2.433 2.849
TGFB inducible early growth response 2 0.866 2.208 2.549
Fanconi anemia, complementation group F (FANCF), mRNA. 0.791 1.626 2.055
hypothetical protein MGC4054 (MGC4054), mRNA. 0.728 1.481 2.033
aquaporin 3 0.704 1.640 2.331
Downregulated
gap junction protein, alpha 7, 45kD (connexin 45) (GJA7), 
mRNA.
1.472 0.586 -2.513
bromodomain adjacent to zinc finger domain, 1A 1.222 0.496 -2.466
cDNA FU 11304 fis, clone PLACE1009997, weakly similar to 
Rattus norvegicus A-kinase anchoring protein AKAP 220 mRNA.
1.224 0.500 -2.448
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), 
mRNA.
0.995 0.417 -2.384
ATP-binding cassette transporter 1 (ABCA1) mRNA, complete cds. 1.092 0.475 -2.301
glutaminase C mRNA, complete cds. 2.005 0.887 -2.262
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heat shock 70kD protein 9B (mortalin-2) 2.107 0.944 -2.233
hypothetical protein FU12701 (FU12701), mRNA. 1.163 0.527 -2.207
DNA sequence from clone RP3-406P24 on chromosome 6 
Contains a thioredoxin-like pseudogene, 2 CpG islands, ESTs, 
STSs and GSSs
1.568 0.712 -2.201
DnaJ (Hsp40) homolog, subfamily B, member 4 1.114 0.507 -2.197
KIAA0924 protein (KIAA0924), mRNA. 1.380 0.647 -2.133
disabled (Drosophila) homolog 2 (mitogen-responsive 
phosphoprotein) (DAB2), mRNA.
1.832 0.898 -2.042
3-hydroxyisobutyryl-Coenzyme A hydrolase 1.600 0.793 -2.017
ribosomal protein S2 1.510 0.749 -2.015
cDNA: FLJ21305 fis clone COL02124. 1.495 0.746 -2.005
thromboxane A2 receptor (TBXA2R), mRNA. 1.055 0.527 -2.002
Table 4.3. Microarray analysis comparing genes upregulated or downregulated following 
treatment with troglitazone. 8.8 x  106 growth arrested confluent A549 cells stimulated with 
troglitazone (10 pM) for 6 hours. RNA was isolated using Trizol, RNA quantified and lOOng per well 
was run on RNA chips on Agilent 2100 Bioanalyzer. RNA samples were processed and analysed as 
described in Methods and Materials.
171
Chapter 4 -  <RgsuCts I I
4.2. Regulation of cytokine induced COX-2 expression and activity 
events by PPARy ligands
4.2.1. Background
Other PPARy ligands such as NSAIDs are widely used in the treatment of 
inflammation, and their efficacy is considered to be a result of their inhibitory effect 
on COX-2. NSAIDs have recently been identified as ligands of PPARs. Paik et al., 
reported that the NSAID, flufenamic acid, showed two opposing effects on COX-2 
expression; it induces COX-2 expression in colonic epithelial cells and macrophages; 
conversely, it inhibits TNFa or LPS-induced COX-2 expression (Paik et al., 2000), 
and similar effects were also seen with 15d-PGJ2. These studies suggested that 
NSAIDs inhibit mitogen-induced COX-2 expression while they induce COX-2 
expression (Paik et al., 2000). However the exact roles of PPARy ligands on the 
regulation of COX-2 expression have not yet been fully recognized.
Having established that two structurally distinct PPARy ligands regulate COX-2 
expression differentially, the effects of these ligands on TNFa and IL-ip induced 
COX-2 expression and activity were next examined.
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4.2.2. Results
Effect of PPARy ligands on TNFa induced COX-2 and PGE2 production
In support of previous observations, TNFa and IL-ip stimulated COX-2 expression 
and PGE2 production (previously shown in Figure 3.9). As expected, the 
combination of troglitazone and TNFa had an additive effect on the induction of 
COX-2 and also a synergistic effect on the PGE2 production (Figure 4.11 A and
4.1 IB). 15d-PGJ2 showed a slight inhibitory effect on TNFa-induced COX-2 
expression, but curiously it appeared to enhance TNFa-induced PGE2 production 
(Figure 4.11 A and 4.11C). Moreover, similar effects were seen when COX-2 
expression was induced by IL-lp in that troglitazone was able to further enhance IL- 
lp  induced COX-2 expression, whereas 15d-PGJ2 showed a slight inhibitory effect 
on IL-lp induced COX-2 expression (Figure 4.1 ID). The effect of ciglitazone, 
another synthetic PPARy ligand with similar structure to troglitazone, was 
investigated. Like troglitazone, ciglitazone was able to enhance both TNFa and IL- 
ip induced COX-2 expression (Figure 4.1 IE).
173







— 7 4 k D a










«**» — 7 4 k D a




I  1  4000






+ - + - TNFa l(K)ng/ml
- + - + IL-ip lOng/ml
- - + + Ciglitazone 10(iM
COX-2
PKB
—  7 4 k D a




15dPGJ2 lOuM TNF lOOng/mJ
Figure 4.11 Effect of PPARy ligands on cytokine induced COX-2 expression and 
PGE2 production.
1.2 x  106 growth arrested confluent A549 cells were pretreated for 1 hr with 
troglitazone (lOpM), 15d-PGJ2 (10 pM) or ciglitazone (10 pM) prior to stimulation 
with TNFa 100 ng/ml or IL-ip 10 ng/ml for 6 hrs (A, D and E). Cells were lysed with 
ice-cold lysis buffer, proteins extracted, quantified and boiled with 5 X sample buffer. 
Protein (25 pg) was resolved by SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted with an anti-COX-2 Ab (A, D and E; upper panel). Proteins were 
visualized with ECL. Blots were stripped and reprobed with anti-PKB Ab to verify 
equal loading and efficiency of protein transfer (A, D and E; lower panels). 
Densitometry was carried out on COX-2 blots in order to quantify results and values 
are graphically represented below the respective blot. Data is representative of more 
than three separate experiments. B and C, 1.2 x  106 growth arrested confluent A549 
cells were pretreated for 1 hr with troglitazone (10 pM) and 15d-PGJ2 (10 pM) prior to 
stimulation with TNFa 100 ng/ml for 24 hrs. Supernatants were collected and assessed 
for PGE2 production by means of ELISA (B and C). Samples were assayed in duplicate 
and results are expressed as mean. Data is representative of three separate experiments.
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Effect of troglitazone and 15d-PGJ2 on TN Fa induced IkB degradation, NFkB 
p65 activation and NFkB gene reporter activity.
Although NFkB activation in response to PPARy agonists in a range of assays was 
not detected, it was next investigated whether PPARy agonists could influence TNFa 
responses at the level of NFkB, having already demonstrated synergistic effects of 
troglitazone on TNFa-stimulated PGE2 production. Pre-treatment with either PPARy 
ligand did not inhibit TNFa induced IkB degradation, p65 phosphorylation (Figure 
4.12A) or p65 activation at 30 mins (Figure 4.12B). It was next investigated whether 
troglitazone or 15d-PGJ2 could affect TNFa induced NFkB reporter activity by 
means of luciferase assays. Troglitazone, but not 15d-PGJ2 inhibited TNFa induced 
NFkB gene reporter activity in a concentration-dependent manner (Figure 4.12C) at 
6 hours. Furthermore, troglitazone also inhibited TNFa induced NFkB gene reporter 
activity at 24 hours (Figure 4.12D). Addition of the PPARy antagonist (GW9662), 
was unable to reverse the inhibitory effects of troglitazone on TNFa induced NFkB 
gene reporter activity (Figure 4.12E). This suggests that troglitazone can inhibit 
TNFa-stimulated NFkB gene reporter activity independently of PPARy.
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Figure 4.12. E ffect o f troglitazone and 15dPG J2 on T N F a  induced IkB degradation, 
N F kB p65 phosphorylation and activation and N F kB gene reporter activity.
3.2 x 106 growth arrested confluent A549 cells were pretreated with troglitazone (10 |xM) or 
15d-PGJ2 (10 pM) for 1 hr prior to stimulation for 30 mins (A and B) and 6 hours (C and D) 
with TNFa 100 ng/ml. Nuclear and cytosolic proteins were extracted as described in Methods 
and Materials. Proteins were quantified and cytosolic protein samples were boiled with 5 X 
sample buffer. 25 pg of cytosolic proteins were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted with an anti-lKB Ab (upper panel, A) or anti- 
phospho-p65 Ab (middle panel, A). Proteins were visualized with ECL. Blots were stripped 
and reprobed with anti-ERK Ab to verify equal loading and efficiency of protein transfer 
(lower panels, A). 7.5 pg of nuclear extracts from the same experiment were assayed for NFkB 
p65 activation/DNA binding by use of a TransAM™ NFkB p65 kit (B). Results are expressed 
as NFkB p65 activation (fold change over basal). C-0.2 x 106 growth arrested, confluent A549- 
KBtkluc cells (A549 cells that have been stably transfected with the NFkB luciferase gene 
reporter construct) were pretreated with troglitazone or 15d-PGJ2 (with the indicated 
concentration) for 1 hr prior to stimulation with TNFa 100 ng/ml for 6 hours and 24 hours (C 
and D) or pretreated with GW9662 at the concentration indicated for 30 mins, prior to further 
pre-treatment with troglitazone (10 pM) or 15d-PGJ2 (10 pM) for 1 hr prior to stimulation with 
TNFa 10 ng/ml for 6 hours (E). Promega Steady-Glo luciferase buffer was added to cells and 
left at room temperature for 10 mins. Lysates were then mixed and 200 pi sample was 
transferred into opaque 96-well plates and luminescence was measured on a Beckman 
Topcount with a 5 sec luminescence program. Results are expressed as percentage change. All 
data is representative of at least three separate experiments. * P < 0.05, ** P < 0.001.
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Effect of selective PPAR agonists on TNFa-induced NFkB gene reporter 
activity
Next it was investigated whether the effects of the synthetic PPARy ligand 
troglitazone on TNFa induced NFkB activity was characteristic of other synthetic 
PPARy ligands. GW262570, BRL49653 and L-165041 attenuated the TNFa induced 
NFkB gene reporter activity response, albeit at high concentrations (30 pM), which 
exceed their EC50 values (Figure 4.13A-C; see Table 4.1 for EC50 values).
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Figure 4.13 Effect of selective PPAR agonists on TNFa-induced NFkB gene 
reporter activity.
0.2 x 106 growth arrested, confluent A549-KBtkluc cells (A549 cells that have been 
stably transfected with the NFkB luciferase gene reporter construct) were pretreated 
with GW262570 (3 nM- 30 pM) (A), BRL49653 (3 nM - 30 pM) (B) or L-165041 
(300 nM- 30 pM) for 1 hr prior to stimulation with TNFa 10 ng/ml for 6 hours. 
Promega Steady-Glo luciferase buffer was added to cells and left at room temperature 
for 10 mins. Lysates were then mixed and 200 pi sample was transferred into opaque 
96-well plates and luminescence was measured on a Beckman Topcount with a 5 sec 
luminescence program. Samples were assayed in duplicate and results are expressed as 
mean percentage change. Data is representative of more than three separate 
experiments.
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4.3. Summary
Summary of section 4.1
• The A549 cell line expresses PPARyi and PPAR / 2  and expression of this 
receptor in this system is limited to the nucleus.
• The synthetic PPARy ligand troglitazone and the endogenous ligand 15d- 
PGJ2 both induced phosphorylation of PKB in a PI3K dependent manner.
• In addition troglitazone, but not 15d-PGJ2, activated the ERK MAPK 
pathway. This effect was sensitive to the MEK inhibitor, PD98059.
• Troglitazone, but not 15d-PGJ2, induced COX-2 and mPGES expression and 
PGE2 production in a time dependent manner.
• COX-2 induction by troglitazone was insensitive to two selective PPARy 
antagonists.
• Selective PPAR agonists showed no induction of COX-2 above basal levels 
with the exception of L-165041 which showed minimal COX-2 expression at 
high concentration.
• Troglitazone-induced COX-2 expression showed differential sensitivity to 
two distinct PI3K inhibitors.
• Furthermore, troglitazone-induced COX-2 expression was sensitive to the 
MEK inhibitor PD98059, to the p38 MAPK inhibitor SB202190 and to the 
PKC inhibitor Ro-32-0432.
• Neither troglitazone nor 15d-PGJ2 convincingly induced I k B  degradation, 
N F k B  p65 phosphorylation, N F k B  p65 activation or N F k B  gene reporter 
activity.
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• Minimal IkB degradation and NFkB p65 activation was seen at 24 hours 
post-treatment with Troglitazone, but these effects were not sensitive to the 
PPARy antagonist, GW9662.
• Interestingly, the COX-2 product PGE2 partially inhibited troglitazone 
induced COX-2 expression. However, the EP agonist sulprostone had no 
effect on troglitazone induced COX-2.
• Microarray analysis revealed differential regulation of gene expression by 
troglitazone and 15d-PGJ2.
Summary of section 4.2
• Troglitazone enhances TNFa induced COX-2 expression and PGE2 
production.
• Whereas 15d-PGJ2 showed slight inhibitory effects on TNFa induced COX-2 
expression but enhanced TNFa induced PGE2 production.
• Troglitazone enhanced IL-ip induced COX-2 and 15d-PGJ2 showed minimal 
inhibitory effects on IL-lp induced COX-2 expression.
• Another synthetic PPARy ligand ciglitazone also enhanced TNFa and IL-lp 
induced COX-2 expression.
• Neither troglitazone nor 15d-PGJ2 had any effect on TNFa induced IkB 
degradation, NFkB p65 phosphorylation or NFkB p65 activation.
• Troglitazone, but not 15d-PGJ2, inhibited TNFa induced NFkB gene reporter 
activity in a concentration dependent manner. This effect however was not 
reverse by the PPARy antagonist GW9662.
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• More selective PPAR agonists inhibited TNFa induced NFkB gene reporter 
activity at high concentrations.
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4.4. Discussion II
This chapter has investigated the disparate effects of two structurally distinct PPARy 
ligands, namely troglitazone and 15d-PGJ2, on biochemical signalling pathways, 
COX-2 expression and gene expression in the lung epithelial cell line A549. I was 
unable to detect any convincing activation of NFkB by either of the PPARy ligands. 
Moreover, use of more selective PPARy agonist and antagonists revealed that the 
effects of troglitazone on COX-2 expression appeared to be independent of PPARy.
Localisation of PPARy
In the inactivated state, the PPARs are believed to be in complexes bound with 
corepressor proteins. In this state, in some but not all cell types, PPARy may have a 
cytoplasmic rather than a nuclear location (Bishop-Bailey and Hla, 1999). Upon 
ligand activation, PPARs dissociate from corepressors and recruit coactivators and 
can translocate from the cytoplasm to the nucleus (Bishop-Bailey and Hla, 1999). 
Although PPARy expression was restricted to the nucleus in A549 cell line, this is in 
line with other cell systems such as the human monocyte-derived macrophages 
(Chinetti et al., 1998).
PPARy mediated signalling pathways
With the aid of pharmacological inhibitors, I was able to determine the involvement 
of several signalling pathways in the induction of COX-2 by troglitazone, namely the 
PI3K and the ERK MAPK pathways. Troglitazone activated the PKB and ERK
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pathways in a PI3K and MEK dependent manner, respectively. Troglitazone also 
induced COX-2 and mPGES expression and PGE2 production. In comparison 15d- 
PGJ2 activated the PI3K pathway, and had no effect on activation of the ERK 
pathway, induction of COX-2, mPGES or PGE2 production. Both the PI3K and ERK 
MAPK pathways have been extensively shown to regulate COX-2 expression 
induced by a variety of cytokines (Matsuura et al., 1999; Chen et al., 2000; Weaver 
et al., 2001; Yang et al., 2002; Liu et al., 2003; Luo et al., 2003; Bradbury et al., 
2004; Chen et al., 2004; Lin et al., 2004), however there is little previous evidence 
suggesting the involvement of these pathways in COX-2 expression induced by 
PPARy ligands. Activation of signalling pathways such as the PI3K and ERK 
MAPK pathways are generally mediated via cell surface receptors. In this chapter I 
have shown that ligands of the nuclear receptor PPARy can activate both pathways at 
time points that are associated with activation of membrane receptors. Previous 
studies in vascular smooth muscle cells have indicated that activation of PI3K and 
ERK pathway by PPARy ligands to be mediated via novel membrane receptors 
(Takeda et al., 2001). Thus the disparate effects of troglitazone and 15d-PGJ2 on 
signalling pathways explain the differential effects seen on functional outputs such 
as COX-2 and mPGES expression and PGE2 production.
Troglitazone induced COX-2 is mediated independently of PPARy
Recently, bisphenyl A diglycidyl ether (BADGE) has been reported as a weak 
antagonist of PPARy (Wright et al., 2000). Although BADGE inhibits adipocyte 
differentiation in cell culture, its use as an antagonist to elucidate the importance of 
PPARy in biological processes may be limited by the low potency of binding. An
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IC50 of ~ 100 pM was reported, and incomplete inhibition of binding, apparently due 
to compound solubility, was observed (Wright et al., 2000). The limited solubility 
also complicates the interpretation of the receptor selectivity. By contrast, GW9662 
is at least 10 000 times more potent than BADGE as measured by inhibition of 
[ HjRosiglitazone binding to PPARy, and an estimate of selectivity versus the other 
PPARs has been established (Leesnitzer et al., 2002). Mass spectrometric analysis of 
the PPARy ligand binding domain treated with GW9662 established Cys as the 
site of covalent modification. This cysteine is conserved among all three PPARs. In 
cell-based reporter assays, GW9662 was a potent and selective antagonist of full 
length PPARy. The functional activity of GW9662 as an antagonist of PPARy was 
confirmed in an assay of adipocyte differentiation (Leesnitzer et al., 2002). As the 
antagonistic activity of GW9662 towards PPARy is retained in cell culture systems, 
this compound is a useful tool for elucidation of the role of PPARy in biological 
processes. Complex behaviour has been reported for some PPARy ligands, such as 
BADGE. This compound acts as an antagonist in some assays or cell lines, but as an 
agonist in others (Bishop-Bailey et al., 2000; Mukherjee et al., 2000). By contrast, 
GW9662 was a subtype-selective PPARy antagonist under the conditions examined. 
The irreversible nature of GW9662 thus facilitates studies of PPARy by enabling use 
of low doses and/or simplified dosing regimens. Despite the increased potency of 
GW9662 to PPARy compared to BADGE, neither antagonist inhibited troglitazone 
induced COX-2 expression thus suggesting that this effect is mediated independently 
of PPARy.
Other techniques may also be used for further work to verify that troglitazone- 
induced COX-2 expression is mediated independently of PPARy. Such techniques
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would involve the use of siRNA. The underlying molecular mechanism of gene 
silencing provides short interfering RNAs (siRNAs) which can target any gene with 
high specificity and efficiency (Schutze, 2004). A specific siRNA directed against 
PPARy could be used to silence the gene and thus its expression. If troglitazone can 
still induce COX-2 expression following gene silencing this would further support 
the hypothesis that troglitazone induced COX-2 expression is mediated 
independently of PPARy.
Involvement of signalling pathways in Troglitazone induced COX-2 expression
Troglitazone induced COX-2 expression was sensitive to the PI3K inhibitor 
LY294002 but insensitive to wortmannin. As suggested in Chapter 3, this could be 
due to the differential sensitivity of LY294002 and wortmannin to PI3K isoforms. 
However studies carried out with LY294002 in this chapter and work done by others 
suggests the role of PI3K in the regulation of COX-2 expression.
Recently, both PPARa and y ligands were shown to activate members of the MAPK 
family (Rokos and Ledwith, 1997; Mounho and Thrall, 1999; Gouni-Berthold et al., 
2001; Lennon et al., 2002; Teruel et al., 2003). This event occurred at time points too 
rapid to account for new protein synthesis, suggesting that these agonists also exert 
PPAR-independent effects. Although these "nongenomic" effects of PPAR ligands 
are contradictory to the classical mechanism of nuclear receptor action, additional 
studies have illustrated that a variety of such compounds (e.g. progesterone, estrogen, 
and vitamin D) evoke similar rapid changes in kinase-mediated signal transduction 
pathways that contribute to their biological mechanism of action (Losel and Wehling, 
2003). The involvement of the p38 MAPK pathway has also be recognised
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downstream of troglitazone signalling (Gouni-Berthold et al., 2001; Bae and Song, 
2003; Gardner et al., 2003). Moreover, in vitro and in vivo experiments have 
revealed that PPARa and y can be phosphorylated by some (a) or all three (y) 
MAPK leading to modulation of transcriptional activity (Hu et al., 1996; Camp et al., 
1999; Juge-Aubry et al., 1999; Barger et al., 2001). Transcriptional changes induced 
by PPARa and y agonists can also be dissociated into distinct MAPK- and PPAR- 
dependent pathways (Baek et al., 2003), suggesting that MAPKs alone mediate some 
of the cellular effects of PPAR ligands. Thus, kinase activation by PPAR agonists 
appears to play an important role in the mechanism of action of these compounds; yet 
few studies have investigated how PPAR agonists stimulate MAPKs. In the study by 
Baek et al. (Baek et al., 2003), the authors reported that troglitazone but not other 
PPARy ligands stimulated the expression of Egr-1. The authors also showed that 
troglitazone uniquely stimulated the ERK pathway that down-regulates the PPARy 
receptor activity, indicating that the increased expression of Egr-1 was not mediated 
by the activity of PPARy receptor (Chinetti et al., 1998; Baek et al., 2003). In terms 
of my findings, troglitazone induced COX-2 is sensitive to the MEK inhibitor 
PD98059, which is thought to be a specific inhibitor (Davies et al., 2000), and the 
p38 inhibitor SB202190 which lends further support to the involvement of the ERK 
and p38 MAPK pathway in troglitazone induced events. In addition, activation of the 
ERK pathway is known to phosphorylated and down-regulate PPARy (Baek et al., 
2003). Thus several mechanisms and pathways may appear to play an important role 
in the regulation of COX-2 by troglitazone.
There is little evidence of the involvement of the PKC pathway downstream of 
PPARy ligand signalling. However, a study by Han & Sidell (2002), demonstrated
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that PPARy induced CD36 expression was dependent of PKC. In this chapter I have 
shown that PKC inhibitor Ro-32-0432 partially attenuated troglitazone induced 
COX-2 expression thus suggesting the involvement of this pathway downstream of 
cell stimulation with troglitazone. Furthermore, ligands of other nuclear receptors 
have also shown to activate the PKC pathway, however these effects have been 
suggest to be mediated via nongenomic actions of nonclassical receptors (Losel and 
Wehling, 2003).
Troglitazone induced COX-2 expression is not mediated via the classical NFkB 
pathway
Involvement of the canonical NFkB pathway was the main NFkB pathway that was 
focussed on. Therefore the effects of troglitazone on other pathways leading to 
NFkB activation such as the NFkBI p i05 pathway can not be ruled out. Following 
cellular stimulation with agonists such as TNFa, IL-1 and LPS, p i05 is 
phosphorylated and proteolysed by proteasomes (Mellits et al., 1993; Donald et al., 
1995; Mackichan et al., 1996). Furthermore p i05 is phosphorylated on serine 903 
and 907 by glycogen synthase kinase (GSK)-3p with which it forms a complex and 
stabilizes p i05 by preventing its degradation in unstimulated cells (Demarchi et al., 
2003). TNFa induced proteolysis of p i 05 is blocked in GSK-3p-deficient fibroblasts 
or by induction of p i05 S903A or S907A point mutations (Demarchi et al., 2003), 
suggesting this event may require p i05 phosphorylation by GSK-3p. GSK-3 is a 
downstream target of activated PKB, and in this system I have shown activation of 
PKB following troglitazone stimulation. Thus activation of the NFkBI p i05 
pathway may be involved in troglitazone induced COX-2 expression.
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Regulation of Troglitazone induced COX-2 expression by PGE2
The regulation of COX-2 by downstream products, such as PGE2 , raises many 
issues. PGE2 is shown to negatively regulate induced COX-2 protein at 
concentrations chosen because they reflect the amount of PGE2 induced by cytokine 
stimulation. This supports the fact that these results are likely to be physiologically 
relevant with the induced PGE2 production providing negative feedback for COX-2. 
This would effectively help limit the COX-2 dependent response (Figure 4.14). 
Evidence for a possible mechanism of action for this effect comes from recent work 
on the signalling pathways activated by PGE2 (Sheng et al., 2001). A549 cell line 
has been shown to express EP3 and EP4 receptors (Yano et al., 2002). The binding 
of PGE2 to its EP4 receptor, a G-protein receptor associated with an increase in 
cAMP following activation, has been shown to activate the PI3K signalling cascade 
and its downstream effector PKB. Evidence presented by Weaver et al., in HT29 cell 
line points to a negative regulatory role for PI3K on COX-2 expression (Weaver et 
al., 2001), thus providing a possible mechanistic pathway of action. However this 
has not been rigorously proven and PI3K does not seem to play a negatively 
regulatory role in this system. Furthermore, there is conflicting evidence from PGE2 
binding causing an increase in cAMP and a resulting positive effect on COX-2 
expression (Fournier et al., 1997; Inoue et al., 2000). In addition, PGE2 has been 
shown to stabilise COX-2 mRNA and stimulation of translation via a positive 
feedback loop mediated through the EP4 receptor and p38 MAPK in IL-ip 
stimulated human synovial fibroblasts (Faour et al., 2001). These hypotheses do not 
fit with the results presented here but may be playing a contributory role albeit with 
the net effect of inhibition of COX-2 by PGE2 . Since the EP3 agonist sulprostone did 
not mimic the effects of PGE2 , this data suggests that PGE2 mediated inhibition of
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troglitazone induced COX-2 is not via the EP3 receptor. Further investigation would 
be required to elucidate the involvement of the EP4 receptor.
Troglitazone
- ve feedback
Figure 4.14. Schematic representation of possible mechanism for PG £2 negatively regulating 
troglitazone induced COX-2
Another possible explanation for the mechanism of action of troglitazone in inducing 
COX-2 may be through activation of other transcriptional pathways. Xie and 
Herschman (Xie and Herschman, 1995) were the first to demonstrate the importance 
of c-jun and CRE site for mediating the induction of COX-2. Moreover, AP-1 and 
the CRE were found to be important for the induction of COX-2 in human epithelial 
cells (Subbaramaiah et al., 1998; Subbaramaiah et al., 2000a; Subbaramaiah et al., 
2000b). Thus the regulation of COX-2 expression by troglitazone may also involve 
the activation of the AP-1 pathway. In support of this hypothesis, microarray 
analysis showed a two-fold (or greater increase) significant increase in the gene 
expression of activating transcription factor 3 and 4- , which are components of the 
AP-1 family.
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Troglitazone induces mPGES expression
Troglitazone induced upregulation of mPGES and thus also PGE2 production. The 
putative promoter of the human mPGES-1 gene (as described in Chapter 3) is GC- 
rich, lacks a TATA box, and contains binding sites for C/EBP a  and p and AP-1, 
two tandem GC- boxes, two progesterone receptor and three GRE elements (Naraba 
et al., 2002). As previously discussed, Egr-1 plays an important role in mPGES 
induction, and expression of this transcription factor can be upregulated by MAPK 
(Guha et al., 2001). In context of my findings, troglitazone was able to activate 
MAPK which may induce activation of Egr-1. Activated Egr-1 can bind to the 
proximal GC box in the mPGES-1 promoter, leading to transcriptional activation of 
the mPGES-1 gene (Murakami and Kudo, 2004). Recent evidence has indicated 
NFkB as another transcription factor important in mPGES expression (Catley et al., 
2003), however since troglitazone was unable to activate NFkB, this transcription 
factor is not likely to play a role in troglitazone induced mPGES expression.
Disparate effect of troglitazone and 15d-PGJ2 on regulation expression assessed 
by microarray anaylsis
Despite the clear evidence that troglitazone induces COX-2 protein expression 
microarray analysis did not show a significant increase in mRNA expression of 
COX-2. COX-2 expression is detectable on the gene chips but following stimulation 
its expression does not vary much and is below the 2 -fold cut off thus explaining 
why COX-2 expression is not on the genelists. Furthermore, the increase in protein 
expression could be due to altered turnover of COX-2, in that the protein 
accumulates because its degradation pattern has been affected.
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There were only 2 genes that were shown to be regulated in the same way by 
troglitazone and 15d-PGJ2 as assessed by microarray analysis. These genes were 
ribosomal protein S2 and heat shock 70kD protein (hsp 70) (highlighted in yellow in 
tables 4.2 and 4.3) and both these genes were downregulated following stimulation 
with either troglitazone or 15d-PGJ2. In addition to playing a role in the heat-shock 
response, in which hsp protect the cell from deleterious effects of an extreme change 
in the cell’s environment i.e. high temperature, hsp 70 can act as molecular 
chaperones. However, hsp 70 has been shown to be upregulated by PPARy ligands in 
rat islet cells (Weber et al., 2003). Furthermore, cyclopentenone PGs (including their 
precursor arachidonic acid) have been shown to activate heat shock stress response 
genes in different experimental models (Santoro et al., 1989; Koizumi et al., 1993; 
Jurivich et al., 1994; Weber et al., 2003). Ribosomal proteins are proteins that form 
complex catalytic machinery required for protein synthesis called ribosomes. Thus it 
would be expected that expression of ribosomal proteins would be upregulated 
following stimulation with PPARy ligands since these ligands are known to regulate 
gene transcription, this however is not the case in A549 cells. The exact relevance of 
theses findings remains unclear.
Several genes were upregulated by troglitazone and 15d-PGJ2 and several 
downregulated by troglitazone, however it is difficult to assess the exact role of each 
of these genes and thus this next section will discuss the possible involvement of 
some of the more important genes (highlight in blue in table 4.3) in troglitazone 
induced events.
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Upregulation of dual specificity phosphatases by troglitazone suggests a possible 
feedback mechanism by which troglitazone induces the expression of enzymes that 
can dephosphorylate proteins which may have been initially activated by troglitazone 
e.g. MAPK or transcription factors.
The upregulation of IL- 8  was not surprising as previous studies have shown PPARy 
ligands can activate IL- 8  transcription and enhance IL- 8  secretion in many cell 
systems including but not limited to lung cells (Jozkowicz et al., 2001; Zhang et al., 
2001; Fu et al., 2002; Harris et al., 2002b). Contradictory to this, reports also 
document that PPARy ligands can inhibit induced IL- 8  expression in A549 cells 
(Trifilieff et al., 2003). It is difficult to interpret these results in the context of my 
findings since IL- 8  expression was not evaluated following cytokine stimulation.
A shortage of oxygen in practically any type of cell, causes an increase in the 
intracellular concentration of the active form of a gene regulatory protein called 
hypoxia-inducible factor 1 (hifl). Hif can stimulate transcription of the vascular 
endothelial growth factor (VEGF). The microarray analysis detected upregulation of 
both hif and VEGF following stimulation with troglitazone, and expression of the 
latter gene may be dependent on the induction of hif.
Care must be taken evaluating microarray data as this method is limited in that the 
expression of a protein is only indicative of the transcriptional level and thus can not 
be used as a definitive measure of protein upregulation or down regulation. This may 
also explain some of the anomalies in the results obtained.
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Debate over the selectivity of 15d-PGJ2
15d-PGJ2 has been employed in many studies to evaluate the role of PPARy and in 
most cases it has shown to have effects similar to those of synthetic PPARy ligands. 
One possible explanation for the disparate effects observed in this study between 
troglitazone and 15d-PGJ2, may be that 15d-PGJ2 is rapidly degraded. Recently, the 
physiological and pharmacological relevance of 15d-PGJ2 has been questioned. For 
example, 15d-PGJ2 is thought to be highly reactive and covalently interacts with 
substances containing nucleophilic groups such as cysteinyl thiol groups of proteins 
including I k B  kinase and H-Ras. Hence, the lack of selectivity for PPARy may limit 
the usefulness of 15d-PGJ2 as a tool for defining the role of this receptor. Moreover, 
the concentration required to activate PPARy has been reported to be in the pM 
range, although it is doubtful whether 15d-PGJ2 ever reaches these levels either in 
cultured cells or in in vivo models of inflammation (Bell-Parikh et al., 2003). 
Against this hypothesis is the fact that 15d-PGJ2 showed effects on PI3K signalling 
pathway, TNFa induced COX-2 and PGE2 expression as well as gene regulation.
Differential effects of troglitazone and 15d-PGJ2 are mediated independently of 
PPARy and NFkB
The COX-2 promoter is known to contain a PPRE (Meade et al., 1999). Despite 
this, the selective PPARy ligands investigated had no effect on COX-2 expression. 
Similarly, I could detect no NFkB activation by troglitazone, which is surprising 
given the role of NFkB in COX-2 expression is well recognised (Mitchell et al., 
1994; Chen et al., 2000). These findings therefore indicate that troglitazone-induced 
regulation of COX-2 is independent of PPARy in the systems used in this study.
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This work lends further compelling evidence to the notion that troglitazone and 15d- 
PGJ2 ligands can operate independently of PPARy. For example previous studies 
using murine PPARy null macrophages to demonstrate that previously reported 
inhibitory actions of PPARy agonists on macrophage cytokine production occur via a 
PPARy-independent mechanism (Chawla et al., 2001). Moreover, unique 
biochemical and functional actions of troglitazone which are not shared by 15d-PGJ2 
which may influence the therapeutic potential of this compound in inflammatory 
settings have been identified. This study also questions the potential of troglitazone 
related compounds as anti-inflammatory drugs given the robust upregulation of the 
pro-inflammatory mediator COX-2 by troglitazone.
Effects of troglitazone on the TNFa induced NFkB pathway
In addition to differential effects of the troglitazone and 15d-PGJ2 alone, disparate 
effects were also seen with the two ligands on TNFa-induced events. The ability of 
troglitazone to inhibit TNFa induced NFkB gene reporter activity has previously 
been seen in adipocytes (Ruan et al., 2003). In my system this effect was shown to 
be independent of PPARy, by the use of the PPARy antagonists GW9662. Despite 
partial inhibition of NFkB reporter activity, pretreatment with troglitazone did not 
attenuate TNFa induced COX-2 or PGE2 production, thus suggesting that the 
residual NFkB activity is sufficient for the induction of COX-2 expression and/or 
other transcription factors are responsible for the induction of COX-2 by TNFa.
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Regulation of cytokine induced COX-2 expression and activity by troglitazone 
and 15d-PGJ2
PPAR ligands have been reported to regulate COX-2 expression, inducing COX-2 in 
human epithelial cells (Meade et al., 1999) but inhibiting its induction in LPS- 
stimulated differentiated U937 cells (Inoue et al., 2000). In addition, 15d-PGJ2 has 
been shown to amplify COX-2 induction in response to stem cell factor, IL-lp and 
IL-10 in mouse bone marrow-derived mast cells, yet this effect was not seen to the 
same extent with synthetic PPARy ligands (Diaz et al., 2002). The concept that 15d- 
PGJ2 and troglitazone modulate the expression of proinflammatory genes differently 
has previously been shown (Petrova et al., 1999; Thieringer et al., 2000; Simonin et 
al., 2002). Several studies have identified new intracellular targets especially in the 
NFkB signalling pathway that are independent of PPARy (Castrillo et al., 2000; 
Rossi et al., 2000; Straus et al., 2000). Importantly though, and in the context of the 
work presented here, little or no evidence has previously been reported on synthetic 
PPARy ligands enhancing cytokine induced COX-2 expression in A549 cell line.
The role of TZDs in the treatment of Type II diabetes has been firmly established. 
The mechanism of action involves regulation of the expression of specific genes 
especially in fat cells but also other cell types such as endothelial cells, macrophages 
and monocytes, vascular smooth muscle cells and colonic epithelium by PPARy. 
TZDs have been shown to interfere with expression and release of mediators of 
insulin resistance originating in adipose tissue (e.g., increased free fatty acids, 
decreased adiponectin) in a way that results in net improvement of insulin sensitivity 
(i.e., in muscle and liver). Interestingly there is an increase in COX-2 expression in 
pancreatic islet cells (Robertson, 1998) and COX-2 is thought to act as a negative
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regulatory of insulin secretion. Although this study does not investigate the effects of 
troglitazone on COX-2 expression in islet cells it does highlight the potential side- 
effects (such as increased COX-2 and PGE2 in lung epithelial cells) that may occur 
by patients taking TZDs for the treatment of Type II diabetes.
The cyclopentenone ring system of 15d-PGJ2 can directly inhibit the DNA binding 
activity of N F k B  through direct alkylation of a cysteine residue located in the DNA 
binding domain of the p65 subunit (Straus et al., 2000). This mechanism, in addition 
to inhibition of IKK, has been shown to act in combination to inhibit transactivation 
of the N F k B  target gene COX-2 in Hela cells and RAW264.7 cells. However, in my 
system 15d-PGJ2 was not able to inhibit I k B  degradation, p65 phosphorylation or 
activation or N F k B  reporter activity, thus suggesting that any inhibitory effect of 
15d-PGJ2 on cytokine induced COX-2 expression is not mediated via inhibition of 
the N F k B  pathway.
The ability of 15d-PGJ2 to enhance TNFa induced PGE2 production may be due to 
inhibition of a NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) 
enzyme. PGDH is catabolic enzyme that controls the biological activities of 
prostaglandins by converting them into inactive keto-metabolites (Nandy et al.,
2003). Studies have shown the distal element of PGDH, to be an integrator of 
transcriptional regulation by AP-1, Ets and CREB proteins (Greenland et al., 2000; 
Nandy et al., 2003). 15d-PGJ2 has been shown to be able to directly inhibit AP-1 
DNA binding by forming a covalent adduct with c-jun (Perez-Sala et al., 2003). In 
addition, anti-AP-1 activity of 15d-PGJ2 has been shown to be a consequence of
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inhibition of c-jun expression and competition for limiting amounts of the general 
coactivator CBP in a PPARy dependent mechanism (Subbaramaiah et al., 2001).
The enhancement of cytokine induced COX-2 and PGE2 by troglitazone and 
ciglitazone may simply be due to an additive effect. However what is of particular 
interest is that troglitazone, but not 15d-PGJ2, can inhibit TNFa induced NFkB 
reporter activity in a PPARy independent mechanism. Furthermore, more specific 
PPAR ligands also produced the same effect albeit at concentrations far exceeding 
their EC50 values. In support these finding are those by Trifilieff et al., who reported 
that selective PPARa, y and 8  agonists inhibited the activation of NFKB-responsive 
gene construct at micromolar concentration (Trifilieff et al., 2003). This data 
suggests that synthetic PPAR ligands affect/inhibit a component of the NFkB 
pathway independently of PPAR. The possible mechanisms involved are discussed 
below.
Dimerization of the NFkB family members is necessary for their DNA-binding 
properties. Multiple homodimeric and heterodimeric combinations of these factors 
bind to consensus kB sequences in the promoter element of NFkB regulated genes, 
resulting in unique patterns of transcriptional activation (Yamamoto and Gaynor,
2004). The p65-p50 heterodimer was defined as the classical NFKB-binding form, 
but this is only one of the multiple species that can bind to kB sites. Although RelB 
homodimers do not bind to NFkB sites, heterodimers of this factor with either p50 or 
p52 can result in RelB-mediated transcriptional activation. Furthermore, studies have 
shown that RelA can be physically associated with both p i00 and p i05 as well as 
iKBa in the cytoplasm of cells (Sun et al., 1994; Dejardin et al., 1995). Sun et al.
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(Sun et al., 1994), further showed that p i00, like IicBa, potently inhibited the 
transcriptional activity of RelA.
Both p50 and p52 can also form transcriptionally active heterodimers with either p65 
or c-Rel. p50 or p52 homodimers can also bind to NFkB sequences. In most tissues, 
these proteins have little intrinsic ability to activate transcription because they lack a 
classical transactivation domain. However, these homodimers can also repress the 
expression of their target genes (Li and Verma, 2002). For example, downregulation 
of cytokine-mediated NFkB activation can result from the replacement of the active 
p65-p50 heterodimer by the binding of p50 homodimers. The interaction of these 
homodimers with histone deacetylase complexes can then reduce cytokine-mediated 
gene expression (Li and Verma, 2002; Zhong et al., 2002).
Curiously, troglitazone inhibited TNFa induced NFkB reporter activity, although the 
significance of this finding remains unclear since troglitazone had no effect on other 
read-outs of TNFa stimulated NFkB activation. Thus this data also suggests that the 
residual effect of TNFa on NFkB is sufficient for the induction of COX-2 and/or 
that other transcriptional pathways are involved in TNFa induced COX-2 expression 
and in the additive effects of troglitazone on TNFa induced COX-2 expression. In 
support of the latter hypothesis is that troglitazone has been shown to increase AP-1 
binding activity in rat synovial fibroblasts (Simonin et al., 2002). This also suggests 
that the decrease in TNFa induced NFkB reporter activity by troglitazone may not 
be the result of a physical interaction between proteins or between protein and DNA 
but rather the consequence of the titration of AP-1 and NFkB coactivators by the 
PPAR system. However, at this point, it is not possible to confirm this hypothesis.
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4.5. Conclusion
The role of PPARy ligands in the modulation of inflammation is nevertheless 
complex, because these ligands exhibit both anti-inflammatory and pro- 
inflammatory functions and thus remains the subject of intensive investigation. My 
findings therefore indicate that troglitazone-induced regulation of COX-2 is 
independent of PPARy in the systems used in this study. This work lends further 
compelling evidence to the notion that troglitazone and 15d-PGJ2 ligands can operate 
independently of PPARy. For example previous studies using murine PPARy null 
macrophages demonstrate that previously reported inhibitory actions of PPARy 
agonists on macrophage cytokine production occur via a PPAR-independent 
mechanism (Chawla et al., 2001). Moreover, I have identified unique biochemical 
and functional actions of troglitazone that are not shared by 15d-PGJ2, which may 
influence the therapeutic potential of this compound in inflammatory settings (Patel 
et al., 2005) This study also questions the potential of troglitazone related 
compounds as anti-inflammatory drugs given the robust upregulation of the pro- 
inflammatory mediator COX-2 by troglitazone.
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5. GENERAL DISCUSSION AND CONCLUSIONS
5.1. General Discussion
5.1.1. Experimental Model
The experimental model used in this work was in vitro culture of human lung 
epithelial cell line and the assessment of PPARy ligands to modulate COX-2. In this 
context COX-2 appears to be behaving as an acute pro-inflammatory agent -  induced 
by pro-inflammatory cytokines and synthetic PPARy ligands and having its 
expression regulated by various signalling pathways. Interestingly different 
signalling pathways were involved in the regulation of COX-2 by cytokines and by 
the synthetic PPARy ligand troglitazone. TNFa-mediated COX-2 expression showed 
involvement of ERK and p38 MAPK as well as the classical NFkB pathway. 
Similarly the involvement of the ERK and p38 MAPK pathways were important in 
troglitazone induced COX-2. In addition the PKC pathway played an important role 
in troglitazone induced COX-2 and these effects were independent of PPARy and 
NFkB. Furthermore, this work shows disparate biochemical and functional effects 
between two PPARy ligands (troglitazone and 15d-PGJ2) which were again mediated 
independently of PPARy. Although allowing detailed manipulation of the regulatory 
pathways involved, the experimental model lacks the ability to pursue the more 
complex points. The system may also over-estimate the signalling pathways 
activated by TNFa and IL-lpand PPARy ligands as transformed cell lines are 
believed to be more sensitive for activation of signalling cascades (Saklatvala et al.,
1999).
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One feature of the literature that is obvious is the heterogeneity in results obtained 
with PPARy ligands between different models and cell types. There may be a 
common theme in the literature, such as TNFa or IL-lp inducing COX-2 which is 
shared in many systems. The conclusions outlined above are therefore from this 
work, rather than using other models which may not be relevant.
As seen in figure 3.18 there are many regulatory elements in an important gene such 
as COX-2 with the possibility that there may be interactions between them. There is 
also an element of redundancy and the possibility that stimulation may activate 
opposing signals. Such complexities make drawing detailed conclusions difficult. 
They also make the teasing out of the individual pathway effects challenging and 
often limited by the available molecular tools.
5.1.2. Comparison between troglitazone and 15d-PGJ2
Troglitazone and 15d-PGJ2 showed differential activation of signalling pathways and 
functional outputs. Troglitazone activated both the PI3K and MAPK pathway and 
induced COX-2 expression, in comparison 15d-PGJ2 only activated the PI3K 
pathway and had no effect on basal or cytokine induced COX-2 expression. The 
COX-2 promoter is known to contain PPRE (Meade et al., 1999). Despite this, the 
selective PPARy ligands investigated had no effect on COX-2 expression. Similarly, 
troglitazone did not induce NFkB activation which was surprising given that the role 
of NFkB in COX-2 expression is well recognized (Mitchell et al., 1994; Chen et al.,
2000). Curiously, troglitazone inhibited TNFa induced NFkB reporter activity, 
although the significance of this finding remains unclear since troglitazone had no
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effect on other readouts of TNFa stimulated NFkB activation. These findings 
therefore indicate that troglitazone-induced regulation of COX-2 is independent of 
NFkB and PPARy this system.
5.1.3. Application to Lung Inflammatory Diseases
The COX pathway is highly complex with multiple points of external and auto­
regulation. Downstream prostaglandins, as well as upstream arachidonic acid 
liberation by phospholipases, will play a physiological role. The original hypothesis 
proposed was that PPARy ligands may attenuate inflammatory responses by 
inhibition of pro-inflammatory genes such as COX-2. However this work questions 
the potential of troglitazone related compounds as anti-inflammatory drugs given the 
robust upregulation of the pro-inflammatory mediator COX-2 by troglitazone (Patel 
et al., 2005).
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5.2. Overall Conclusions
• The human lung epithelial cell line A549 expresses PPARy and PI3K isoforms 
(Class IA and Class II).
• The PI3K inhibitors have differential selectivity for PI3K isoforms and thus this 
work has highlighted the potential pitfalls of using these inhibitors in elucidating 
the role of PI3K.
• Pro-inflammatory cytokines (TNFa and IL-1 p) activated PI3K, MAPK and NFkB 
signalling pathways which may be involved in their induction of COX-2 
expression in the A549 cell line.
• Two structurally distinct PPARy ligands have disparate effects on both basal and 
cytokine induced biochemical and functional events. These effects were shown to 
be PPARy and NFkB independent.
• The PI3K, MAPK and PKC pathways play important roles in troglitazone induced 
COX-2 expression.
• The unique biochemical and function effects of troglitazone, which are not shared 
by 15d-PGJ2, may influence the therapeutic potential of this compound in 
inflammatory settings.
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5.3. Future Work
Future work may help to further identify the mechanisms by which PPARy ligands act 
in an inflammatory response and thus further evaluate their potential as regulators of 
inflammation. These studies would be aided by further work described below:
• Supporting the work presented here with work in other models using alternative 
techniques. In particular, regarding the work based on PI3K inhibition, different 
techniques should be used such as molecular inhibition using dominant negative 
or constitutively active transfected constructs. Also dominant negative expression 
of PPAR (similar to that used by Gumell et al., (2000) may be used to verify that 
the above described effects are PPARy independent.
• This area of COX-2 research concentrates on the enzyme rather than its products, 
which are the focus of its functional activity. The relevance of troglitazone 
induced PGE2 production warrants more research.
• Investigation into other transcriptional pathways (such as AP-1) pathway to 
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6. APPENDIX
6.1. Buffers and solutions
6.1.1 Solutions and buffers for SDS-PAGE and western blotting
Lysis Buffer 4 x Resolving gel buffer
1 % (v/v) Nonidet P-40, 1.5M Trizma base
150nM NaCl, pH 8.8
50mM Tris pH 7.5, 0.4% (w/v) SDS
5mM EDTA, MilliQ water
lOmM sodium fluoride*
ImM phenylmethylsulfonyl fluoride* 4 x Stacking gel buffer
lOpg m l'1 leupeptin* 0.5M Trizma base
lOpg m l'1 aprotinin* pH 6.8
lpg ml"1 soybean trypsin inhibitor* 0.4% (w/v) SDS




NB * denotes added on the day on use
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SDS-PAGE running buffer
25mM Trizma base 
192mM glycine 











48mM Trizma base 
0.0375% SDS 







Tris-buffered saline- Tween (TEST)







6.1.2. Recipes for various percentage SDS page gels
Final
percentage gel
7.5% 10% 12% Stacking gel
4x Resolving 
buffer
5.0ml 5.0ml 5.0ml 4x Stacking 
buffer
3.0ml
MilliQ 9.84ml 8.17ml 6.84ml 6.85ml
Acrylamide 5.0ml 6.67ml 8.0ml 2.0ml
APS (10%) 150jli1 150|il 150)0.1 150|il
TEMED 15pl 15|il 15 pi 15pl
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6.1.3. Buffers for Nuclear Extract Preps
Buffer 1 Buffer 2
lOmM HEPES lOmM HEPES
lOmM KC1 400mM NaCl
lOOpM EDTA lOOpM EDTA
lOOpM EGTA lOOpM EGTA
ImM Sodium molybdate* ImM Sodium molybdate*
ImM Sodium vanadate* ImM Sodium vanadate*
lOmM Sodium fluoride* lOmM Sodium fluoride*
MilliQ water MilliQ water
NB *denotes added on the day on use
6.1.4. Buffers for in vitro lipid kinase assay




1.5mM KH2P 04 
0.01% NP-40
1 OOpM Sodium orthovanadate * 
PBS
Tris/LiCl Buffer
lOOmM Tris pH7.4 
5mM LiCl






1 OOpM Sodium orthovanadate * 
MilliQ
ATP Kinase buffer




lOmM Tris HC1 pH7.4
Preparation of Pi-Appropriate amount 0  
pH 7.4, ImM EDTA was added to gi 
resuspeneded by sonicating in an ice bath f<
‘'P I was dried under nitrogen. lOmM Tris 
ve a concentration of 2mg/ml. PI was 
or lOmins
NB * denotes added on the day on use
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6.2. A ntibodies and conditions used for im m unoblotting


































1:7,000 in 1% 
Marvel










1:7,000 in 1% 
Marvel
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